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Summary 
 
Introduction 
 
Numerous large clinical trials of cardiovascular risk lowering agents have been 
conducted in the hope of reducing the excess cardiovascular risk found in 
patients with diabetes mellitus. However, the relationship between glucose and 
cardiovascular disease remains complex and various areas require further study. 
Even in patients with diabetes, an individual’s cardiovascular risk is highly 
variable depending on other clinical characteristics, the assumption that glucose 
is a continuous risk factor has often been based on weak evidence from 
relatively short studies, the effect of commonly used cardiovascular risk 
lowering agents often has unexpected effects on new-onset diabetes and statins 
have not yet been studied in detail, and whether glucose-lowering therapies 
actually reduce cardiovascular risk has remained a contentious issue despite the 
conduct of large clinical trials. Furthermore, the realisation that the 
combination of diabetes and chronic heart failure, a common complication of 
coronary disease, carries a particularly poor prognosis suggests that prediction of 
diabetes in this population may be clinically valuable. 
 
Aims 
 
I aimed to address the following different, though related, questions regarding 
glucose and cardiovascular disease: 
1. Are anticipated cardiovascular event rates in diabetes endpoint trials 
actually achieved? Is it possible to easily identify patients with diabetes 
that are at particular risk of events (information that is crucial to 
investigators who wish to design clinical trials)? 
2. Is fasting glucose concentration independently and convincingly 
associated with increased risk of cardiovascular events in those without 
diabetes? 
3. Do statins, the most commonly prescribed medications worldwide, have 
any influence on the risk of developing diabetes?  
4. If statins do indeed affect new-onset diabetes, is there any evidence of a 
dose-dependent effect? 
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5. How effectively can clinicians predict the development of diabetes in 
chronic heart failure using commonly recorded clinical information? 
6. Does intensive glucose-lowering therapy reduce the risk of cardiovascular 
events in patients with diabetes? 
 
Methods 
 
To address these questions three approaches were used, namely (i) systematic 
review of previously published data from large cardiovascular endpoint trials 
conducted in patients with diabetes; (ii) analyses of existing datasets from two 
large clinical trials; (iii) meta-analyses of published and unpublished data from 
large clinical trials. 
 
Results and interpretation 
 
1. In a systematic review of 29 trials with 116,790 patients with diabetes, it 
was apparent that the majority of large cardiovascular endpoint trials 
conducted in patients with diabetes vastly overestimated the likely 
cardiovascular event rates in initial power calculations. Introduction of (i) 
previous history of cardiovascular disease and/or (ii) presence of 
proteinuria, as binary trial inclusion criteria, provides a simple and 
effective way to identify patients at high risk, something that is sought 
after for appropriate clinical trial power calculations. 
2. In a population of 6,447 men without diabetes at baseline, impaired 
fasting glycaemia was not associated with increased risk of cardiovascular 
events over 15 years. Similarly, when baseline fasting glucose values 
<7.0mmol/L were split into quintiles, patients in the highest quintile were 
at similar risk of all vascular endpoints to those in the lowest. By contrast, 
impaired fasting glycaemia was a powerful risk factor for developing 
diabetes. 
3. A meta-analysis of published and unpublished data from most large 
placebo- and standard care-controlled statin trials, which included data 
for 91,140 trial participants without diabetes at baseline, revealed that 
statin therapy is associated with a 9% higher risk for developing diabetes. 
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4. A subsequent meta-analysis of unpublished data from five large trials 
comparing intensive statin therapy with moderate dose therapy found 
that intensive statin therapy increases the risk of developing diabetes by 
12% compared to moderate dosing, in keeping with a dose-dependent 
effect. While statin therapy remains effective at reducing cardiovascular 
risk it appears that patients on statin therapy, especially those on 
intensive regimens, should be considered for diabetes screening. 
5. In an analysis of data for 1,620 patients with chronic heart failure and no 
diabetes at baseline studied for 2.8 years, the strongest predictors of 
new-onset diabetes were similar to those in the general population. In 
particular, the combination of HbA1c and body mass index provided a c-
statistic of 0.79. 
6. In a meta-analysis of published data for 33,040 patients with diabetes who 
participated in clinical trials comparing intensive glucose-lowering 
therapy with standard therapy, non-fatal myocardial infarctions were 
reduced by 17% on intensive therapy but no other cardiovascular 
endpoints were reduced. Death rates were similar in both groups. 
 
Conclusion 
 
While diabetes is associated with excess cardiovascular risk, risk varies 
considerably depending on other risk factors. Glucose is, at best, a weak risk 
factor in those without diabetes, and glucose-lowering in patients with diabetes 
has only yielded a modest reduction in non-fatal myocardial infarctions but not 
other events; by contrast, measures of glycaemia are powerful predictors of 
new-onset diabetes in patients with and without chronic heart failure. Finally, 
the relationship between glucose and vascular disease is further complicated by 
the fact that numerous medications designed to reduce cardiovascular risk 
appear to have surprising effects on the risk of developing diabetes. 
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Chapter 1 
 
1.1 Rationale for research conducted 
 
Biomarkers are biological markers commonly used to indicate the presence of a 
specific disease, the risk of developing that disease, or response to therapy. The 
term most often refers to a protein present in the bloodstream which can be 
measured, but it may also refer to numerous other entities. The study of 
biomarkers tends to fall into three categories: 
 
o Association of a biomarker with the presence of or risk of developing 
disease 
 
When a biomarker is first described, initial research usually pursues statistical 
associations between the presence and/or concentration of the biomarker and 
the disease process in question. These data tend to be derived from 
observational studies, whether prospective, cross-sectional or retrospective. 
While demonstration of a statistical association between biomarker and disease 
development is an important initial step, such evidence does not necessarily 
equate to clinical utility. To add clinical benefit, it is necessary that a biomarker 
is not only associated with a disease, but that it meaningfully improves the 
ability to predict development of that disease. Consequently, studies of 
association are often coupled with or followed by studies of risk prediction. 
 
o Prediction of a disease or event using the biomarker 
 
Accurate prediction of disease presents the attractive possibility that those at 
risk of that disease can be targeted for screening and for preventative action to 
reduce this risk. Numerous risk prediction tools exist for cardiovascular disease, 
the leading cause of mortality in the western world. Examples include the 
Framingham Risk Score (1), QRISK2 (2) and ASSIGN (3). Other risk scores exist for 
type 2 diabetes, such as QDScore (4), though use of them in clinical practice 
remains limited. For a biomarker to be of clinical value it must be demonstrated 
that it meaningfully adds to risk prediction information yielded by such risk 
scores using established risk factor information. Such information has generally 
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been provided by showing that addition of the biomarker to a disease prediction 
model leads to an improvement in the model’s area under the receiver operating 
curve (AUROC) or c-statistic. More recently, the bar has been raised such that 
now a biomarker must not only demonstrate the ability to improve this c-
statistic, but also its ability to improve other derived statistics such as 
reclassification and discrimination indices (5). While an improvement in risk 
prediction is a valuable characteristic for a biomarker, proof of a causal link 
between it and a disease state addresses a different question of substantial 
importance but this is considerably more difficult to demonstrate. It is important 
to keep in mind that risk factors do not necessarily have to carry causal links 
with the disease in question to improve disease prediction. 
 
o Proving that a biomarker causes disease 
 
To prove a causal link between a putative risk factor (in this case biomarker) and 
a disease, Bradford Hill proposed the following nine criteria (6): 
1. Strength of association: the stronger the association, the more likely that 
a causal relationship exists 
2. Consistency of observation: an association should be replicated by 
different investigators 
3. Specificity of the association: more accurate definition of the disease and 
more accurate measurement of the putative factor should strengthen 
observed associations 
4. Temporality: exposure to the putative factor should precede the disease 
5. Biological gradient: a dose-response relationship 
6. Plausibility: the proposed causal relationship is consistent with other 
knowledge 
7. Coherence 
8. Experimentation: demonstration that a change in exposure to the putative 
causal factor leads to a change in clinical outcome.  
9. Analogy 
 
Criterion 8, ‘experimentation’, is probably the most important of the nine 
criteria in medical research and it demonstrates the need to conduct randomised 
controlled trials to properly establish causation. It is well established that the 
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randomised controlled trial is the gold standard approach to address whether 
therapeutic techniques which change biomarker levels in apparently beneficial 
ways actually lead to improvements in important clinical events. Another 
powerful statistical technique to assess a causal link between biomarker and 
disease which is expanding rapidly is the use of Mendelian randomisation (7).  
 
Glucose, diabetes and cardiovascular disease 
 
These considerations are relevant in the specific case of glucose, diabetes and 
cardiovascular disease and form the basis for this thesis. The relationship 
between circulating glucose concentrations and cardiovascular disease has long 
been of clinical interest. It is the association between diabetes mellitus, a 
condition defined by elevated concentrations of plasma glucose concentration 
under stipulated conditions, and cardiovascular disease that has received 
particular attention since it was noted that those with diabetes appear to be at 
particular risk of suffering cardiovascular events (8). This elevated 
cardiovascular risk in patients with diabetes has been confirmed in numerous 
observational studies (9;10) and has led to numerous trials of risk-lowering 
medicines such as antihypertensive agents, lipid modifying agents and 
antithrombotic agents with the aim of reducing this excess risk. Of particular 
relevance, large trials of glucose-lowering agents have been conducted in 
patients with diabetes based on the hypothesis that glucose itself is the causal 
agent which, at least partially, accounts for this elevated cardiovascular risk. 
Another possibility is that the noted association between diabetes and 
cardiovascular disease is explained by other confounding factors such as 
established cardiovascular risk factors (for example HDL-cholesterol) and 
possibly also other unmeasured factors.  
 
Prior to the conduct of research contained in this thesis, it was apparent that 
while major efforts had been directed towards understanding the complex 
relationship between glycaemia and cardiovascular disease, certain key 
questions had either not previously been asked or, as yet, conclusively 
answered. I therefore wished to investigate a set of different, though linked, 
issues which fall within the overall theme of glycaemia and cardiovascular 
disease. In this Chapter I will describe the rationale that led to the research 
 25 
conducted. The research areas are described in brief below and, importantly, all 
fall within the realm of large clinical trials.  
 
One area of concern that became apparent during my reading through many 
major cardiovascular trials conducted in patients with diabetes was the 
difficulty researchers experienced when formulating power calculations. It 
appeared likely that although patients with diabetes are at elevated 
cardiovascular risk, it was being assumed that this additional risk was somewhat 
larger than is actually the case. The potential problem is that trials are likely to 
accrue fewer clinical events than anticipated, thereby leading to extensions of 
trials or, worse, to underpowered trial results (11). Given the expense incurred 
in conducting such trials and the huge importance of their findings to patient 
treatment and even financial strength of pharmaceutical companies, accurate 
prediction of cardiovascular event rates is hugely appealing and sought after. Of 
similar critical importance is the ability of trial designers to include in their trial 
inclusion criteria simple but effective characteristics to identify those patients 
who are at high risk of suffering cardiovascular risk i.e. those most likely to 
benefit from the treatment in question and, by extension, those who will allow 
investigators to obtain clinically useful, adequately powered and conclusive 
results. The importance of this point was further emphasised by a leading figure 
from one of the major international pharmaceutical companies who visited the 
BHF Glasgow Cardiovascular Research Centre in 2010 and made this very point 
while expressing frustration at the lack of a ‘biomarker’ that would provide this 
all-important information to allow improved trial design in diabetes. Review of 
data from large trials conducted in diabetes suggested the possibility that a 
simple and inexpensive solution may exist. Cardiovascular event rates in some 
trials of participants with diabetes and either proteinuria or existing 
cardiovascular disease appeared markedly elevated compared to when these two 
characteristics were absent. Indeed event rates in trials involving patients with 
diabetes but not proteinuria or cardiovascular disease appeared surprisingly low. 
While appreciating that overall cardiovascular risk depends on a multitude of 
variables, it seemed a plausible and practical idea that using either as binary 
inclusion criteria may be a useful approach for future trials. These thoughts led 
to work which was conducted over 2009-2010 and which is fully described in 
Chapter 2. In a systematic review of data from large cardiovascular endpoint 
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trials in patients with diabetes I wanted to examine (i) how accurate power 
calculations have tended to be in previously published studies; and (ii) what 
impact the use of either the presence of cardiovascular disease or proteinuria as 
inclusion criteria would have on event rates, and thereby power calculations, in 
clinical trials. 
 
A second area where I perceived a need for additional data was in establishing 
what, if any, relationship exists between glucose levels and cardiovascular 
disease in patients without diabetes. While the study of diabetes has received 
major attention, consideration of a causal relationship between circulating 
glucose concentrations and incident cardiovascular events implies that such a 
continuous relationship should also exist in patients who do not have diabetes. 
At the time of writing, few large studies had examined this relationship using 
current diagnostic criteria for diabetes and many had focused on cardiovascular 
and all-cause mortality with less data available on cardiovascular morbidity (12). 
Given that diabetes requires considerable time after diagnosis to increase 
vascular risk (13), observational research in cohorts with intermediate categories 
of dysglycaemia (impaired fasting glycaemia, impaired glucose tolerance) 
seemed likely to have been to some extent limited by relatively short follow-up 
durations with the result that high quality data were required from longer 
studies. Few studies had also sought to simultaneously compare the strengths of 
associations between glucose levels and both incident cardiovascular disease and 
incident diabetes. I set out to investigate the associations between fasting 
glucose concentration, cardiovascular events and new-onset diabetes using a 
high quality dataset available after completion of a major statin trial in the west 
of Scotland in the 1990s (14). This dataset had the distinct advantage of post-
trial follow-up using electronic data linkage which allowed patients to be 
followed for 15 years (15). This work, which was conducted during 2009-2010, is 
provided in Chapter 3. 
 
The relationship between biomarker and disease process may be further 
complicated by the influence of other variables, often unsuspected. For example 
it has long been known that some medications aimed at reducing cardiovascular 
risk actually influence the risk of developing diabetes and glycaemic control in 
those with diabetes. Well known examples include thiazide diuretics and beta 
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blockers, anti-hypertensive agents both known to increase diabetes risk (16;17), 
and nicotinic acid (18), a lipid-modifying agent known to cause a deterioration in 
glycaemic control in those with diabetes. By contrast, angiotensin converting 
enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARB) have been 
shown to reduce the risk of developing diabetes (19). Statins are the most 
prescribed medicines worldwide and this trend has accelerated in recent times 
such that as many as one in three adults over the age of 45 in the UK is currently 
on a statin. Atorvastatin and rosuvastatin are among the ten highest grossing 
medicines in the world. When any class of agents is so widely used, careful 
scrutiny of any detrimental effects is required as they may affect substantial 
numbers of people. By 2008 numerous large statin trials had published data on 
cardiovascular events (20), the majority confirming benefit in terms of 
cardiovascular risk reduction. Additional studies of potentially important side-
effects had confirmed that statin therapy had no influence on the likelihood of 
developing cancer  but that high-dose statin therapy in particular increased 
one’s risk of developing a range of skeletal muscle pathologies ranging from mild 
myopathy and myalgia to the rare rhabdomyolysis (21). One issue which had not 
been examined was whether statin therapy had any influence on the risk of 
developing diabetes and the vast majority of major statin trial publications 
provided no relevant data. When one major trial selected new-onset diabetes as 
a specified secondary endpoint and observed a 25% increase (22), it was clear 
that there was a need for a systematic review of all available evidence to 
establish whether any effect does exist. Over 2008-2010, I co-led a collaborative 
project to collect as much published and unpublished data from large placebo- 
and standard care-controlled trials as possible. This work is described in detail in 
Chapter 4. Crucially, investigating the effect of statin therapy using data from 
randomised trials provided data of high quality and also immediately satisfied 
the majority of the Bradford Hill criteria. 
 
The intriguing results of the research conducted in Chapter 4 to evaluate any 
effect of statin therapy on new-onset diabetes led to further collaborative 
research. The logical progression of the findings from placebo- and standard 
care-controlled trials was to seek data from those trials which had compared 
intensive-dose statin therapy to moderate dose therapy regarding new-onset 
diabetes. As before, numerous trials had been published in this area but very 
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little published information was available to address this issue. It again proved 
possible to form a new collaboration with the relevant trialists, pool unpublished 
trial data and thereby investigate the possibility of a dose-dependent effect of 
statin therapy on new-onset diabetes which would have been expected 
according to the Bradford Hill criteria. In addition, weaknesses present in the 
analysis of placebo- and standard care-controlled trials could be addressed, in 
particular the possibility of including not only data regarding new-onset diabetes 
but also cardiovascular events. This work was conducted over the course of 
2009-2011 and is provided in Chapter 5. These two chapters, 4 and 5, between 
them contain the largest and highest quality data yet obtained and analysed to 
address the question of whether statin therapy affects new-onset diabetes.  
 
A further point to consider when studying a link between biomarker and disease 
is that observed associations are likely to differ between various patient groups. 
For glucose and diabetes, one particularly important group to highlight is 
patients with chronic heart failure, a condition whose prevalence and incidence 
is increasing and which is expensive to treat. Most cases of chronic heart failure 
are attributable to coronary heart disease (23). Recent research has revealed 
the strong association between chronic heart failure and type 2 diabetes with a 
particularly high prevalence and incidence of diabetes in those with heart failure 
(24). Importantly, it also appears that patients with diabetes and chronic heart 
failure are at particular risk of morbidity, and that the risk of developing chronic 
heart failure is also elevated in patients with diabetes. Consequently, the study 
of the development of diabetes in chronic heart failure is increasingly 
considered very important. At the time of my research there were no published 
data assessing statistical prediction of new-onset diabetes in chronic heart 
failure. Suitable high quality data to address this question were available from a 
previously conducted trial of an angiotensin receptor antagonist. With the 
assistance of my co-supervisors I was able to obtain the necessary data and the 
subsequent work is detailed in Chapter 6. 
 
Arguably the most important question when examining the relationship between 
biomarker and disease, in this case glucose and cardiovascular disease, is to 
establish whether interventions to lower glucose have any beneficial effect on 
cardiovascular outcomes. I had the opportunity to contribute substantially 
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towards a project led by colleagues at the University of Cambridge in which we 
pooled exiting data from large trials comparing intensive glucose lowering 
therapy with standard therapy in patients with type 2 diabetes. This work is 
included in the Appendix. 
 
Each topic is presented separately with its own introduction, methods section, 
results and discussion. This partly reflects the fact that the majority of the data 
in this thesis have been published in peer-reviewed journals. Permission to 
reproduce these data was obtained in all cases and copies of the relevant 
certificates are included at the end of the thesis. 
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1.2 Aims of the thesis 
 
Chapter 2  
o To investigate whether event rates in cardiovascular endpoint trials 
conducted in patients with diabetes have been overestimated in pre-trial 
power calculations  
o To examine cardiovascular event rates in trials including diabetic 
participants with and without baseline cardiovascular disease, or 
proteinuria, respectively to assess what impact the presence of either of 
these risk factors has on event rates. 
 
Chapter 3  
o To investigate the relationship between fasting plasma glucose and the 
risk of incident cardiovascular events, all-cause death and also the 
development of diabetes using an existing database from a large placebo-
controlled statin trial 
 
Chapter 4  
o To investigate whether statin therapy increases the risk of developing 
diabetes using data from large placebo- and standard care-controlled 
trials 
 
Chapter 5  
o To examine the associations of intensive-dose statin therapy compared to 
moderate-dose therapy with the development of diabetes and the 
occurrence of major cardiovascular events, respectively, using data from 
large clinical trials 
 
Chapter 6  
o To investigate which commonly measured clinical and laboratory 
characteristics are associated with the development of diabetes in chronic 
heart failure 
 
Data for intensive vs. standard glucose lowering in type 2 diabetes are available 
in the Appendix. 
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Chapter 2. 
 
A systematic review of event rates in clinical trials in diabetes mellitus: the 
importance of quantifying baseline cardiovascular disease history and 
proteinuria and implications for clinical trial design 
 
2.1 Introduction  
 
Demonstration of the cardiovascular safety and efficacy of pharmacological 
treatments used in diabetes is an important clinical issue. The cardiovascular 
safety of treatments for diabetes was brought to the world’s attention by a 
meta-analysis of trials using the thiazolidinedone, rosiglitazone, conducted by 
the Cleveland Clinic’s Nissen and Wolski which was published in 2007 (25). In 
their manuscript, the authors combined cardiovascular endpoint data from 42 
different trials and found that rosiglitazone therapy was associated with a 43% 
higher risk of myocardial infarction. The ensuing controversy initiated by that 
analysis highlighted the small-scale and short-term nature of many studies of 
new anti-diabetic drugs. In the rosiglitazone meta-analysis, only four of the 42 
trials included more than 1000 patients and most lasted less than one year. This, 
along with the recruitment of relatively young diabetic subjects with little co-
morbidity, meant that these studies individually accrued small numbers of 
cardiovascular events and lacked the statistical power to detect harm or benefit 
from the treatment being investigated.  
 
These and additional trials in other disease areas (e.g. cyclooxygenase-2 
inhibitors for the prevention of colonic adenomas (26), erythropoietin 
stimulating agents in chronic kidney disease (27), sibutramine and rimonabant 
for weight loss) led to the realisation that unexpected adverse cardiovascular 
outcomes on medications may only be detected in large clinical trials and that 
currently used surrogate measures of drug efficacy are not a reliable guide for 
establishing clinical cardiovascular benefit or safety.  
 
The subsequent debate of these issues culminated in the release by the Food 
and Drug Administration (FDA) of guidance for the pharmaceutical industry on 
the evaluation of cardiovascular risk during the development of new therapies to 
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treat type 2 diabetes mellitus (28;29) in December 2008. Central to these new 
recommendations is the principle that trials must include a sufficient proportion 
of participants at high risk of cardiovascular events to ensure that an adequate 
number of end-points is obtained, thereby permitting a meaningful estimate of 
the effect of treatment. However, the FDA document provided little advice on 
which patients are likely to yield these high event rates and how to identify 
them. The guidance simply states that “patients with relatively advanced 
disease, elderly patients and patients with some degree of renal impairment” 
should be included. Importantly, the guidance does not suggest what size of 
effect inclusion of these groups of patients might have on event rates. In 
summary, large clinical trials of glucose-lowering and other potential 
cardiovascular risk modifying agents are needed in diabetes to properly evaluate 
their effects. 
 
There are also examples of large and longer-term studies in patients with 
diabetes which have produced cardiovascular event rates well below those 
anticipated, leading to changes in primary endpoints during the running of the 
trial or to underpowered results.  
 
I therefore reviewed large scale randomised clinical trials in participants with 
diabetes mellitus in order to evaluate achieved cardiovascular disease event 
rates. The first hypothesis was that event rates in diabetes outcome trials have 
been overestimated in pre-trial power calculations, driven in part by the 
questionable presumption that type 2 diabetes is a coronary heart disease ‘risk 
equivalent’ condition as was suggested by a previous high profile observational 
study (30). I also examined cardiovascular event rates in trials including diabetic 
participants with and without baseline cardiovascular disease, or proteinuria, 
respectively, both well established cardiovascular risk factors (31-33) and 
commonly used binary inclusion criteria in diabetes trials, to assess what impact 
the presence of either of these risk factors has on event rates.  
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2.2 Methods 
 
I examined all-cause death and cardiovascular event rates in published 
randomised controlled trials in participants with diabetes mellitus, limited to 
trials where baseline history of structural cardiovascular disease and/or baseline 
proteinuria were either directly quoted or calculable from the data provided. 
These two risk factors were selected as they represent vascular end-organ 
damage and therefore, theoretically, will convey the overall impact of a 
combination of vascular risk factors in a simple way. This also reflects the 
recruitment process in clinical trials where simple criteria are selected which 
participants must satisfy to take part. 
 
Data Sources and Searches 
 
Studies of antihypertensive agents, lipid modifying agents, anti-platelet agents 
and glucose-lowering agents published between 1st January 1998 and 1st June 
2010 that provided relevant information were gathered. An initial search was 
performed on 10th June 2009 and this was updated on 29th September 2010. I and 
my co-supervisor, Prof J McMurray, conducted separate searches of Medline and 
EMBASE using these criteria together with the terms ‘diabetes mortality’, 
‘diabetes cardiovascular’, ‘diabetes stroke’, ‘diabetes myocardial infarction’, 
‘diabetes retinopathy’, ‘diabetes microalbuminuria’, ‘diabetes hypertension’ 
and ‘diabetes peripheral arterial disease’ limited to randomised controlled trials 
in adults published in English. In some trials which included both diabetic and 
non-diabetic participants, data relating to diabetes were included in the primary 
publication whereas for other trials there were subsequent and separately 
published subgroup analyses with the necessary data. 
 
Study Selection  
 
For inclusion studies were required to: (a) include ≥1000 patients with diabetes, 
(b) report a follow-up period of ≥1 year and (c) provide data needed to calculate 
at least one of the four event rates listed below (see Data extraction and Quality 
Assessment). Both trials which enrolled only diabetic participants and trials with 
both diabetic and non-diabetic participants were included provided events in the 
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diabetic subgroup were available separately. Trials conducted specifically in 
patients with unrelated high risk conditions, namely heart failure, arrhythmia, 
dialysis, organ transplant or following a recent cardiovascular event (within 3 
months of recruitment) were excluded. Twenty-nine trials (11;34-66) were 
eventually identified and are considered in this chapter. No trial recruited 
patients where presence of cardiovascular disease and proteinuria were either 
both required or both excluded at baseline. 
 
Data extraction and Quality Assessment 
 
I extracted baseline characteristic data and endpoint data from the selected 
published trials in tabular form and discrepancies were resolved by consensus 
with my co-supervisors. The four endpoints examined were (i) All-cause 
mortality, (ii) Cardiovascular mortality, (iii) Myocardial infarction (a composite 
of fatal and non-fatal events), and (iv) Stroke (fatal and non-fatal events). I also 
examined published power calculations for the selected trials, in which the 
primary endpoint consisted of death and/or major cardiovascular disease events, 
to assess how often predicted event rates are achieved in these trials.  
 
Data Synthesis and Analysis 
 
To assess how accurately primary endpoint (however defined in the individual 
trials) event rates were predicted in published power calculations, I divided 
achieved primary endpoint event rates from trials with anticipated event rates, 
thereby calculating how many obtained above or below expected rates. A ratio 
of 1.0 indicates that the actual event rate was equal to the predicted event 
rate, <1.0 indicates that the actual event rate was lower than the predicted 
event rate and >1.0 that the actual event rate was higher than the predicted 
event rate. Crude unadjusted event rates, expressed as events per 1000 patient 
years, were calculated for each study ([number of events/number of patients] X 
[1000/average follow-up in years (mean or median as available)]). I included all 
participants regardless of allocation to treatment group given that most trials 
compared two or more active treatments or treatment regimens though some 
trials did use placebo as control. Weighted mean event rates and weighted 
standard deviations (SD) were calculated according to trial stratification (see 
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below) as described by Bland and Kerry (67). Weighted mean event rates were 
calculated by dividing the total number of events in a specified category by 
patient-years of follow-up and expressing this per 1000 patient years. For 
estimating weighted SDs, the difference between the weighted sum of squares 
(calculated by adding the products of squared event rates and patient-years of 
follow-up from all trials in a specified category) and a correction term derived 
from the weighted mean was first calculated; this term, divided by degrees of 
freedom, provides weighted variance from which weighted SD follows.  
 
Power calculations were performed using overall event rates for myocardial 
infarction plus stroke combined to allow comparison of the difference in patient 
numbers required in those with and without prior cardiovascular disease or 
proteinuria. A standard power equation was used to calculate numbers of 
participants needed per treatment arm (68): 
 
n = 10.51 [(R+1) – p2 (R2+1)] / p2 (1-R)2 
 
n sample size for each group 
p1 event rate in treatment group 
p2 event rate in control group 
R risk ratio (p1/p2) 
 
Presentation of results 
 
Trials were stratified according to the presence or absence of baseline 
cardiovascular disease and proteinuria respectively. Baseline cardiovascular 
disease was defined as objective evidence of coronary artery disease, peripheral 
arterial disease or cerebrovascular disease. For the purposes of this chapter, the 
term proteinuria reflects all categories of increased urinary protein excretion 
including microalbuminuria, macroalbuminuria and proteinuria.  
 
(i) History of cardiovascular disease at baseline: In this category I selected 
trials where a history of cardiovascular disease was reported or calculable from 
baseline data. I divided trials into those where cardiovascular disease was (1) 
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present in all participants, (2) present in some but not all participants 
(referred to as ‘Mixed’ trials), or (3) absent in all participants.  
 
(ii) Proteinuria at baseline: In this category I selected trials where 
proteinuria was required to be (1) present in all participants, (2) present in 
some but not all participants (referred to as ‘Mixed’ trials), or (3) absent in all 
participants.  
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2.3 Results 
 
Of the 5758 manuscripts identified in the search criteria, I identified 159 
relevant papers representing 29 trials (Figure 2.1). The 29 trials meeting the 
inclusion criteria included data on 116,790 diabetic participants with 
approximately 518,611 patient years of follow-up. Of these, 21 trials reported 
myocardial infarction numbers, 22 trials reported stroke numbers, 21 trials 
reported cardiovascular death numbers and 28 reported total mortality numbers. 
Baseline demographic data, clinical history, laboratory results and event rates 
are presented for those trials reporting baseline cardiovascular disease in Table 
2.1 and for those trials reporting baseline proteinuria in Table 2.2. In 11 of the 
29 trials, I was also able to compare the original published power calculations to 
actual achieved event rates based on clinical primary endpoints (i.e. death 
and/or cardiovascular disease events). 
 
Predicted event rates are often overestimated in diabetes trials, leading to 
inaccurate power calculations 
 
Of the 11 trials in diabetic participants which included death and/or 
cardiovascular disease events in their original primary endpoint power 
calculations, only one trial achieved an event rate in excess of what was 
predicted in the control arm. Only four trials achieved an event rate >75% the 
anticipated rate in the control arm (Figure 2.2). It therefore appears that initial 
power calculations often underestimate the numbers of patients that a trial will 
require as achieved endpoint rates tend to be somewhat lower than expected. 
 
Baseline history of cardiovascular disease predicts very high event rates in 
diabetes whereas event rates are low with no history of cardiovascular disease  
 
For all-cause death, the presence of cardiovascular disease at baseline was 
associated with three-fold higher death rate (Figure 2.3.1) compared to trials 
with no baseline cardiovascular disease (weighted mean rates 28.9 vs. 10.0 
events/1000 patient years). 
For cardiovascular disease death, the presence of cardiovascular disease at 
baseline was also associated with much higher event rates than when absent, 
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namely five-fold higher (Figure 2.3.2) (16.7 vs. 3.6 events/1000 patient years). 
For myocardial infarction and stroke, baseline cardiovascular disease was again 
associated with significantly higher event rates (four-fold [23.1 vs. 5.2 
events/1000 patient years] and two-fold [12.1 vs. 5.4 events/1000 patient 
years], respectively) (Figure 2.3.3, 2.3.4). Summaries of event rates are 
provided in Table 2.3. Prevalence of proteinuria was low in trials of diabetic 
participants without baseline cardiovascular disease. 
 
Baseline proteinuria predicts considerably higher event rates in diabetes 
whereas event rates are low with no baseline proteinuria 
 
For all-cause death, baseline proteinuria was associated with a six-fold higher 
death rate than in its absence (Figure 2.3.1) (39.9 vs. 6.3 events/1000 patient 
years). 
For cardiovascular disease death, the presence of baseline proteinuria was 
associated with 16-fold higher event rates than when absent (Figure 2.3.2) (18.7 
vs. 1.2 events/1000 patient years).  
There were insufficient data to compare the associations of the presence or 
absence of baseline proteinuria on stroke and myocardial infarction rates. 
Summaries of event rates are provided in Table 2.3. Specific definitions of 
proteinuria used in the various trials are provided in Table 2.4. 
 
Observations from ‘Mixed’ trials 
 
Event rates in ‘Mixed’ trials (reflecting intermediate levels of baseline 
cardiovascular disease and proteinuria) fell between the rates found in the other 
trials where baseline cardiovascular disease or proteinuria were either exclusion 
or inclusion criteria. Event rates varied considerably, typically four fold (Figure 
2.3.1-4). 
 
The impact of event rates on power calculations 
 
Using combined total myocardial infarction plus stroke numbers as a theoretical 
composite primary endpoint, I calculated that trials with either baseline 
cardiovascular disease or proteinuria in all participants would have required in 
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the order of four-fold fewer participants than in the absence of these risk 
factors (Table 2.5).
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Table 2.1. Baseline characteristics of trials in diabetic participants which reported cardiovascular disease prevalence.  
 
 Study name Features Agent N 
Follow-
up (yrs) 
Age 
(yrs) 
BMI 
(kg/m2
) 
Any 
CVD 
(%) 
HT (%) 
Total / LDL-
cholesterol 
(mmol/L) 
HbA1c 
(%) 
Proteinuria 
(%) * 
MI/103 pt 
yrs (n) 
Stroke/10
3 pt yrs 
(n) 
CVD 
death/103 
pt yrs (n) 
Death/103 pt 
yrs (n) 
CARDS (34) CVD risk statin 2838 3.9 62 29 0 84 5.4/3.0 7.8 17 8.5 (94) † 5.4 (60) 5.6 (62) 12.9 (143) 
JPAD (35) No CVD aspirin 2539 4.4 65 24 0 58 5.2/- 7.1 18 2.3 (26) 5.4 (60) 1.2 (13) 6.5 (72) ABSENT 
PPP (36) CVD risk aspirin 1031 3.6 64 29 0 62 5.8/- 7.6 - 4 (15) 5.1 (19) 4.8 (18) 12.1 (45) 
INVEST (37) HT various 6400 2.7 66 31 100 100 -/- - - - (-) - (-) 20.3 (351) 42 (725) 
PERSUADE 
(38) 
CHD ACEi 1502 4.3 62 - 100 39 -/- - - 20.7 (134) 6.3 (41) 16.6 (107) 25.7 (166) 
TNT (39) CHD statin 1501 4.9 63 30 100 71 4.5/2.5 7.4 - 23.9 (176) § 17.3 (127) - (-) 21.1 (155) 
LIPID (40) CHD statin 1077 6 64 - 100 52 5.6/3.7 - - 35.7 (231) ‡ 13.5 (87) - (-) - (-) 
POPADAD 
(41) 
PAD aspirin 1276 6.7 60 29 100 - 5.5/3.1 8 - 17.0 (145) 10.2 (87) 9.1 (78) 22.8 (195) 
PROactive 
(42) 
HbA1c ≥6.5% glitazone 5238 2.9 62 31 100 76 4.8/2.9 7.8 44 - (-) 12.7 (193) 17.3 (263) 23.9 (363) 
PRESENT 
DAVID (43) 
PAD, DM 
>5yrs 
anti-platelet 1209 2 64 28 100 57 -/- - - 14.1 (34) 10.8 (26) 14.1 (34) 19.9 (48) 
FIELD (44) 
Various, no 
statin 
fibrate 9795 5 62 30 22 57 5.0/3.1 6.9 22 11.6 (568) ‡ 6.8 (333) 5.5 (267) 13.9 (679) 
ACCORD (45) 
HbA1c 
≥7.5%, CVD 
risk 
various 10251 3.5 62 32 35 85 4.7/2.7 8.1 - 12.6 (453) 4.1 (148) 6.4 (229) 12.8 (460) 
ADVANCE 
(46) 
Various 
ACEi/diuretic
; oral DM 
11140 5 66 28 32 75 -/3.1 7.5 31 11.6 (647) ‡ 8.7 (484) 9.7 (542) 18.5 (1031) 
ETDR (47) Retinopathy aspirin 3711 5.6 47 27 35 18 5.9/- 9.7 24 - (-) - (-) - (-) 34.0 (706) 
VADT (48) HbA1c ≥7.5% Oral DM 1791 5.6 60 31 40 72 4.7/2.8 9.4 51 14.2 (142) 6.4 (64) 7.3 (73) 19.6 (197) 
HOPE (49) CVD risk ACEi 3577 4.5 65 29 69 56 -/- - 32 25.7 (414) 11.4 (184) 17.6 (284) 27.6 (444) 
HPS (50;51) CVD risk statin 5963 4.8 62 29 51 40 5.7/3.2 7.0 || - - (-) 11.9 (342) 19.1 (546) 29 (830) 
LIFE (52) HT, LVH ARB or BB 1195 4.7 67 30 35 100 5.8/- - 11.5 16.2 (91) 20.7 (116) 17.6 (99) 29.7 (167) 
MIXED 
TRIALS 
ALLHAT (53) HT, CVD risk various 13101 4.9 67 31 36 100 -/- - - 22.3 (-)‡ 11.5 (-) - (-) 31.8 (-) 
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Footnote to Table 2.1 
*: refers to proteinuria prevalence using trial specific definition; †: only includes MIs that were first cardiovascular event in any specific patient; ‡: Non-fatal MI 
plus coronary heart disease death; §: as in ‡ plus resuscitated cardiac arrest; ||: taken from a subset of 1087 patients;  
Abbreviations: BMI: body mass index, SBP: systolic blood pressure, MI: myocardial infarction, CVD: cardiovascular disease, CHD: coronary heart disease, PAD: 
peripheral arterial disease, DM: diabetes mellitus, Oral DM: oral hypoglycaemic agent, HT: hypertension, ACEi: ACE inhibitor, ARB: angiotensin II receptor blocker, 
BB: Beta blocker, CCB: calcium channel blocker, LVH: left ventricular hypertrophy, normA: normoalbuminuria, microA: microalbuminuria 
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Table 2.2. Baseline characteristics of trials in diabetic participants which reported proteinuria prevalence 
 
 Study name Features Agent N 
Follow-
up (yrs) 
Age BMI 
Any 
CVD 
% 
HT % 
Total / LDL 
-cholesterol 
HbA1c 
(%) 
Proteinuria 
(%) * 
MI/103 pt 
yrs (n) 
Stroke/103 
pt yrs (n) 
CVD 
death/103 
pt yrs (n) 
Death/103 pt 
yrs (n) 
DIRECT (55) 
Retinopathy, 
normA 
ARB 1905 4.7 57 29 -  62 5.3/- 8.2 0 - (-) - (-) - (-) 8 (72) 
ABSENT 
BENEDICT 
(56) 
HT, normA ACEi, CCB 1204 3.6 62 29 -  100 5.4/4.2 5.8 0 - (-) - (-) 1.2 (5) 2.8 (12) 
DIABHYCAR 
(57) 
microA, 
proteinuria 
ACEi 4912 4 65 29 25 56 -/- 7.8 100 7.1 (139) 11.9 (234) 18.0 (354) 33.5 (658) 
IDNT (58;59) 
Proteinuria, 
HT 
ARB, CCB 1590 3 59 31 29 100 -/- 8.2 100 25.8 (123) 14.5 (69) 21.4 (102) 43.4 (207) 
 
PRESENT 
RENAAL (60) Nephropathy ARB 1513 3.4 60 30 -  93 5.9/3.7 8.5 100 22.9 (118) - (-) - (-) 60.9 (313) 
ADOPT 
(61;62) 
New DM oral DM agent  4360 4 56 32 -  51 5.3/3.1 7.4 16 3.9 (68) 3 (52) - (-) 5.5 (96) 
FIELD (44) 
Various, no 
statin 
fibrate 9795 5 62 30 22 57 5.0/3.1 6.9 22 
11.6 (568) 
† 
6.8 (333) 5.5 (267) 13.9 (679) 
RECORD (11) HbA1c 7-9% glitazone 4447 5.5 58 32 - 80 -/- 7.9 19 4.9 (120) 4.5 (109) 5.4 (131) 12 (293) 
ADVANCE (46) Various 
ACEi/diuretic; 
oral DM agent 
11140 5 66 28 32 75 -/- 7.5 31 
11.6 (647) 
† 
8.7 (484) 9.7 (542) 18.5 (1031) 
ETDR (47) Retinopathy aspirin 3711 5.6 47 27 35 18 5.9/- 9.7 24 - (-) - (-) - (-) 34 (706) 
UKPDS 
(63;64) 
New DM various 3867 10 53 28 -   -  5.4/3.5 7.1 1.9 - (-) - (-) - (-) 18.2 (702) 
VADT (48) HbA1c ≥7.5% Oral DM agent 1791 5.6 60 31 40 72 4.7/2.8 9.4 51 14.2 (142) 6.4 (64) 7.3 (73) 19.6 (197) 
INSIGHT (65) HT CCB, diuretic 1302 3.5 66 -  - 100 -/- -  6.4 - (-) 7.9 (36) 8.3 (38) 22.7 (103) 
HOPE (49) CVD risk ACEi 3577 4.5 65 29 69 56 -/- - 32 25.7 (414) 11.4 (184) 17.6 (284) 27.6 (444) 
LIFE (52) HT, LVH ARB or BB 1195 4.7 67 30 35 100 5.8/- -  11.5 16.2 (91) 20.7 (116) 17.6 (99) 29.7 (167) 
MIXED 
TRIALS 
CHARISMA 
(66) 
CVD risk clopidogrel 6555 2.3 - - - - -/- - 31 12.9 (194) - (-) 16.2 (244) 24.3 (366) 
 
*: refers to proteinuria prevalence using trial specific definition; †: Non-fatal myocardial infarction plus coronary heart disease death 
Abbreviations: See Table 2.1
Table 2.3. Summary of event rates in diabetic trial participants stratified by the absence or presence of baseline cardiovascular disease 
and proteinuria 
 
 All-cause death CVD death MI Stroke 
Event rates (events/1000 pt years) in trials stratified by baseline CVD prevalence 
No CVD  Weighted mean event rate (SD) 10.0 (3.7) 3.6 (2.6) 5.2 (3.5) 5.4 (0.2) 
Mixed trials Weighted mean event rate (SD) 22.6 (9.5) 10.2 (5.5) 15.6 (7.0) 9.0 (3.9) 
All CVD Weighted mean event rate (SD) 28.9 (9.6) 16.7 (4.3) 23.1 (7.9) 12.1 (3.5) 
Event rates (events/1000 pt years) in trials stratified by baseline proteinuria prevalence 
No proteinuria Weighted mean event rate (SD) 6.3 (3.4) 1.2 (-) - (-) - (-) 
Mixed trials Weighted mean event rate (SD) 18.6 (7.4) 9.3 (4.6) 11.6 (5.7) 7.5 (3.5) 
All proteinuria Weighted mean event rate (SD) 39.9 (12.7) 18.7 (1.8) 12.9 (10.0) 12.4 (1.4) 
 
Abbreviations: CVD: cardiovascular disease; MI: myocardial infarction; SD: weighted standard deviation 
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Table 2.4. Definitions of proteinuria in trials as measured at baseline 
 
Study Urine parameter 
tested 
Definition of abnormality 
Diabetes Trials 
CARDS (34) Albumin Positive Micral test OR urine albumin/creatinine ratio ≥2.5mg/mmol OR urine albumin excretion ≥20ug/min 
JPAD (35) Protein Urine protein ≥15mg/dL 
PROactive (42) Albumin Positive Micral test 
BENEDICT (56) Albumin Urine albumin ≥20ug/min 
DIRECT (55) Albumin Urine albumin ≥20ug/min 
DIABHYCAR (57) Albumin and protein 
Microalbuminuria: Urine albumin 20-200 mg/L 
Proteinuria: ≥200ug/L 
IDNT (58;59) Protein ≥900mg/d 
RENAAL (60) Albumin Urine albumin creatinine ratio ≥300mg/g 
ADOPT (61) Albumin Urine albumin creatinine ratio ≥3.4mg/mmol 
FIELD (44) Albumin 
Microalbuminuria: urine albumin creatinine ratio 3.5-35mg/mmol 
Macroalbuminuria: urine albumin creatinine ratio >35mg/mmol 
RECORD (11) Albumin Urine albumin creatinine ratio >2.5mg/mmol in men, >3.5mg/mmol in women 
ADVANCE (46) Albumin 
Microalbuminuria: urine albumin creatinine ratio 30-300ug/mg 
Macroalbuminuria: urine albumin creatinine ratio >300ug/mg 
VADT (48) - Not stated 
ETDR (47) Protein Worse than ‘none/trace’ on urine dipstick 
Other Trials (patients with and without diabetes) 
INSIGHT (65) Protein Urine protein ≥0.5g/d 
HOPE (49) Albumin Urine albumin creatinine ratio ≥2mg/mmol 
LIFE (52) Albumin Urine albumin creatinine ratio ≥33.9mg/mmol (≥300mg/g) 
CHARISMA (66) Albumin Urine albumin ≥30ug/mL 
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Table 2.5. Power calculations: how participant numbers are affected by baseline history of cardiovascular disease or proteinuria 
 
 MI plus stroke 
(events/1000 pt 
years) 
Participants required
*
 
Trials stratified by baseline CVD prevalence   
No CVD 10.6 16985 
Some CVD 24.6 6828 
All CVD 35.2 4513 
Trials stratified by baseline proteinuria prevalence 
  
No proteinuria 6.5
†
 28243
† 
 
Some proteinuria 19.1 9043 
All proteinuria 25.3 6616 
 
*: Assumptions for power calculations: (1) Primary endpoint is for total number of myocardial infarctions plus total number of strokes combined, with 90% power, 
alpha 0.05 and 5 year trial duration, assuming a 20% reduction in events in the active arm compared to the control arm; (2) each patient does not suffer more than 
one cardiovascular event 
†: Combined event rate for trials with no baseline proteinuria estimated using correlation between death and total myocardial infarction and stroke combined 
across all trials 
MI: myocardial infarction; CVD: cardiovascular disease 
 
Figure 2.1. Flow diagram summarising the literature search to identify rates of 
mortality and cardiovascular endpoints in diabetic participants from large 
randomised controlled trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medline search from 01/01/1998 
– 1/6/2010 using terms specified 
in Methods 
29 randomized controlled trials 
identified from the remaining 
159 manuscripts 
505 full text 
articles selected 
5253 manuscripts immediately excluded for 
reasons including surrogate marker as primary 
endpoint, intervention of non-medicinal 
intervention or unrelated medication, 
completely irrelevant article or not a trial 
(most had ≥1 reason for exclusion) 
5758 manuscripts 
identified 
346 manuscripts excluded:  
• 145: <1000 patients with diabetes and/or 
<1 year follow-up 
• 75: trials in high risk groups (heart failure, 
dialysis, arrhythmia, cardiovascular event 
within 3 months) 
• 35: trials with no diabetic participants 
• 35: only baseline data available 
• 4: long-term follow-up data from existing 
trials 
• 32: trials where event rates were not 
calculable 
• 20: baseline CVD and proteinuria 
prevalence not reported or calculable 
Figure 2.2. A comparison of anticipated and achieved primary endpoint event rates in the control arms of endpoint trials in diabetes 
 
 
Footnote: Anticipated event rate in FIELD based on predicted 500 deaths in 8000 participants over 5 years (primary outcome measure was changed during the trial 
due to low event rate) 
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Figure 2.3. All-cause death (2.3.1), cardiovascular disease death (2.3.2), myocardial infarction (fatal and non-fatal) (2.3.3) and stroke 
(fatal and non-fatal) rates (2.3.4) in clinical trials of diabetic participants stratified by baseline prevalence of (i) history of 
cardiovascular disease, and (ii) proteinuria 
Figure 2.3.1 
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Figure 2.3.2 
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Figure 2.3.3 
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Figure 2.3.4 
 
 
Footnote: dots represent individual trial event rates and are weighted according to trial participant numbers; diamonds represent weighted mean event rates 
CVD: cardiovascular disease
2.4 Discussion 
 
This analysis of mortality and cardiovascular event rates in diabetic participants 
in large clinical trials reveals three key messages. First, history of either 
cardiovascular disease or evidence of proteinuria at baseline in patients with 
diabetes is associated with substantially higher rates of death and cardiovascular 
disease events in trials compared to those with predominantly uncomplicated 
diabetes.  
 
Second, event rates in patients with diabetes without cardiovascular disease or 
proteinuria are particularly low in absolute terms with significant implications 
for trial design in terms of required participant numbers. The mortality rates in 
the five trials which included participants with diabetes without a history of 
either cardiovascular disease or proteinuria, with a mean age of 57-65 years (34-
36;55;56), ranged from only 3 to 13 deaths per 1000 patient years of follow-up. 
To place this in context, data from the Centers for Disease Control’s National 
Center for Health Statistics show mortality rates in the general United States 
population of 9.3/1000 pt years for individuals in the age group 55-64 and 
22.4/1000 pt years for subjects in age group 65-74 between 2002 and 2004. It is 
apparent that trials in diabetic participants with a low prevalence of 
cardiovascular disease and proteinuria will generate few endpoints and 
consequently either require huge participant numbers to achieve adequately 
powered results, or otherwise potentially lead to under-powered results. This is 
strongly at odds with the design of many clinical trials where the presence of 
uncomplicated diabetes is often assumed to carry a cardiovascular disease risk 
equivalent to non-diabetic subjects with underlying cardiovascular disease, 
probably based on existing cohort studies (30) though other larger studies have 
challenged this assumption (69).  
 
Third, it is apparent that prediction of event rates in diabetes populations with 
heterogeneous combinations of risk factors is difficult, as evidenced by the 
regular overestimation of anticipated events in trial power calculations. It 
appears that if trial designers do not have information regarding the likely 
prevalence of baseline cardiovascular disease and proteinuria in their trial 
population, anticipated event rates will be difficult to predict accurately with 
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any degree of certainty. The consequences of the above observations for clinical 
trial design are significant. The symmetry between rates of mortality and 
cardiovascular disease endpoints for proteinuria and cardiovascular disease 
categories is also of interest.  
 
Published FDA guidance (29) now states that for new diabetes medications 
‘concerns about cardiovascular risk should be more thoroughly addressed during 
drug development’. The guidance document highlights the need to conduct trials 
which obtain sufficient endpoints. However, apart from simply suggesting that 
patients with ‘relatively advanced disease, elderly patients and patients with 
some degree of renal impairment’ should be included in trials, no specific 
definitions of such patients are provided and the likely impact of including such 
patients in trials on event rates is not considered. The data presented here are 
therefore intended to guide those designing trials in diabetic populations, both 
for drug development and also for other pharmaceutical trials conducted in 
diabetic patients.  
 
It is of course well established that microalbuminuria and history of 
cardiovascular disease are powerful risk factors for death and vascular events in 
diabetes (31-33), as again highlighted here. What is striking, however, is the 
substantial difference in event rates observed between trial populations with or 
predominantly without these risk factors and this difference is greater than 
expected based on existing cohort study data. One possibility which may 
partially explain these findings is the ‘healthy participant effect’ where trial 
volunteers represent a healthier cohort than may be expected in the general 
population. Whatever the explanation, it is apparent that simple extrapolation 
from cohort studies to predict event rates and calculate study power is 
problematic. It should be recognised that earlier trials in diabetes had far less 
access to large datasets on which to base their power calculations than is the 
case now. Also, the introduction of effective cardiovascular risk reducing agents 
such as statins has led to a significant reduction in cardiovascular morbidity in 
diabetes. Nonetheless, it appears that the majority of trials have based their 
power calculations on cohort studies, rather than previous trials. It may 
therefore be advisable to base power calculations on data from existing trials, as 
presented herein. 
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The potential for benefit from a pharmaceutical agent is also an important 
consideration when deciding on an appropriate trial population. As argued by 
Goldfine (28), those with advanced disease at high risk constitute an appropriate 
population if the likelihood of benefit is reasonable and the risk of harm low. 
However, these same individuals may also be at higher risk of and less able to 
tolerate adverse events. Careful consideration of preclinical data and 
mechanism of action are therefore warranted. Furthermore, evidence of benefit 
for an intervention in a specified group (e.g. patients with established coronary 
disease or microalbuminuria) may not necessarily be generalisable to all with 
diabetes and may require potentially narrower drug approval indications for 
therapies where benefit is sought. This is less likely to be an issue with newly 
developed glucose lowering agents where evidence of non-inferiority will often 
be the goal of a trial. Clearly, limiting trial inclusion criteria to only certain 
groups of patients will also reduce the numbers eligible to participate which 
itself may lengthen the recruitment period and increase the cost of screening. 
 
The data presented in this chapter have strengths and weaknesses which should 
be highlighted. Firstly, clinical endpoints were adjudicated due to the nature of 
clinical trials, a major advantage over many cohort studies. Follow-up in some of 
the studies assumed the same follow-up for diabetic participants as in the total 
cohort (i.e. trials with diabetic and non-diabetic participants) but this was not 
explicitly stated in all cases. Furthermore, in five studies (39;40;44;46;53) I used 
data for non-fatal myocardial infarction combined with coronary heart disease 
death, rather than fatal myocardial infarction, to substitute for total myocardial 
infarction. Therefore, true myocardial infarction numbers will be lower than the 
numbers presented though the difference is likely to be small. Without 
availability of individual participant data, I could not properly address the 
association of baseline lipids, smoking, hypertension and indeed disease duration 
on event risks though body mass index (BMI) and age were generally comparable 
across trials. However, of these factors, only hypertension tends to be used as a 
specific inclusion criterion in trials and examination of trial event rates suggests 
that using a threshold blood pressure value as inclusion criteria would have a 
limited effect on accrued clinical events. Furthermore, while individual 
participant data can provide insights into risks associated with biomarkers under 
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specified conditions, it carries less advantages over summary data (as used here) 
when examining trial inclusion criteria which, by necessity, tend to be simple 
and few in number. Calculated event rates provided crude estimates only; in 
specific trials, true event rates may have been slightly different due to loss of 
patients to follow-up, and trials did not report all four specified endpoints with 
the effect that I used different numbers of trials and patients to calculate event 
rates. Furthermore, as discussed above, definitions of microalbuminuria and 
proteinuria varied between trials.  
 
This summary and synthesis of event rates from existing data is intended to help 
inform the design of future cardiovascular disease trials in patients with 
diabetes. For evaluation of drug safety or efficacy, better selection of trial 
subjects will be economical in terms of limiting drug exposure and financial 
outlay, and potentially testing new therapies on those most likely to derive 
benefit. It is hoped that this analysis may aid sponsors and investigators wishing 
to comply with the FDA guidance. 
 
These data were published in the American Heart Journal in 2011 (70).  
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Chapter 3. 
 
Fasting plasma glucose in non-diabetic participants and the risk for incident 
cardiovascular events, diabetes, and mortality: results from the West of 
Scotland Coronary Prevention Study 
 
3.1 Introduction 
 
It is already conclusively established that diabetes mellitus is an independent 
risk factor for the development of cardiovascular events and death (71). Any 
relationship between fasting glucose levels in the non-diabetic range 
(<7.0mmol/L) and future cardiovascular disease has remained much debated. 
Some reports have claimed that elevated fasting plasma glucose (FPG) in the 
non-diabetic range is indeed associated with higher risk of cardiovascular disease 
while other reports have found more complex relationships. However, the 
quality of these data has often been variable. Methodological weaknesses of 
certain studies and meta-analyses have been (i) the inclusion of older studies 
with patients whose FPG levels would now be considered diagnostic of diabetes, 
(ii) that many studies have yielded few endpoints, and (iii) that statistical 
analysis has often failed to adjust for well established cardiovascular risk 
factors.  
 
In a 2004 meta-analysis of 14 studies by Levitan et al (72), investigators reported 
a risk ratio of 1.27 for cardiovascular events when comparing the highest FPG 
category to the lowest in participants without diabetes. Further inspection of 
included studies reveals that seven of the 14 studies included patients with FPG 
≥7.0mmol/L and only three of the remaining seven found any significant 
association between higher FPG and cardiovascular events. Other evidence has 
suggested that their may be a J-shaped relationship between FPG and coronary 
heart disease, with higher cardiovascular risk at both lower and higher FPG 
levels. Important studies include the Australian Diabetes, Obesity and Lifestyle 
study (AusDiab) (73) and the Diabetes Epidemiology - Collaborative analysis of 
Diagnostic criteria in Europe (DECODE) study (74) (see Figure 3.1). In addition, 
the meta-analysis of Levitan suggested a threshold effect with lowest 
cardiovascular risk at a FPG of 5.6mmol/L, though it should again be highlighted 
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that this analysis includes some patients who, by current criteria, would now be 
classified as having diabetes at baseline (see Figure 3.2); the possibility of a J-
shaped relationship also suggests that reporting continuous associations between 
glucose and cardiovascular disease may be statistically erroneous. Two more 
recent data sets have found no relationship between non-diabetic FPG and 
cardiovascular disease, namely a study in Korean men (75) and another in British 
women (76).  
 
Similar analyses have been conducted to evaluate any potential relationship 
between glycaemia and cardiovascular disease by comparing event rates in those 
with impaired fasting glycaemia (IFG) (FPG 6.1-6.9mmol/L) to those with 
normoglycaemia. A weak association was observed in a study of a Chinese cohort 
(77); furthermore, in the DECODE study, IFG was associated with a higher rate of 
all-cause death in men than in other non-diabetic men (hazard ratio [HR] 1.21) 
in age-adjusted analyses but there was no such relationship in women (12). 
 
In an attempt to clarify the conflicting literature, I investigated the relationship 
between FPG and the risk of incident cardiovascular events, all-cause death and 
also the development of diabetes using an existing database from a large statin 
trial. 
 
Figure 3.1. Unadjusted all-cause and cardiovascular mortality rates (95% CI) for fasting plasma glucose in individuals without previously 
diagnosed diabetes in the AusDiab study 
 
 
 
Footnote 1: Y axis in log scale 
Footnote 2: Figure taken from Barr et al (73) and reproduced with the permission of Springer © 
FPG: fasting plasma glucose; CVD: cardiovascular disease
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Figure 3.2. Dose-response relationship of cardiovascular disease with fasting and post-challenge blood glucose levels  
 
Note that for studies with FPG below the diabetes threshold (<7mmol/L), cardiovascular risk is not clearly elevated, unlike for studies with FPG above the 
threshold 
Taken from Levitan et al (72), copyright © 2004, American Medical Association; all rights reserved
3.2 Methods 
 
Aims 
 
The aim of this analysis was to investigate the relationships between FPG 
concentrations in the non-diabetic and diabetic range and both the occurrence 
of incident cardiovascular events and new-onset diabetes. This was achieved 
using the West of Scotland Coronary Prevention Study (WOSCOPS) database, 
details of which are provided below. 
 
Background 
 
WOSCOPS was the second large trial investigating the effect of statin therapy on 
cardiovascular endpoints to be published (14;15). WOSCOPS was designed to 
investigate the effect of pravastatin therapy, compared to placebo, on the 
composite endpoint of non-fatal myocardial infarction and coronary heart 
disease death. In the WOSCOPS analyses published to date, participants treated 
with pravastatin were at significantly lower risk of coronary events (14); 
furthermore, post trial follow-up for 15 years using computerised data 
demonstrated that patients treated with pravastatin in the original trial 
continued to be at lower risk of coronary events, in keeping with a ‘legacy 
effect’ of statin therapy (15). 
 
Patients  
 
In WOSCOPS, 6595 moderately hypercholesterolaemic men (serum low density 
lipoprotein [LDL]-cholesterol 4.5–6.0 mmol/L and triglycerides <6.0 mmol/L) 
with no history of myocardial infarction were randomised to pravastatin 40 mg 
daily or placebo and followed initially for an average of 4.9 years, with an 
additional follow-up to 15 years using linkage of computerised data held by 
National Health Service (NHS) Scotland, a technique previously shown to 
demonstrate good agreement with event adjudification by end-point committee 
(78). All subjects provided written informed consent for the original trial, and 
ethical approval was obtained for the trial (prior to the current requirement for 
online registration in a trial database). Men attended the screening clinic 
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(before randomisation to pravastatin or placebo) fasted and had blood samples 
taken for various analyses including plasma glucose. FPG measurements were 
carried out in quality-controlled NHS routine laboratories, and subsequent FPG 
measurements were made throughout the study every six months. A range of 
other physical and biochemical cardiovascular risk factors and other 
demographic variables was assessed and recorded at baseline. 
 
Diagnoses of events 
 
Specific diseases and events examined in the current analysis were as follows: 
 
Diabetes mellitus. Baseline diabetes: Baseline diabetes was defined as either 
patients with FPG ≥7.0mmol/L or prior history of diabetes.  
New-onset diabetes: Incident diabetes after baseline was defined as (i) two 
subsequent FPG measurements ≥7.0 mmol/L or (ii) commencement of 
hypoglycaemic agents during the study. Information regarding the development 
of diabetes was limited to the five years of the original trial and not to 
subsequent long-term (fifteen year) follow-up as was available for recording of 
cardiovascular events. 
 
Cardiovascular endpoints and all-cause mortality. Follow-up of clinical 
cardiovascular events and mortality was based on linkage of records held by NHS 
Scotland and was conducted by Professor Ian Ford (Robertson Centre for 
Biostatistics, University of Glasgow). Using this method, follow-up data were 
available up to fifteen years for cardiovascular events and mortality. Personal 
identifiers for study participants were electronically linked to hospital discharge 
records (Scottish Morbidity Record 01) and General Register Office death records 
(held by the Information and Statistical Division [ISD] of NHS Scotland) by means 
of established record-linkage methods. Data on outcome events were extracted 
from the databases with the use of appropriate ‘International Classification of 
Diseases’ [ICD] codes (versions 9 and 10 – see definitions below). Approval for 
record linkage was given by the Privacy Advisory Committee at ISD, NHS 
Scotland.  
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Cardiovascular events were defined as:  
1. Cardiovascular events: a composite of non-fatal cardiovascular events and 
fatal cardiovascular events (ICD 10: I00–I99); 
2. Coronary events: a composite of non-fatal coronary events and coronary 
death (ICD 10: I20–I25 [ischaemic heart disease]); 
3. stroke: a composite of non-fatal and fatal stroke (ICD 10: I60–I69 
[cerebrovascular diseases]); 
4. Coronary heart disease death; 
5. All-cause mortality  
 
Statistics 
  
To examine the potential relationships between non-diabetic FPG and future 
cardiovascular events, coronary heart disease death, all-cause death, and new-
onset diabetes, FPG for participants with no history or biochemical evidence of 
diabetes at baseline was divided into fifths (quintile 1 [Q1]–Q5), thereby 
allowing comparison of time to first event of interest by Cox proportional hazard 
models. Q2 was selected as referent based on previous analyses suggesting a 
possible J-shaped relationship between FPG and cardiovascular disease mortality 
(73;74). However, sensitivity analyses using Q1 as a referent were also 
performed. The HRs were adjusted for treatment and age in a minimally 
adjusted model and additionally for the following baseline covariates 
[treatment, age, cholesterol (high density lipoprotein [HDL]- and LDL-
cholesterol), triglycerides, BMI, smoking status (current and ex-smoker), blood 
pressure (systolic and diastolic), hypertension, use of nitrate therapy, history of 
angina, social deprivation score (as analysed by deprivation category [DEPCAT], 
based on home post code), use of specific medications at baseline (aspirin, 
angiotensin converting enzyme [ACE]-inhibitors, β-blockers, calcium channel 
blockers, diuretics, other antihypertensive agents)] in a fully adjusted model to 
better evaluate the importance of FPG for predicting future outcomes. Given 
the possible weighting of events by FPG close to the diabetes threshold (~7.0 
mmol/L), the uppermost FPG quintile was further divided into fifths (Q5a–Q5e) 
for more detailed analysis. Analyses were also conducted for each treatment 
group (placebo and pravastatin) separately in further sensitivity analyses. 
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Cardiovascular disease risk was also assessed in those with baseline IFG using 
two definitions: (i) the National Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATPIII) (defined as FPG 6.1–6.9 mmol/L) (79), and (ii) the 
American Diabetes Association (ADA) definition (FPG 5.6–6.9 mmol/L) (80). 
Finally, cardiovascular event risk was studied in those with diabetes at baseline 
and in those who had developed diabetes during the 5 years of the original 
WOSCOPS trial over the subsequent ten years of follow-up.  
 
Results are reported as number (percentage) of patients with events, HRs (95% 
confidence interval [CI]), and corresponding p values; p values were two-sided 
and p<0.05 was considered statistically significant. The validity of the 
proportional hazards assumption was assessed by testing the significance of 
interaction between glucose and the logarithm of time as a time-dependent 
covariate. All analyses were carried out using the statistical software SAS 
(version 9.1, SAS Institute, Cary, NC, USA).  
 
Note 
 
Professor Ian Ford and colleagues from the WOSCOPS steering committee 
provided access to the WOSCOPS database and Professor Ford was responsible 
for setting up the method for long-term follow-up of patients after WOSCOPS 
i.e. linkage of records held by NHS Scotland.  
3.3 Results 
 
Baseline characteristics of the cohort 
 
Data were available for 6447 WOSCOPS participants with no history of diabetes 
at baseline and with FPG <7.0mmol/L. Baseline characteristics, split according 
to quintiles of baseline FPG, are provided in Table 3.1. The glucose cut-offs 
employed were ≤4.3mmol/L (Q1, n=1448), >4.3-4.6mmol/L (Q2, the referent, 
n=1657), >4.6-4.8mmol/L (Q3, n=1150), >4.8-5.1mmol/L (Q4, n=1116) and >5.1-
6.9mmol/L (Q5, n=1076). The following continuous variables displayed small 
though statistically significant and apparently adverse changes across quintiles 
of higher FPG as analysed by ANOVA (unadjusted analyses): higher age, higher 
BMI, higher systolic blood pressure, higher diastolic blood pressure, higher total 
cholesterol and higher triglycerides. There was no difference in either LDL- or 
HDL-cholesterol across quintiles. With regard to categorical variables, the 
following variables were significantly different across increasing fasting glucose 
quintiles: there were fewer smokers, more patients with angina and 
hypertension, and more patients on nitrates. As described in the Methods, Q5 
was also split into five subgroups, Q5a-Q5e for additional comparisons with Q2, 
the referent. Glucose cut-offs for these analyses were >5.1-5.2mmol/L (Q5a, 
n=223), >5.2-5.4mmol/L (Q5b, n=354), >5.4-5.5mmol/L (Q5c, n=95), >5.5-
5.8mmol/L (Q5d, n=226) and >5.8-6.9mmol/L (Q5e, n=178). 
 
Cardiovascular events and all-cause mortality over 15 years and diabetes over 5 
years 
 
Over fifteen years of follow-up, the numbers of cardiovascular and mortality 
events in the entire cohort (n=6447) were as follows:  
o 2381 cardiovascular events 
o 1474 coronary events 
o 405 strokes 
o 361 coronary heart disease deaths 
o 1244 all-cause deaths 
Over five years, there were 168 cases of new-onset diabetes in the cohort. 
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Risk of cardiovascular events and mortality according to glycaemic categories 
 
Comparing risk of cardiovascular events and all-cause mortality across fifths of 
non-diabetic FPG by HR relative to Q2, none of the other quintiles (Q1, Q3-Q5) 
were at significantly increased or decreased risk of these events in age and 
treatment adjusted analyses (Model 1) (Table 3.2). In this minimally adjusted 
model, the HRs for cardiovascular events in Q1, Q3, Q4 and Q5 compared to Q2 
were 1.05 (95% CI 0.94-1.19), 1.04 (95% CI 0.91-1.17), 1.06 (0.93-1.20) and 1.04 
(0.92-1.18) respectively. HRs for all-cause mortality in Q1, Q3, Q4 and Q5 in the 
minimally adjusted model were 1.10 (0.94-1.30), 0.93 (0.78-1.11), 1.12 (0.94-
1.32) and 1.05 (0.88-1.25) respectively. These findings were consistent after 
additionally adjusting for a range of diabetes and cardiovascular risk factors and 
potential confounders (Model 2), namely BMI, smoking, blood pressure, 
hypertension, cholesterol (HDL & LDL), triglycerides, use of nitrates, history of 
angina, social deprivation score (estimated from post code by DEPCAT) and 
various medications (aspirin, ACE-inhibitors, B-blockers, calcium channel 
blockers, diuretics). Most HRs were also somewhat attenuated in the fully 
adjusted model. The HRs for cardiovascular events in Q1, Q3, Q4 and Q5 
compared to Q2 were 1.05 (0.94-1.19), 1.04 (0.91-1.17), 1.06 (0.93-1.20) and 
1.04 (0.92-1.18) respectively for Model 2. Furthermore in model 2, HRs for all-
cause mortality were 1.07 (0.90-1.25), 0.90 (0.75-1.07), 1.05 (0.88-1.24) and 
0.96 (0.80-1.15). 
 
Similarly, there was little evidence of higher risk of events in the five subgroups 
of Q5 (Table 3.3). In the minimally adjusted model, the HRs for cardiovascular 
events in Q5a, Q5b, Q5c, Q5d and Q5e compared to Q2 were 1.16 (0.93-1.44), 
0.96 (0.79-1.16), 1.31 (0.96-1.80), 0.98 (0.78-1.25) and 1.21 (0.95-1.54) 
respectively. HRs for all-cause mortality in Q5a, Q5b, Q5c, Q5d and Q5e in the 
minimally adjusted model were 0.97 (0.70-1.34), 0.85 (0.65-1.13), 1.53 (1.02-
2.30), 1.18 (0.87-1.60) and 1.25 (0.91-1.72) respectively. All-cause mortality in 
Q5c yielded the only statistically significant finding, quite likely a chance finding 
given the number of analyses conducted. Results were again attenuated after 
adjustment for potential confounders. The HRs for cardiovascular events in Q5a, 
Q5b, Q5c, Q5d and Q5e compared to Q2 were 1.01 (0.81-1.27), 0.86 (0.71-1.05), 
1.10 (0.80-1.51), 0.87 (0.69-1.11) and 1.05 (0.82-1.35) respectively for Model 2. 
 66 
Furthermore in model 2, HRs for all-cause mortality in these subgroups were 
0.86 (0.62-1.19), 0.79 (0.60-1.04), 1.24 (0.82-1.87), 1.12 (0.82-1.52) and 1.11 
(0.80-1.54). 
 
All of these findings were consistently non-significant when Q1 was used as the 
referent (data not shown). Analysing risk of events using FPG as a continuous 
variable in fully adjusted models, HRs per 1mmol/L higher glucose for 
cardiovascular events (HR 0.95 [95%CI 0.88-1.04]), coronary events (HR 0.93 
[95%CI 0.84-1.04]), strokes (HR 1.01 [95%CI 0.83-1.22] and coronary heart 
disease death (HR 0.90 [95%CI 0.73-1.11]) were also not found to be significant. 
However, as argued in the Methods section, analysis of glucose in a continuous 
fashion implies that risk is linear, an assumption which is unproven and 
unsupported by these findings. 
 
Risk of cardiovascular events and mortality in participants with IFG 
 
The risk of cardiovascular events and all-cause mortality was estimated in those 
who met two different criteria for IFG, namely that of NCEP ATPIII (defined as 
FPG 6.1-6.9mmol/L) and the ADA (defined as FPG 5.6-6.9mmol/L) (Table 3.4).  
 
o NCEP ATP III definition: the risk of all cardiovascular events was non-
significantly elevated in those with IFG relative to those with lower FPG in 
the minimally adjusted Model 1. In the fully adjusted Model 2, all HRs 
were further attenuated towards 1.0. The HRs for cardiovascular disease 
and all-cause mortality in IFG were 1.14 (0.83-1.55) and 1.02 (0.66-1.60) 
respectively compared to non-diabetic participants without IFG (Model 2). 
 
o ADA criteria: as with the NCEP ATP III criteria for IFG, HRs for clinical 
events were not significantly elevated compared to those with lower 
glucose values in either Model 1 or Model 2 though the point estimates 
were generally slightly lower for ADA criteria than NCEP ATP III. Event 
numbers were relatively low for stroke and coronary heart disease death 
for both sets of IFG criteria. The HRs for cardiovascular disease and all-
cause mortality in IFG were 0.95 (0.78-1.15) and 1.01 (0.79-1.31) 
respectively compared to non-diabetic participants without IFG (Model 2). 
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Risk of cardiovascular events and mortality in participants with diabetes at 
baseline 
 
In contrast with the above results which showed no significant elevation in the 
risk of cardiovascular events with increasing glucose in the non-diabetic range, 
risks of cardiovascular events (HR 1.32 [1.05-1.66], coronary events (HR 1.46 
[1.10-1.92]) and all-cause mortality (HR 1.37 [1.02-1.83]) were significantly 
increased in Model 2 (fully adjusted model) in the 148 participants with diabetes 
at baseline compared to all subjects without diabetes at baseline. This provides 
external confidence in the findings from analyses in the WOSCOPS cohort. Those 
with diabetes at baseline had non-significantly elevated rates of coronary death 
(HR 1.47 [0.88-2.45]) though event numbers were lower for this analysis. 
 
Risk of cardiovascular events and mortality in those who developed diabetes 
during the original WOSCOPS 5 year trial 
 
Risks of cardiovascular events, coronary events and all-cause mortality were 
calculated from the end of the trial (at 5 years) over the subsequent 10 years in 
the 138 WOSCOPS participants who had developed diabetes but not suffered any 
coronary or cardiovascular events during the original trial (it should be noted 
that these are 138 patients from a total of 168 who developed diabetes during 
WOSCOPS; thirty were excluded from this analysis having suffered clinical events 
over the 5 years of the WOSCOPS trial – this step was necessary to avoid 
statistical complications). Risk of cardiovascular events (HR 1.29 [0.98-1.69]), 
coronary events (HR 1.36 [0.97-1.92]), stroke (HR 1.24 [0.67-2.29]), coronary 
heart disease death (HR 1.57 [0.82-3.00]) and all-cause mortality (HR 1.05 [0.71-
1.56]) were non-significantly increased in these subjects. 
 
The impact of randomisation to pravastatin or placebo on any relationship 
between glucose and cardiovascular events 
 
There was no significant difference in the association of FPG with risk of 
endpoints by pravastatin/placebo randomisation, this despite the known effects 
of statin therapy on cardiovascular risk. P values for any interaction between 
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statin and placebo treated participants were as follows: all cardiovascular 
events, p=0.29; coronary events, p=0.75; strokes, p=0.99; coronary heart disease 
deaths, p=0.72; and all-cause mortality, p=0.69. There were only three specific 
statistically significant differences between the results for statin- and placebo-
treated participants: Q3 yielded a borderline higher risk for cardiovascular 
events on placebo (HR 1.19 [1.00-1.14]), Q5a showed higher risk for 
cardiovascular events on placebo (HR 1.40 [1.03-1.89]) and Q5c showed higher 
risk of death on placebo (HR 1.93 [1.13-3.27]). Importantly, given the 
consistency of findings in the treatment arms, it was statistically defendable to 
combine the participants regardless of statin or placebo allocation (treatment is 
included in all adjustment models). For completeness, all results separated by 
treatment allocation are provided (Tables 3.5 and 3.6). 
 
Risk of developing diabetes in those without diabetes at baseline 
 
There were 168 cases of new-onset diabetes over the 5 years of the original 
WOSCOPS trial. The risk of new-onset diabetes over 5 years was estimated by 
quintiles of baseline FPG, the same as employed for the cardiovascular endpoint 
analyses. Risk of new-onset diabetes over the 5 years was compared with risk of 
cardiovascular events over 15 years across the glucose quintiles. As already 
described, higher FPG levels in the non-diabetic range were not associated with 
increased risk of cardiovascular events over 15 years. In contrast, there was a 
marked increase in the risk of developing diabetes in Q5 in Model 1 (age and 
treatment adjusted model) (HR 26.5 [95%CI 12.98-54.17]) compared to Q2. This 
association remained powerful in the fully adjusted Model 2 (HR 22.05 [95%CI 
10.75-45.22]) which employed the same adjustments as for the cardiovascular 
analyses. Treatment allocation to placebo or pravastatin was not a relevant 
factor and no statistically significant interaction was found (Table 3.7).  
 
As would be expected, both criteria for IFG, namely the NCEP ATPIII (HR 23.2 
[95%CI 15.7-34.3]) and ADA criteria (HR 17.3 [95%CI 12.6-23.7]), demonstrated 
strongly elevated risks for developing diabetes compared to patients with normal 
FPG levels at baseline. 
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Figure 3.3 summarises the contrasting relative risks of developing diabetes and 
cardiovascular events according to FPG quintiles over five and fifteen years 
respectively. 
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Table 3.1. Baseline Characteristics split by quintiles of baseline fasting plasma glucose 
Quintiles of Glucose (mmol/L) 
Q1 Q2 Q3 Q4 Q5 
 
≤ 4.3 
n=1448 
>4.3-4.6 
n=1657 
>4.6-4.8 
n=1150 
>4.8-5.1 
n=1116 
>5.1-6.9 
n=1076 
Unadjusted 
p-value1 
Continuous variables [Mean (SD)] 
Age (years) 54.8 (5.5) 54.8 (5.6) 55.2 (5.5) 55.6 (5.6) 55.6 (5.3) <0.0001 
BMI (kg/m2) 25.1 (2.9) 25.7 (3.0) 25.9 (3.1) 26.3 (3.3) 26.8 (3.3) <0.0001 
Systolic BP (mmHg) 132.9 (16.9) 134.0 (16.9) 135.9 (16.9) 137.1 (17.2) 138.5 (17.8) <0.0001 
Diastolic BP (mmHg) 82.6 (10.2) 83.2 (10.4) 84.0 (10.2) 85.0 (10.0) 85.5 (10.3) <0.0001 
Total Cholesterol (mmol/L) 6.96 (0.57) 6.99 (0.57) 7.03 (0.58) 7.07 (0.58) 7.13 (0.62) <0.0001 
HDL Cholesterol (mmol/L) 1.14 (0.25) 1.14 (0.25) 1.15 (0.24) 1.15 (0.24) 1.12 (0.24) 0.071 
LDL Cholesterol (mmol/L) 4.96 (0.44) 4.95 (0.45) 4.96 (0.46) 4.97 (0.45) 4.98 (0.46) 0.38 
Triglycerides (mmol/L)2 1.54 (1.48) 1.63 (1.49) 1.67 (1.48) 1.77 (1.49) 1.92 (1.48) <0.0001 
Categorical variables [n(%)] 
Current smoker 738 (51.0) 717 (43.3) 483 (42.0) 461 (41.3) 450 (41.8) <0.0001 
Nitrate use 19 (1.3) 21 (1.3) 22 (1.9) 36 (3.2) 33 (3.1) 0.0002 
History of angina 61 (4.2) 66 (4.0) 52 (4.5) 64 (5.7) 84 (7.8) <0.0001 
History of hypertension 164 (11.3) 221 (13.3) 178 (15.5) 191 (17.1) 243 (22.6) <0.0001 
 
1   Unadjusted p-value from ANOVA (continuous variable), chi-square test (categorical variable). 
2  Summary statistics for triglycerides based on geometric means. 
BMI: body mass index; BP: blood pressure 
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Table 3.2. Associations of fasting plasma glucose by quintiles with cardiovascular endpoints and mortality over 15 years 
Model 1: adjusted for randomised treatment and age.  
Model 2: Adjusted for BMI, smoking, BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, history of angina, social deprivation score (DEPCAT), 
various medications (aspirin, ACE-inhibitors, B-blockers, calcium channel blockers, diuretics, other).  
FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease. 
  Q1 Q2 Q3 Q4 Q5  
Glucose (mmol/L)  ≤4.3 (N=1448) >4.3-4.6 (N=1657) >4.6-4.8 (N=1150) >4.8-5.1 (N=1116) >5.1-6.9 (N=1076) 
  HR (95%CI) Referent HR (95%CI) HR (95%CI) HR (95%CI) 
 
 
P-value 
CVD events Events (%) 524 (36.2) 589 (35.6) 432 (37.6) 432 (38.7) 404 (37.6)  
 Model l 1.05 0.94-1.19 1.0 1.04 0.91-1.17 1.06 0.93-1.20 1.04 0.92-1.18 0.44 
 Model 2 1.04 0.92-1.17 1.0 1.01 0.89-1.15 1.00 0.89-1.14 0.95 0.83-1.08 0.25 
CHD events  Events (%) 331 (22.9) 362 (21.8) 264 (23.0) 265 (23.8) 252 (23.4)  
 Model 1 1.08 0.93-1.26 1.0 1.03 0.88-1.21 1.06 0.90-1.24 1.05 0.89-1.24 0.47 
 Model 2 1.07 0.92-1.25 1.0 1.01 0.86-1.19 0.98 0.83-1.15 0.93 0.79-1.10 0.19 
Stroke Events (%) 88 (6.1) 87 (5.2) 82 (7.1) 75 (6.7) 73 (6.8)  
 Model 1 1.18 0.88-1.59 1.0 1.30 0.96-1.76 1.22 0.89-1.66 1.25 0.91-1.71 0.39 
 Model 2 1.13 0.84-1.53 1.0 1.21 0.89-1.64 1.12 0.82-1.53 1.05 0.77-1.45 0.95 
CHD death Events (%) 77 (5.3) 95 (5.7) 62 (5.4) 69 (6.2) 58 (5.4)  
 Model 1 0.97 0.72-1.32 1.0 0.89 0.65-1.23 0.98 0.72-1.34 0.85 0.61-1.18 0.86 
 Model 2 0.93 0.69-1.26 1.0 0.85 0.62-1.18 0.90 0.66-1.23 0.74 0.53-1.03 0.33 
All-cause mortality Events (%) 283 (19.5) 301 (18.2) 203 (17.6) 242 (21.7) 215 (20.0)  
 Model 1 1.10 0.94-1.30 1.0 0.93 0.78-1.11 1.12 0.94-1.32 1.05 0.88-1.25 0.84 
 Model 2 1.07 0.90-1.25 1.0 0.90 0.75-1.07 1.05 0.88-1.24 0.96 0.80-1.15 0.53 
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Table 3.3. Associations of fasting plasma glucose with cardiovascular events by quintiles of Q5 relative to Q2 over 15 years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1: adjusted for randomised treatment and age. Model 2: Adjusted for BMI, smoking, BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, 
history of angina and social deprivation score (DEPCAT), various medications (aspirin, ACE-inhibitors, B-blockers, calcium channel blockers, diuretics, other).  
FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease.  
  Q2 Q5a Q5b Q5c Q5d Q5e 
Glucose (mmol/L)  
>4.3-4.6 
N=1657 
>5.1-5.2 
N=223 
>5.2-5.4 
N=354 
>5.4-5.5 
N=95 
>5.5-5.8 
N=226 
>5.8-6.9 
N=178 
  Referent HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI 
CVD events Events (%) 589 (35.6) 90 (40.4) 124(35.0) 41 (43.2) 76 (33.6) 73 (41.0) 
 Model l 1.0 1.16 0.93-1.44 0.96 0.79-1.16 1.31 0.96-1.80 0.98 0.78-1.25 1.21 0.95-1.54 
 Model 2 1.0 1.01 0.81-1.27 0.86 0.71-1.05 1.10 0.80-1.51 0.87 0.69-1.11 1.05 0.82-1.35 
CHD events 
Events (%) 362 (21.8) 48 (21.5) 85 (24.0) 25 (26.3) 47 (20.8) 47 (26.4) 
 Model 1 1.0 0.98 0.73-1.33 1.08 0.85-1.37 1.30 0.86-1.94 1.00 0.74-1.36 1.25 0.92-1.69 
 Model 2 1.0 0.84 0.62-1.14 0.95 0.74-1.20 1.07 0.71-1.61 0.87 0.64-1.18 1.02 0.75-1.38 
Stroke Events (%) 87 (5.2) 19 (8.5) 17 (4.8) 7 (7.4) 14 (6.2) 16 (9.0) 
 Model 1 1.0 1.57 0.96-2.58 0.84 0.50-1.42 1.49 0.69-3.23 1.20 0.68-2.11 1.65 0.97-2.81 
 Model 2 1.0 1.27 0.77-2.10 0.74 0.44-1.26 1.06 0.49-2.30 1.06 0.60-1.87 1.39 0.81-2.38 
CHD death Events (%) 95 (5.7) 9 (4.1) 19 (5.4) 4 (4.2) 11 (4.9) 15 (8.4) 
 Model 1 1.0 0.68 0.34-1.34 0.88 0.54-1.44 0.77 0.28-2.10 0.87 0.47-1.63 1.38 0.80-2.38 
 Model 2 1.0 0.52 0.26-1.03 0.73 0.44-1.20 0.55 0.20-1.50 0.78 0.42-1.47 1.08 0.62-1.88 
All-cause mortality Events (%) 301 (18.2) 41 (18.4) 59 (16.7) 25 (26.3) 47 (20.8) 43 (24.2) 
 Model 1 1.0 0.97 0.70-1.34 0.85 0.65-1.13 1.53 1.02-2.30 1.18 0.87-1.60 1.25 0.91-1.72 
 Model 2 1.0 0.86 0.62-1.19 0.79 0.60-1.04 1.24 0.82-1.87 1.12 0.82-1.52 1.11 0.80-1.54 
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Table 3.4. Hazard Ratio (95%CI) of cardiovascular endpoints and all-cause mortality among participants with impaired fasting glycaemia 
(two definitions) relative to normoglycaemia 
  
No diabetes with FPG 
≤6.0mmol/L 
(N=6352) 
Impaired fasting glucose: 
NCEP ATPIII (FPG 6.1-6.9mmol/L); N=95 
No diabetes 
with FPG ≤5.5mmol/L 
N=6144 
Impaired fasting glycaemia: ADA (FPG 5.6-
6.9mmol/L); N=303 
  Referent HR 95%CI Referent HR 95%CI 
CVD events 
 
Events (%) 
 
2341 (36.9) 
40 (42.1) 
 
2268 (36.9) 
113 (37.3) 
 Model l 1.0 1.25 (0.92–1.71) 1.0 1.05 (0.87-1.27) 
 Model 2 1.0 1.14 (0.83-1.55) 1.0 0.95 (0.78-1.15) 
CHD events 
 
Events (%) 
 
1448 (22.8) 
 
26 (27.4) 
 
1402 (22.8) 
 
72 (23.8) 
 Model 1 1.0 1.27 (0.86-1.87) 1.0 1.07 (0.84-1.36) 
 Model 2 1.0 1.09 (0.74-1.61) 1.0 0.93 (0.73-1.18) 
Stroke 
 
Events (%) 
 
397 (6.2) 
 
8 (8.4) 
 
381 (6.2) 
 
24 (7.9) 
 Model 1 1.0 1.39 (0.69-2.81) 1.0 1.29 (0.85-1.94) 
 Model 2 1.0 1.25 (0.62-2.53) 1.0 1.17 (0.77-1.78) 
CHD death 
 
Events (%) 
 
353 (5.6) 
 
8 (8.4) 
 
342 (5.6) 
 
19 (6.3) 
 Model 1 1.0 1.55 (0.77-3.12) 1.0 1.12 (0.71-1.78) 
 Model 2 1.0 1.34 (0.66-2.72) 1.0 1.00 (0.62-1.59) 
All-cause 
mortality 
 
Events (%) 
 
1224 (19.3) 
 
20 (21.1) 
 
1181 (19.2) 
 
63 (20.8) 
 Model 1 1.0 1.12 (0.72-1.75) 1.0 1.08 (0.84-1.39) 
 Model 2 1.0 1.02 (0.66-1.60) 1.0 1.01 (0.79-1.31) 
Model 1: adjusted for randomised treatment and age. 
Model 2: In addition adjusted for BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, history of angina, social deprivation score (DEPCAT), various 
medications (aspirin, ACE-inhibitors, B-blockers, calcium channel blockers, diuretics, other) 
FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease.  
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Table 3.5. Associations of fasting plasma glucose by quintiles with cardiovascular endpoints and mortality (over 15 yrs) according to 
randomised treatment group 
   Q1 Q2 Q3 Q4 Q5  
Glucose 
(mmol/L) 
  
≤4.3 
N=1448 
>4.3-4.6 
N=1657 
>4.6-4.8 
N=1150 
>4.8-5.1 
N=1116 
>5.1-6.9 
N=1076 
 
 
P-value 
   HR (95%CI) Referent HR (95%CI) HR (95%CI) HR (95%CI)  
CVD events  Events (%) 524 (36.2) 589 (35.6) 432 (37.6) 432 (38.7) 404 (37.6)  
 Pravastatin Model l 0.99 0.84-1.18 1.0 0.89 0.74-1.07 0.96 0.80-1.16 0.99 0.82-1.19 0.98 
  Model 2 1.03 0.87-1.22 1.0 0.89 0.74-1.07 0.90 0.75-1.09 0.89 0.74-1.08 0.23 
 Placebo Model 1 1.08 0.91-1.27 1.0 1.19 1.00-1.41 1.18 1.00-1.40 1.16 0.97-1.38 0.29 
  Model 2 1.06 0.89-1.25 1.0 1.14 0.96-1.35 1.12 0.94-1.33 0.98 0.81-1.17 0.51 
CHD events  Events (%) 331 (22.9) 362 (21.8) 264 (23.0) 265 (23.8) 252 (23.4)  
 Pravastatin Model l 1.00 0.80-1.25 1.0 0.94 0.74-1.19 0.97 0.76-1.23 1.06 0.84-1.35 0.41 
  Model 2 1.06 0.85-1.33 1.0 0.95 0.75-1.21 0.88 0.69-1.12 0.94 0.74-1.20 0.55 
 Placebo Model 1 1.12 0.91-1.36 1.0 1.12 0.91-1.39 1.17 0.94-1.44 1.11 0.89-1.38 0.82 
  Model 2 1.10 0.90-1.35 1.0 1.08 0.87-1.34 1.09 0.88-1.35 0.90 0.72-1.13 0.13 
Stroke  Events (%) 88 (6.1) 87 (5.2) 82 (7.1) 75 (6.7) 73 (6.8)  
 Pravastatin Model l 1.15 0.75-1.76 1.0 1.17 0.75-1.83 1.16 0.74-1.81 1.17 0.75-1.83 0.91 
  Model 2 1.12 0.73-1.74 1.0 1.16 0.74-1.81 1.08 0.69-1.70 0.95 0.60-1.50 0.37 
 Placebo Model 1 1.21 0.80-1.82 1.0 1.43 0.95-2.15 1.27 0.83-1.95 1.31 0.85-2.02 0.21 
  Model 2 1.14 0.75-1.72 1.0 1.26 0.83-1.90 1.15 0.75-1.78 1.14 0.73-1.78 0.37 
CHD death  Events (%) 77 (5.3) 95 (5.7) 62 (5.4) 69 (6.2) 58 (5.4)  
 Pravastatin Model l 0.89 0.58-1.38 1.0 0.85 0.54-1.35 0.78 0.48-1.26 0.80 0.49-1.29 0.68 
  Model 2 0.91 0.59-1.41 1.0 0.81 0.51-1.28 0.67 0.41-1.09 0.66 0.41-1.08 0.26 
 Placebo Model 1 0.99 0.66-1.51 1.0 0.95 0.61-1.48 1.25 0.83-1.88 1.02 0.66-1.60 0.55 
  Model 2 0.96 0.63-1.45 1.0 0.92 0.59-1.43 1.14 0.75-1.73 0.79 0.50-1.26 0.70 
All-cause 
mortality 
 
 
Events (%) 
 
283 (19.5) 
 
301 (18.2) 
 
203 (17.6) 
 
242 (21.7) 
 
215 (20.0) 
 
 Pravastatin Model l 1.13 0.90-1.42 1.0 0.92 0.71-1.19 1.01 0.79-1.29 1.00 0.78-1.29 0.47 
  Model 2 1.15 0.91-1.45 1.0 0.92 0.71-1.18 0.94 0.73-1.21 0.91 0.71-1.18 0.15 
 Placebo Model 1 1.06 0.84-1.34 1.0 0.94 0.73-1.20 1.23 0.97-1.55 1.12 0.88-1.44 0.32 
  Model 2 1.00 0.80-1.27 1.0 0.90 0.70-1.16 1.16 0.92-1.47 1.02 0.80-1.31 0.59 
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Footnote to Table 3.5 
Model 1: adjusted for age. Model 2: Additionally adjusted for BMI, smoking, BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, history of angina 
and social deprivation score (DEPCAT), various medications (aspirin, ACE-inhibitors, B-blockers, calcium channel blockers, diuretics, other).  
FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease.  
 76 
 Table 3.6. Associations of fasting plasma glucose by fifths (Q5a-e) of the uppermost glucose quintile <7mmol/L with cardiovascular 
endpoints and mortality (over 15 yrs) according to randomised treatment group 
   Q2 Q5a Q5b Q5c Q5d Q5e 
Glucose 
(mmol/L) 
  
>4.3-4.6 
N=1657 
>5.1-5.2 
N=223 
>5.2-5.4 
N=354 
>5.4-5.5 
N=95 
>5.5-5.8 
N=226 
>5.8-6.9 
N=178 
   Referent HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI 
CVD events  
 
Events (%) 
 
589 (35.6) 
 
90 (40.4) 
 
124 (35.0) 
 
41 (43.2) 
 
76 (33.6) 
 
73 (41.0) 
 Pravastatin Model 1 1.0 0.95 0.68-1.32 0.87 0.65-1.16 1.21 0.79-1.87 0.95 0.67-1.35 1.21 0.86-1.71 
  Model 2 1.0 0.84 0.61-1.17 0.80 0.60-1.07 1.00 0.64-1.54 0.91 0.64-1.30 1.07 0.75-1.52 
 Placebo Model 1 1.0 1.40 1.03-1.89 1.05 0.80-1.36 1.41 0.88-2.24 1.02 0.74-1.42 1.21 0.86-1.70 
  Model 2 1.0 1.18 0.87-1.60 0.90 0.69-1.18 1.18 0.74-1.89 0.84 0.61-1.17 0.99 0.70-1.40 
CHD events  
 
Events (%) 
 
362 (21.8) 
 
48 (21.5) 
 
85 (24.0) 
 
25 (26.3) 
 
47 (20.8) 
 
47 (26.4) 
 Pravastatin Model 1 1.0 0.90 0.58-1.41 0.93 0.65-1.35 1.62 0.97-2.70 0.94 0.59-1.49 1.41 0.92-2.16 
  Model 2 1.0 0.78 0.50-1.22 0.84 0.58-1.23 1.31 0.78-2.20 0.90 0.56-1.43 1.20 0.78-1.86 
 Placebo Model 1 1.0 01.06 0.70-1.59 1.21 0.89-1.64 0.95 0.49-1.85 1.05 0.70-1.57 1.11 0.72-1.71 
  Model 2 1.0 0.90 0.59-1.36 0.99 0.73-1.36 0.73 0.37-1.44 0.86 0.57-1.29 0.85 0.55-1.32 
Stroke  
 
Events (%) 
 
87 (5.2) 
 
19 (8.5) 
 
17 (4.8) 
 
7 (7.4) 
 
14 (6.2) 
 
16 (9.0) 
 Pravastatin Model 1 1.0 1.69 0.87-3.28 0.97 0.49-1.93 0.83 0.20-3.42 0.89 0.35-2.25 1.40 0.63-3.11 
  Model 2 1.0 1.37 0.70-2.69 0.81 0.41-1.64 0.55 0.13-2.29 0.82 0.32-2.08 1.06 0.47-2.39 
 Placebo Model 1 1.0 1.39 0.66-2.95 0.69 0.31-1.52 2.32 0.92-5.85 1.47 0.71-3.00 1.91 0.93-3.91 
  Model 2 1.0 1.11 0.52-2.37 0.65 0.29-1.45 1.72 0.67-4.42 1.30 0.63-2.69 1.68 0.80-3.51 
CHD death  
 
Events (%) 
 
95 (5.7) 
 
9 (4.1) 
 
19 (5.4) 
 
4 (4.2) 
 
11 (4.9) 
 
15 (8.4) 
 Pravastatin Model 1 1.0 0.69 0.27-1.72 0.82 0.40-1.67 0.37 0.05-2.65 0.66 0.24-1.84 1.28 0.58-2.83 
  Model 2 1.0 0.52 0.20-1.33 0.69 0.33-1.41 0.26 0.04-1.92 0.64 0.23-1.79 1.07 0.48-2.83 
 Placebo Model 1 1.0 0.65 0.23-1.80 0.94 0.47-1.85 1.24 0.38-3.97 1.07 0.48-2.35 1.48 0.70-3.14 
  Model 2 1.0 0.51 0.18-1.43 0.75 0.37-1.50 0.83 0.26-2.72 0.88 0.40-1.97 1.05 0.49-2.26 
All-cause 
mortality 
 
 
Events (%) 
 
301 (18.2) 
 
41 (18.4) 
 
59 (16.7) 
 
25 (26.3) 
 
47 (20.8) 
 
43 (24.2) 
 Pravastatin Model 1 1.0 0.87 0.54-1.38 0.89 0.61-1.31 1.17 0.61-2.21 0.99 0.61-1.60 1.34 0.86-2.08 
  Model 2 1.0 0.76 0.47-1.22 0.82 0.56-1.21 0.94 0.49-1.79 0.98 0.61-1.58 1.22 0.78-1.90 
 Placebo Model 1 1.0 1.08 0.68-1.70 0.82 0.55-1.22 1.93 1.13-3.27 1.35 0.90-2.02 1.16 0.72-1.84 
  Model 2 1.0 0.99 0.62-1.57 0.76 0.51-1.15 1.59 0.93-2.74 1.23 0.82-1.85 1.03 0.64-1.65 
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Footnote to Table 3.6 
Model 1: adjusted for age. Model 2: Additionally adjusted for BMI, smoking, BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, history of angina 
and social deprivation score (DEPCAT), various medications (aspirin, ACE-inhibitors, B-blockers, calcium channel blockers, diuretics, other).  
FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease.  
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Table 3.7. Associations of fasting plasma glucose by quintiles with the development of diabetes (over 5 years) according to randomised 
treatment group 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1: adjusted for age. Model 2: Additionally adjusted for BMI, smoking, BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, history of angina 
and social deprivation score (DEPCAT), various medications (aspirin, ACE-inhibitors, B-blockers, calcium channel blockers, diuretics, other).  
FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease.  
 
  
 Q1 Q2 Q3 Q4 Q5 
Glucose 
(mmol/L) 
 
 
≤4.3 
N=1448  
>4.3-4.6 
N=1657 
>4.6-4.8 
N=1150 
>4.8-5.1 
N=1116 
>5.1-6.9 
N=1076 
  
 HR (95%CI) Referent HR (95%CI) HR (95%CI) HR (95%CI) P value 
Incident 
diabetes  
 
Events (%) 
 
9 (0.6%) 
 
8 (0.5%) 
 
9 (0.8%) 
 
14 (1.3%) 
 
128 (11.9%) 
 
 
Pravastatin Model l 0.90 0.24-3.35 1.0 0.86 0.20-3.58 2.03 0.65-6.41 18.15 7.27-45.35 <0.0001 
 
 Model 2 1.04 0.28-3.89 1.0 0.88 0.21-3.68 1.88 0.60-5.94 13.83 5.48-34.86 <0.0001 
 
Placebo Model 1 1.89 0.45-7.91 1.0 2.85 0.71-11.39 3.30 0.85-12.78 40.05 12.62-127.13 <0.0001 
 
 Model 2 2.00 0.48-8.42 1.0 2.92 0.73-11.70 3.21 0.83-12.47 35.06 10.97-112.07 <0.0001 
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Figure 3.3. Risk of cardiovascular disease over 15 years compared to risk of diabetes over 5 years by baseline fasting plasma glucose 
levels in WOSCOPS (fully adjusted model)* 
 
 
*note that Q1, Q3, Q4, Q5 data are all compared to referent Q2 (FPG >4.3-4.6mmol/L) whereas cardiovascular (CVD) risk for baseline diabetic patients is compared 
to all individuals without diabetes at baseline
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3.4 Discussion 
 
Analysis of the relationship between FPG and both cardiovascular events and all-
cause mortality in western men in WOSCOPS demonstrated that FPG in the non-
diabetes range was not associated with increased risk of cardiovascular events, 
coronary heart disease death, or all-cause mortality. As might have been 
expected, participants with a history of diabetes or biochemically confirmed 
new-onset diabetes at baseline were at increased risk of cardiovascular disease. 
In stark contrast to the lack of association of FPG with cardiovascular events and 
mortality in those without diabetes at baseline, there was a substantial and 
independent increase in the risk of new diabetes in participants in the highest 
quintile of FPG. These data demonstrate that an elevated FPG level in the non-
diabetic range is a powerful risk marker for developing diabetes in the future 
but not for cardiovascular events over as long as 15 years of follow-up.  
 
The relationships between various measures of glycaemia in individuals without 
diabetes and the development of cardiovascular disease have received much 
attention recently and led to important publications since the publication of 
these WOSCOPS results. The measures of glycaemia studied have included not 
only FPG but also post-prandial glucose and Haemoglobin A1c (HbA1c), a 
component of circulating haemoglobin which provides information on circulating 
glucose levels over the last two to three months. WOSCOPS did not include 
measurements of either HbA1c or post-challenge glucose. It is important to 
provide the context to the WOSCOPS results by also describing available data for 
post-prandial glucose and cardiovascular disease.  
 
Post-prandial glucose: The best data available to assess any link between post-
prandial glucose levels and subsequent cardiovascular events come from a 
manuscript combining results from both the population-based Reykjavik study 
(Iceland) and a linked meta-analysis of fifteen cohorts (81). The Reykjavik study 
had access to 1 hour post-prandial glucose levels, rather than the more typical 2 
hour samples, but had the considerable advantages of considerable power 
(18,569 participants with 4,664 coronary events) and lengthy follow-up (23.5 
years). The HR for coronary events in non-diabetic individuals was modest at 
1.03 (1.01-1.05) per 1 mmol/L higher post-load glucose in analyses adjusted for 
 81 
most established cardiovascular risk factors. In the linked meta-analysis of 15 
cohorts with 12,652 coronary events in 102,382 participants, the HR for coronary 
events was slightly higher at 1.05 (1.03-1.07) per 1 mmol/l higher post-load 
glucose (81). There is therefore a significant but modest independent 
relationship between post-prandial glucose and risk of coronary heart disease. 
 
HbA1c: In a separate meta-analysis of HbA1c data accompanying the Reykjavik 
study (81), 1% higher HbA1c was associated with 20% higher coronary risk in 
those without diabetes, an appreciably stronger relationship than has been 
observed for either fasting or post-prandial glucose. Also, in the Atherosclerosis 
Risk in Communities (ARIC) study, participants with no history of diabetes and 
with baseline HbA1c 5.5-5.9%, 6.0-6.4% and ≥6.5% had 23%, 78% and 95% higher 
risk of coronary events respectively than those with HbA1c 5.0-5.4% in a 
multivariable-adjusted model (82). The available evidence therefore suggests 
that HbA1c has a stronger relationship with subsequent vascular risk. Despite 
this stronger relationship, addition of HbA1c to algorithms predicting vascular 
risk appears to yield minimal improvement in predictive capability. Using the 
EPIC-Norfolk cohort, Simmons and colleagues addressed this question of risk 
prediction (83). Over 8.5 years in the 10,295 participants, AUROC for the 
Framingham risk score was not improved with addition of HbA1c for women 
(0.80 for Framingham analyses with and without HbA1c) and AUROC was only 
minimally improved for men (0.72 without HbA1c and 0.73 with HbA1c). 
Similarly, data from the ARIC study showed a statistically significant but limited 
improvement in the prediction of cardiovascular disease with the addition of 
HbA1c to multivariable prediction models (82). Addition of HbA1c to the ARIC 
prediction model led to a modest improvement in the net reclassification index 
for coronary heart disease prediction but for neither ischaemic stroke nor all-
cause death. It also had little impact in models already containing conventional 
cardiovascular risk factors and FPG. 
 
Fasting glucose: two large datasets have recently published data on fasting 
glucose and cardiovascular disease. Data from Sarwar et al’s meta-analysis of 
255,171 non-diabetic participants from 23 cohorts with 10,808 cases of coronary 
heart disease concluded that the relationship is of borderline significance (HR 
1.06 [1.00–1.12] per 1 mmol/l higher fasting glucose). In recently published 
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Emerging Risk Factor Collaboration (ERFC) data (84), vascular risk was lowest in 
those with a FPG of 3.9-5.6mmol/L and a J-shaped relationship was evident. 
Those with FPG 5.6-6.1mmol/L were at 11% (HR 1.11 [1.04-1.18]) higher risk and 
those with FPG 6.1-7mmol/L at 17% higher risk (HR 1.17 [1.08-1.26]) in analyses 
adjusted for age, smoking status, BMI, and systolic blood pressure. In ERFC, 
addition of either FPG or IFG status to a vascular risk prediction model did not 
significantly improve risk prediction (84). ERFC results are summarised in Figure 
3.4. Of note, very few studies in these large datasets have had follow-up 
durations as long as WOSCOPS. 
  
Prior to publication of the ERFC meta-analyses and Reykjavik study with its 
meta-analysis, other studies investigating potential associations between FPG 
<7.0 mmol/L and incident cardiovascular events had produced variable results. 
The WOSCOPS results are in disagreement with meta-analyses of this earlier 
literature and many of the early studies (72). However, many of these earlier 
studies included patients who, by current definitions, had diabetes at baseline, 
and reporting of data may have been subject to some small study publication 
bias. A recent report in 652,901 Korean men, linked to national databases and 
followed up for 9 years, concluded that FPG had little if any association with the 
risk of subsequent myocardial infarction, and that the risk of ischaemic stroke 
was only clearly increased when FPG was ≥6.5 mmol/L (adjusted for classical 
risk factors) (75). This population of Asian men is dissimilar to western 
populations as seen by the rates of myocardial infarction and stroke (stroke rate 
is considerably higher in the Korean cohort); however, their results are broadly 
consistent with WOSCOPS.  
 
It has long been known that the risk of both cardiovascular disease and mortality 
is higher in subjects with diabetes than in those without diabetes (84). This 
observation was confirmed in WOSCOPS, and the observed risk levels are of a 
similar magnitude to those recently reported in national Scottish record linkage 
studies (85). This lends external validity to the observations.  
 
Wide appreciation of the association between diabetes and the risk of 
cardiovascular disease and mortality has prompted interest in the potential role 
of plasma glucose as a mediator of vascular disease. There are many theoretical 
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pathways for glucose (usually at very high concentrations) to mediate increased 
risk (e.g. inhibition of vascular smooth muscle cell apoptosis (86), stimulation of 
inflammation and oxidative stress, LDL oxidation, and increased thrombotic 
potential (87)). In addition, there has been intense interest in the use of 
intensive glucose-control therapy among people with diabetes to potentially 
reduce vascular risk. The relevant trials have produced mixed results with the 
exception of reductions in coronary events that were consistently observed in all 
trials (88). It is possible both in people with diabetes and those free from it that 
HbA1C and post-prandial glucose are better markers of cardiovascular risk than 
FPG. Based on the combined literature and new large meta-analytical data, 
however, even if the risk associations for these two markers are considerably 
stronger than for FPG, they are unlikely to add meaningfully to cardiovascular 
risk prediction (82;84). 
 
The WOSCOSPS analyses have numerous strengths, including the use of a well-
characterised cohort without history of cardiovascular disease or diabetes, a 
fifteen year follow-up period allowing for study of any legacy effect by FPG, a 
standardised method for identifying the relevant clinical endpoints, and a large 
number of incident events thereby providing considerable power. Despite having 
only 5 years of follow-up for new-onset diabetes data, this was easily sufficient 
to demonstrate the clear contrast in the importance of elevated FPG for the 
development of cardiovascular disease and diabetes. It is also necessary to 
highlight some weaknesses in the data. Data were not available for women, only 
men, and although another group has recently reported broadly consistent 
results in cohorts of women (76), it is possible that vascular risk does increase in 
women at lower levels of FPG (89). The WOSCOPS database is taken from a 
statin trial conducted specifically in hypercholesterolaemic men with no history 
of myocardial infarction, implying that this patient group may not reflect the 
variation found in unselected populations; however, there was no clear 
interaction of statin allocation on associations of FPG with the risk of the various 
endpoints, baseline randomisation was adjusted for where required, and there is 
no established association between total cholesterol and glycaemia anyway. The 
WOSCOPS dataset may have lacked the necessary power to demonstrate a weak 
association between IFG and vascular events. Finally, although the WOSCOPS 
analyses may examine associations or lack thereof between glucose and 
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cardiovascular disease, causality cannot be proved or disproved in a prospective 
study of this nature. Regardless, it would appear that FPG levels in the non-
diabetic range have either no relationship with the risk of subsequent 
cardiovascular events or possibly a very weak association at the upper end 
which, if incorporated into risk prediction algorithms, will not enhance risk 
prediction.  
 
In conclusion, results from WOSCOPS investigating any link between FPG levels in 
the non-diabetic range and incident cardiovascular events and mortality suggest 
that no significant association exists in this white western male population. 
Consequently, the current FPG threshold for diagnosing diabetes therefore 
appropriately identifies western men at elevated risk of not only microvascular 
disease, but also cardiovascular disease. 
 
The data provided in this chapter were published in the European Heart Journal 
in 2010 (90). 
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Figure 3.4. Hazard ratios for coronary heart disease and ischaemic stroke by baseline fasting blood glucose concentration in the 
Emerging Risk Factor Collaboration 
 
 
 
Taken from Sarwar et al. (84) and reproduced with the permission of Elsevier © 
HR: hazard ratio; CI: confidence interval
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Chapter 4. 
 
Statins and risk of incident diabetes: a collaborative meta-analysis of 
randomised placebo- and standard care-controlled statin trials 
 
4.1 Introduction 
 
Statins are the most prescribed medications worldwide. In England, there were 
one million statin prescriptions per week in 2008 with an estimated third of the 
population aged >45yr on a statin (91). Statin therapy is effective for reducing 
the risk of cardiovascular events and its efficacy is related to a reduction in LDL-
cholesterol levels (20). Statin therapy is also generally recognised as being safe 
and well tolerated apart from myalgia and myopathy. A recent article from a 
large British General Practitioner database has claimed that statin therapy 
increases the risk of developing a wide range of complications including, 
somewhat unexpectedly, cataracts and other side-effects (92). However, such 
analyses are clearly severely weakened by their design which compares patients 
receiving statins to those not on statins, inevitably very different populations, 
and the inability to account for all confounding factors including, for example, 
confounding by indication. The most powerful method to properly investigate 
the possibility of medication-induced side-effects is by examining datasets from 
large randomised trials and by performing meta-analyses of large randomised 
trials. 
 
One issue that has received attention recently is the possibility that statin 
therapy may influence the chance of developing diabetes. Prior to 2010, only six 
large placebo- and standard care-controlled statin trials had published data on 
the development of diabetes with the result that definitive conclusions could not 
be drawn. This was demonstrated by a meta-analysis published in 2009 which 
included only this previously published data (93) (see Figure 4.1). While the 
possibility that statins may cause some patients to develop diabetes had not 
been seriously considered before 2008, the publication of the Justification for 
the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) (22), a placebo-controlled trial of rosuvastatin in patients at 
apparently low cardiovascular risk, raised this issue. JUPITER included 17,802 
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adult patients, none with any history or biochemical evidence of diabetes (based 
on FPG concentrations), and followed them up for a median of 1.9 years until 
the study was prematurely discontinued when the trial met a pre-specified 
stopping rule due to cardiovascular benefit. However, analysis of the 
development of diabetes which was a prespecified secondary analysis revealed 
that 25% more cases of diabetes occurred in the rosuvastatin-treated arm. This 
was not expected by the investigators who had hypothesised that treatment with 
rosuvastatin may actually reduce future diabetes risk. 
 
The hypothesis that statin therapy may influence diabetes risk was initially 
introduced by another statin trial, WOSCOPS, in which middle aged 
hypercholesterolaemic men with no history of myocardial infarction were 
randomised to pravastatin or placebo and followed up for 5 years (14). A 
publication of WOSCOPS data in 2001 found that pravastatin therapy was 
associated with a reduction in new-onset diabetes of 30% though event numbers 
were relatively small (94).  
 
Of the other four trials which had previously published results on new-onset 
diabetes, none found any significant effect (50;95;96). Interestingly, three of 
the four yielded non-significant 15% higher risks for developing diabetes on 
statin therapy. Although the other trial, Long-term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) (40), found a non-significant lower risk of diabetes 
on pravastatin, it is important to realise that this finding was based on only 
those patients who were normoglycaemic at baseline.  
 
It is already well established that other commonly prescribed cardiovascular risk 
lowering agents can have an effect on the development of diabetes. On the one 
hand, thiazide diuretic therapy and beta-blockers are known to elevate diabetes 
risk (16;17) and nicotinic acid, an HDL-cholesterol raising agent, can also lead to 
a deterioration in glycaemic control in diabetes (18). Clearly this does not and 
should not mean that these agents are not prescribed where relevant, as their 
cardiovascular efficacy is well established. On the other hand, ACE-inhibitors 
and ARBs reduce the risk of future diabetes (19). 
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These mixed findings for statins and new-onset diabetes have led to calls for a 
systematic evaluation of the possible effect of statin therapy on new-onset 
diabetes (97). It is clearly of major public health importance to neither over-
estimate clinical benefit nor under-estimate risk to patients. Consequently I, in 
conjunction with colleagues, planned a collaborative meta-analysis of large 
placebo-controlled and standard-care controlled statin trials to resolve this 
uncertainty. 
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Figure 4.1. Meta-analysis of the effect of statin therapy on the development of diabetes using only previously published data  
 
 
Figure taken from Rajpathak et al (93); reproduced with permission of the American Diabetes Association 
CI: confidence interval
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4.2 Methods 
 
Aim of the analysis 
 
The aim of this meta-analysis was to establish whether statin therapy has any 
impact on the development of diabetes. This was achieved by combining both 
published and unpublished data from large statin trials in a meta-analysis, the 
first to fully address this question. 
 
Selection criteria for trials 
 
I gathered data from all relevant large placebo-controlled and standard care-
controlled endpoint trials that were specifically designed to evaluate the effect 
of statin therapy on cardiovascular events and/or mortality. Specifically, trials 
with >1000 patients and with follow-up longer than one year were sought, 
consistent with other large meta-analyses (20). Features which rendered trials 
unsuitable included inclusion of clinically unstable patients (defined as patients 
undergoing organ transplant or haemodialysis), trials in patients with pre-
existing diabetes, trials of different statin doses and trials in which the primary 
outcome was a change in a surrogate marker of cardiovascular disease. Given 
the nature of the endpoint namely new-onset diabetes, which theoretically is 
partially subject to the frequency and nature of participant follow-up, trials also 
needed to follow up patients in both treatment arms identically. 
 
Literature Search strategy 
 
The literature study is summarised in the flow diagram (Figure 4.2). On January 
8th 2009 I searched Medline, Embase and the Cochrane Central Register of 
Controlled Trials, from 1994 to 2009, to identify relevant trials. The start date of 
1994 was chosen given that the first large scale statin trial, the Scandinavian 
Simvastatin Survival Study (4S), was published in 1994 (98). The word “statin” 
was used as title word and keyword for the search and the search was 
supplemented by using the names for specific statins: “rosuvastatin, 
“atorvastatin”, “simvastatin”, “pravastatin”, “fluvastatin” and “lovastatin”. 
Trials were limited to those including only adult patients and only those 
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published in English. Relevant data had previously been published in six trials, 
representing the minority of potentially relevant trials.  
 
Data sources 
 
Data searches revealed six statin trials which had previously published data on 
the development of diabetes stratified by randomised treatment (22;40;94-
96;99). For these published trials, information regarding the number of non-
diabetic patients at baseline was abstracted together with the number 
developing diabetes, baseline BMI, baseline age, baseline LDL-cholesterol and 
change in LDL-cholesterol during the trial. 
 
As it was clear that the majority of large statin trials had not published data 
regarding development of diabetes, both Professor Naveed Sattar and I 
contacted investigators from nine additional statin trials with a Data Collection 
Sheet (see Figure 4.3) (98;100-107), requesting their participation in a 
collaborative meta-analysis (data from one trial, Prospective Study of 
Pravastatin in the Elderly at Risk [PROSPER] (108), was already made available 
by the Robertson Centre for Biostatistics, University of Glasgow). Investigators 
from six trials agreed to this request (98;100-104). For the remaining three trials 
from whom data were not received, one trial’s investigators expressed a desire 
to collaborate but did not have access to the relevant data (Cholesterol And 
Recurrent Events Study [CARE]) (107), one trial’s investigators declined the 
request though the data have subsequently been published (Stroke Prevention by 
Aggressive Reduction in Cholesterol Levels [SPARCL]) (105), and investigators 
from the third trial failed to issue a response (Lescol Intervention Prevention 
Study [LIPS]) (106). Questions in the Data Collection Sheet were about the 
number of participants at baseline without a history of diabetes, the number 
developing diabetes, the relative change in LDL-cholesterol during the trial 
(stratified by treatment arm), baseline BMI, age and the methods available to 
diagnose diabetes. 
 
In accordance with recent Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (109;110), a checklist of PRISMA criteria was 
completed and is provided in Table 4.1. 
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Diagnostic criteria for new-onset diabetes 
 
The various trials with unpublished data had access to slightly different methods 
for diagnosing diabetes, given that the trials were originally designed to assess 
cardiovascular benefit and not new-onset diabetes. The general diagnostic 
criteria for diabetes required that a participant must satisfy one or more of the 
following: 
  
o Commencement of glucose lowering medication during the trial 
o Adverse event report of new-onset diabetes during the trial 
o Elevated FPG during the trial: at least one FPG result per patient was 
available for all trials with previously unpublished data but these were 
measured at different time intervals according to trial protocols. 
Therefore variable numbers of participants might be concluded as 
developing diabetes depending on the frequency of measurement and the 
requirement for either one or two elevated glucose values. In an attempt 
to approach expected rates of incident diabetes, it was stipulated that 
trials which measured FPG every six months (or more often) must use two 
FPG values ≥7.0mmol/L as a diagnostic criterion for diabetes, but that in 
trials where FPG was measured less frequently, one elevated glucose 
≥7.0mmol/L was sufficient to confirm a diagnosis of diabetes. The 
rationale behind this approach was supported by data from the 
Management of Elevated Cholesterol in the Primary Prevention Group of 
Adult Japanese (MEGA) trial (100); using only a single elevated glucose 
value provided implausibly high diabetes rates. Using the approach 
described above, however, yielded diabetes incidence rates close to what 
would be expected normally. 
 
Reanalysis of previously published data was carried out for WOSCOPS. A paper 
published in 2001 showed that pravastatin therapy in WOSCOPS was associated 
with significantly fewer cases of new-onset diabetes (94). However, this analysis 
employed non-standard diagnostic criteria for diabetes, namely the requirement 
that a follow-up FPG must be >2.0mmol/L higher than baseline FPG. In an 
attempt to standardise criteria, WOSCOPS data were reanalysed using standard 
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criteria as described above and the requirement for a >2.0mmol/L rise in FPG 
was dropped. 
 
Quality assessment 
 
An established tool (111) was used to independently evaluate the quality of each 
trial. Nine characteristics were assessed: randomisation, concealment of 
treatment allocation, similarity of groups at baseline, eligibility criteria, blinding 
of (i) outcome assessors (ii) patient and (iii) care provider to allocated 
treatment, point estimates, and intention-to-treat analysis thereby allowing 
each trial to be awarded a Delphi score of 0 (poorest quality) to 9 (highest 
quality). Disagreement was resolved through consensus and discussion with 
colleagues. 
 
Statistics 
 
Weighted mean follow-up duration was calculated for the combined dataset. 
Only three of the six trials with previously published data on incident diabetes 
had published the data as a HR. Consequently, it was necessary to adopt a 
standard approach across all the trials by calculating an odds ratio (OR) (with 
95% CI) for developing diabetes on a statin. An overall OR was calculated for the 
pooled data using a random effects meta-analytical method which assumes that 
the true underlying effect varies between trials. This approach is more 
defendable than using a fixed effects meta-analysis which provides a less 
conservative estimate and potentially misleadingly narrow CIs. Statistical 
heterogeneity of results between trials was assessed with the I2 statistic, derived 
from Cochran’s Q [100 X (Q-df/Q)] (112), which provides a measure of the 
proportion of overall variation that is attributable to between-trial 
heterogeneity.  
 
Meta-regression analyses were employed to investigate potential sources of 
heterogeneity between trial results i.e. to explain why trials might produce 
varying results, other than by chance. Factors that were investigated by meta-
regression were baseline age, baseline BMI and change in LDL-cholesterol during 
the trial; these three factors were selected as they represent either diabetes 
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risk factors (age, BMI) or can provide insight into a dose-dependent effect of 
statin therapy (LDL-cholesterol change) and they were selected a priori. Due to 
the relatively small number of trials (n=13), it was not statistically defendable to 
analyse additional factors. To test for publication bias, a funnel plot was 
generated and the Egger test performed (113); however, these approaches were 
of limited use as almost all relevant data had been included.  
 
Although five different statins were studies in the thirteen trials, it was deemed 
appropriate to combine their results based on homogeneity of effect (20) and 
the results eventually obtained. Individual statins were evaluated in sensitivity 
analyses. The following sensitivity analyses were also undertaken: 
 
o Meta-analysis of only those trials which included measurement of FPG 
o Meta-analysis of only placebo-controlled trials (i.e. excluding trials with a 
standard care group as control arm) 
o Meta-analysis of all trials except JUPITER (22), the hypothesis-generating 
trial 
o Meta-analysis of all trials except MEGA (100) which included only 
Japanese subjects  
o Meta-analysis of trials of hydrophilic statins, namely pravastatin and 
rosuvastatin 
o Meta-analysis of trials of lipophilic statins namely atorvastatin, 
simvastatin and lovastatin. 
 
In an attempt to express the effect of statin therapy in absolute terms and to 
allow comparison to cardiovascular benefit, the number of patients developing 
diabetes per 1000 patient years on statin and control therapies was calculated.  
 
Statistical software and Acknowledgement 
 
Statistical analyses were carried out in conjunction with a colleague at the 
University of Cambridge, Dr Sreenivasa Rao Kondapally Seshasai. Both he and I 
performed the relevant meta-analyses and sensitivity analyses independently 
using different software packages. Dr Seshasai used Stata version 10.1 software 
while I employed Review Manager software. In the published article, figures 
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provided by Stata are included. Dr Seshasai was responsible for all the meta-
regression analyses performed for this project and for all figures in the published 
manuscript.  
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Table 4.1. Checklist of PRISMA criteria  
Section/Topic Item Checklist item Is this item included in 
the text? 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both Yes 
Abstract 
Structured 
summary 
2 Provide a structured summary including, as applicable, background, objectives, data sources, 
study eligibility criteria, participants, interventions, study appraisal and synthesis methods, 
results, limitations, conclusions and implications of key findings, systematic review 
registration number 
Yes 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Yes 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design 
Yes 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), 
and, if available, provide registration information including registration number 
Yes but not externally 
registered 
Eligibility 
criteria 
6 Specify study characteristics (such as length of follow-up) and report characteristics (such as 
years considered, language, publication status) used as criteria for eligibility, giving rationale 
Yes 
Information 
sources 
7 Describe all information sources (such as databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched 
Yes 
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Search 8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated 
Yes 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis) 
Yes 
Data collection 
process 
10 Describe method of data extraction from reports (such as piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators 
Yes 
Data items 11 List and define all variables for which data were sought and any assumptions and 
simplifications made 
Yes 
Risk of bias in 
individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used 
in any data synthesis 
Yes: Delphi score 
Summary 
measures 
13 State the principal summary measures (such as risk ratio, difference in means). Yes 
Synthesis of 
results 
14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (such as I
2 
statistic) for each meta-analysis 
Yes 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as 
publication bias, selective reporting within studies) 
Yes. However, as much of 
the data were 
unpublished, the funnel 
plot is considered of 
lesser importance.  
Additional 
analyses 
16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified 
Yes 
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Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram 
Yes 
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (such as study size, 
PICOS, follow-up period) and provide the citations 
Yes 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see 
item 12). 
Yes 
Results of 
individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary 
data for each intervention group and (b) effect estimates and confidence intervals, ideally 
with a forest plot 
Yes 
Synthesis of 
results 
21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency 
Yes 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Yes though, as noted 
above, funnel plot of 
limited use as much of the 
data are unpublished 
Additional 
analyses 
23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-
regression) (see item 16) 
 
Yes 
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (such as health care providers, users, and policy 
Yes 
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makers) 
Limitations  25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such 
as incomplete retrieval of identified research, reporting bias) 
Yes 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research 
Yes 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of 
data) and role of funders for the systematic review 
No external funding 
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Figure 4.2. Flow diagram of literature search to identify new-onset diabetes in large statin trials 
 
2841 papers in search of 
Medline, Embase, Cochrane 
Central 
41 articles identified from 19 
potentially relevant trials, 6 
with published data 
 
2800 papers excluded (not RCT, high vs. low dose 
statin trials, RCT of a non statin intervention, trial 
examining surrogate markers, trial investigating 
patients with diabetes) 
3 trials excluded: incident diabetes data not 
published and not available for this analysis 
(CARE, SPARCL, LIPS; total n=8985) 
 
Trial investigators contacted 
for 9 unpublished trials 
(PROSPER already available to 
authors) 
3 trials excluded (GREACE, ALLIANCE had 
different follow-up procedures for each arm with 
possibility of bias for incident diabetes endpoint; 
POST-CABG compared different statin doses) 
 
13 studies fulfilled 
criteria, included in 
meta-analysis 
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Figure 4.3. Formal Question Sheet used to request data from statin trials with 
unpublished data 
 
From N Sattar, D Preiss and colleagues – WOSCOPS/PROSPER groups 
 
Data request for statin-incident diabetes meta-analysis: 
 
Dear colleague, thank you for considering our proposal to join the above meta-
analysis. The following is a summary of the data required to enable us 
incorporate data from your trial into the meta-analysis.  
 
1. Total number of non-DM subjects at baseline ___ 
a. numbers allocated to placebo ___  
b. numbers allocated to Statin ___ 
 
2. Number developing diabetes in each group: placebo___ and statin ___  
 
3. Methods of diagnosis of diabetes: which of the following used?  
(Please tick as appropriate) 
a. Physician reported ____ 
b. Drugs or insulin ___ 
c. Biochemistry ___ (criteria used?) 
 
4. Mean age of all non-DM participants at baseline___ 
 
5. Mean BMI of all non-DM participants at baseline___ 
 
6. Mean LDL-cholesterol at: 
 
a. Baseline: placebo___ and statin ___  
b. End of study, or fixed time during study: placebo ___ and statin ___  
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4.3 Results 
 
Data from 13 large statin trials were included in this meta-analysis. Trials were 
of high quality with a median Delphi score of 9 (range 6-9) (Table 4.2). The 
available data for patients with no history of diabetes at baseline in these trials 
are detailed in Table 4.3. Brief details of the trials which are relevant to this 
analysis are provided below. 
 
The Trials 
 
o Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-
LLA) (96): this placebo-controlled double-blinded randomised trial 
compared Atorvastatin 10mg daily to placebo in patients with 
hypertension and cardiovascular risk factors but no history of coronary 
heart disease 
 
o Heart Protection Study (HPS) (99): this impressively large placebo 
controlled double blinded randomised statin trial compared simvastatin 
40mg daily to placebo in patients with a history of cardiovascular disease 
 
o JUPITER (22): this highly publicised placebo-controlled double-blinded 
randomised trial is the most recently published and compared 
rosuvastatin 20mg daily to placebo in patients with no history of 
cardiovascular disease 
 
o WOSCOPS (94): in this placebo-controlled double-blinded trial, male 
participants with hypercholesteraemia and no history of myocardial 
infarction were randomised to pravastatin 40mg daily or placebo 
 
o LIPID (40): participants with a history of myocardial infarction or unstable 
angina in the preceding three years were randomised to pravastatin 40mg 
daily or placebo in this controlled double-blinded trial 
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o Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) 
(95): this is one of only two previous large scale statin trials conducted in 
a heart failure cohort, specifically those with New York Heart Association 
(NYHA) functional classification of heart failure (classes II-IV) and aged 
>60; treatment arms were rosuvastatin 20mg daily or placebo in this 
double-blinded randomised trial 
 
o PROSPER (108): in PROSPER, a placebo controlled double-blinded 
randomised trial, elderly patients (age 70-82 years) with previous 
cardiovascular disease or at high risk were randomised to pravastatin 
40mg or placebo 
 
o MEGA (100): this open-label trial was conducted in Japan and involved 
Japanese patients with no history of cardiovascular disease but with 
hypercholesteraemia who were randomised to pravastatin 10-20mg daily 
or no treatment 
 
o AirForce/Texas Coronary Atherosclerosis Prevention Study (AFCAPS 
TexCAPS) (104): in this placebo-controlled double-blinded randomised 
trial, patients with no history of cardiovascular disease were treated with 
lovastatin 20-40mg or placebo 
 
o 4S (98): this was the first large statin trial to be published; in this 
placebo-controlled double-blinded randomised trial, patients with a 
history of prior myocardial infarction or angina were treated with 
simvastatin 20-40mg or placebo 
 
o Antihypertensive Lipid Lowering Heart Attack Trial – Lipid Lowering 
Therapy (ALLHAT-LLT) (101): this was an open-label trial comparing 
pravastatin 40mg daily to no treatment in patients with coronary heart 
disease or with cardiovascular risk factors 
 
o Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 
(GISSI)–Heart Failure (GISSI-HF) (102): this was the second statin trial 
conducted in heart failure; patients with chronic heart failure (NYHA II-IV) 
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were randomised to rosuvastatin 10mg daily or placebo in a double-
blinded trial 
 
o GISSI-Prevenzione (103): this open-label trial compared treatment with 
pravastatin 20mg to no treatment in patients with a history of myocardial 
infarction in the previous six months; the trial was stopped before its 
planned end-date 
 
General information 
 
Results were available for 91,140 participants with approximately 364,560 
patient years of follow-up. Data for average trial follow-up, for baseline age and 
BMI, the relative reduction in LDL-cholesterol reduction achieved, the frequency 
of FPG measurement, and the methods of diabetes diagnosis are provided in 
Table 4.3. The new cases of diabetes, specified for treatment arms in each trial, 
are provided in Table 4.4. As discussed in the methods sections, the incidence of 
diabetes provided confidence in the diagnostic measures that were used as trials 
with participants at theoretically highest risk for developing diabetes did 
demonstrate the highest incidences. Of the 13 trials only two, namely JUPITER 
and PROSPER, demonstrated individually significant associations between statin 
therapy and incident diabetes. In JUPITER, there was a 26% (4-51%) higher risk of 
diabetes on statin therapy and in PROSPER a 32% (3-69%) higher risk. The other 
trials had non-significant results with four giving an OR <1 and seven an OR >1. 
 
Pooled results for statins and new-onset diabetes 
 
In the combined cohort of 91,140 patients, 45,521 (49.9%) were treated with 
statins and 45,619 (50.1%) with control therapy. Over a weighted mean follow-up 
period of 4 years, 4,278 developed diabetes consisting of 2,226 (4.89% of the 
cohort) on statins and 2,052 (4.5%) on control therapy. This represents 174 
additional cases of diabetes on statin therapy. Expressed in relative terms this 
equates to 9% (2-17%) higher risk of developing diabetes on statin therapy. 
Expressed in absolute terms, the additional 174 cases of diabetes on statin 
therapy can also be expressed as one extra case for every 255 (95%CI 150-852) 
patients treated for 4 years. Approximately 12.2 cases of diabetes were 
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diagnosed per 1000 patient years on statin therapy and 11.3 cases of diabetes 
occurred per 1000 patient years of control therapy. A forest plot of results is 
provided in Figure 4.4. 
 
Individual statins 
 
Five statins were studied in the 13 trials. Consequently, there were small 
numbers of studies conducted for any specific statin. For atorvastatin and 
lovastatin, only one trial was available and results were non-significant. For 
simvastatin, rosuvastatin and pravastatin, two trials, three trials and six trials 
were available respectively. Rosuvastatin was the only statin to individually 
demonstrate a statistically elevated risk of new-onset diabetes (18%). However, 
CI for all statins overlapped, suggesting that there is no clear difference 
between agents i.e. a class effect. A forest plot of results for the individual 
statins is provided in Figure 4.5. 
 
Heart failure trials 
 
When analysing only the two heart failure trials, namely CORONA and GISSI-HF, 
there were 22 more cases of diabetes in patients treated with rosuvastatin 
compared to placebo (325 vs. 303). The combined results did not reach 
statistical significance (OR 1.11 [0.94-1.31]) despite yielding low heterogeneity 
(I2=0%), but this analysis lacked power with only 6,912 participants. 
 
Funnel plot 
 
A funnel plot was undertaken to investigate the possibility of publication bias 
(see Figure 4.6). It should be noted, however, that almost all published and 
unpublished data were eventually included which renders this analysis less 
helpful. Overall the data showed no evidence of publication bias either 
graphically or by the Egger test (p=0.144). 
 
Sensitivity analyses 
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The following sensitivity analyses were conducted: (i) only placebo-controlled 
trials (MEGA, ALLHAT-LLT, GISSI-Prevenzione excluded), (ii) only trials which 
measured FPG post-randomisation, (iii) trials of lipophilic statins, (iv) trials of 
hydrophilic statins, (v) all trials except JUPITER, (vi) all trials except MEGA (vii) 
all trials using 99% CI. Results are provided in Table 4.5. While some of these 
analyses gave nominally non-significant results, all yielded similar ORs of 1.07-
1.10 with overlapping CI.  
 
Heterogeneity of results between studies 
 
Heterogeneity, as assessed by the standard I2 statistic, was low in the combined 
dataset (I2=11%) which indicates that most variation between individual trial 
results was likely attributable to chance. As specified a priori, three variables 
were subjected to univariate meta-regression analyses in an attempt to explain 
any existing residual risk. These were (i) baseline age, (ii) baseline BMI, and (iii) 
the relative reduction in LDL-cholesterol. Figures of these analyses are provided 
(see Figure 4.7.1-3). Of these, only age demonstrated a significant interaction 
with higher risk of diabetes in trials with older patients (p=0.019). There was no 
clear evidence of a trend towards higher risk of diabetes in trials which achieved 
the biggest relative reduction in LDL-cholesterol (p=0.102). BMI did not appear 
to be an important factor in analyses including (p=0.177) and excluding MEGA 
(p=0.118).  
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Table 4.2. Delphi scores for trials included in meta-analysis 
 
Parameter A B C D E F G H I Total 
           
Trial           
ASCOT-LLA 1 1 1 1 1 1 1 1 1 9 
HPS 1 1 1 1 1 1 1 1 1 9 
JUPITER 1 1 1 1 1 1 1 1 1 9 
WOSCOPS 1 1 1 1 1 1 1 1 1 9 
LIPID 1 1 1 1 1 1 1 1 1 9 
CORONA 1 1 1 1 1 1 1 1 1 9 
PROSPER 1 1 1 1 1 1 1 1 1 9 
MEGA 1 0 1 1 1 0 0 1 1 6 
AFCAPS 
TexCAPS 
1 1 1 1 1 1 1 1 1 9 
4S 1 1 1 1 1 1 1 1 1 9 
ALLHAT-LLT 1 0 1 1 1 0 0 1 1 6 
GISSI-HF 1 1 1 1 1 1 1 1 1 9 
GISSI 
Prevenzione 
1 0 1 1 1 0 0 1 1 6 
 
Delphi parameters (Yes = 1, No = 0) 
A. Was a method of randomisation performed? 
B. Was treatment allocation concealed? 
C. Were randomised groups similar at baseline? 
D. Were trial eligibility criteria specified? 
E. Was the outcome assessor blinded? 
F. Was the care provider blinded? 
G. Was the patient blinded? 
H. Were point estimates and measures of variability presented for primary 
outcome measures? 
I. Did the analysis include an intention-to-treat analysis? 
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Table 4.3. Data for non-diabetic participants in thirteen placebo- and standard care-controlled statin trials that reported incident 
diabetes        
 N (all) 
N (non-DM 
patients) 
Follow up 
(years) 
Method of DM diagnosis 
BMI 
(kg/m2) 
Age 
Relative %LDL-C 
reduction 
FPG after 
baseline 
ASCOT-LLA 
(96)  
10305 7773 3.3∫‡ (i) WHO 1999 criteria 28.6∫ 63∫ 
34.8%∫ (12 
month) 
12 / 12 
HPS (99) 20536 14573 5.0 (i) Physician reported (ii) Medication 27.2 65 
29.4% (average in 
trial) 
- 
JUPITER (22) 17802 17802 1.9‡ (i) Physician reported 28.4‡ 66‡ 50% (12 months) - 
WOSCOPS 
(94) 
6595 5974 4.8 (i) Two FPG ≥7.0mmol/L (ii) Medication 25.9 55 23.7% (12 months) 6 / 12 
LIPID (40) † 9014 6997 6.0 (i) One FPG ≥7.0mmol/l (ii) Medication - 62‡ 25% (over 5 years) 12 / 12 
CORONA (95)  5011 3534 2.7∫‡ (i) Physician reported 27∫ 73∫ 45.1%∫ (3 months) - 
PROSPER 
(108) 
5804 5023 3.2 (i) One FPG >7.0mmol/L (ii) Medication 26.5 76 30.7% (12 months) 12 / 12 
MEGA (100)  7832 6086 5.3 (i) Physician reported (ii) Medication (iii) Two FPG ≥7.0mmol/l 23.8 58.3 17.1% (12 months) 6 / 12 
AFCAPS 
TexCAPS 
(104) 
6605 6211 5.2∫ (i) Physician reported (ii) Medication (iii) One FPG ≥7.0mmol/l 27.0∫ 58∫ 26.7% (12 months) 12 / 12 
4S (98)  4444 4242 5.4‡ (i) Physician reported (ii) Medication (iii) One FPG ≥7.0mmol/l 25.9 58.6 36.7% (12 months) Study end 
ALLHAT-LLT 
(101) 
10355 6087 4.8∫ (i) One FPG ≥7.0mmol/L 29.0 66.4 18.1% (24 months) 24 / 12 
GISSI HF 
(102) 
4574 3378 3.9‡ (i) Two FPG ≥7.0mmol/l 26.7 67 34.9% (12 months) 
1, 3, 6, 12 / 12 
then 12 monthly 
GISSI 
PREVENZIONE 
(103)  
4271 3460 2.0‡ (i) One FPG ≥7.0mmol/L 26.3 59.3 11.5% (12 months) 
6, 12 and 24 
months 
TOTAL 113148 91140 ≈4.0 - - - - - 
 
∫: data from total cohort (including diabetes at baseline), †: includes only subjects with normal fasting glycaemia at baseline, ‡: median.  
DM: diabetes mellitus, CVD: cardiovascular disease, CHD: coronary heart disease, MI: myocardial infarction, NYHA: New York Heart Association,  
BMI: body mass index, FPG: fasting plasma glucose 
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Table 4.4. Numbers of patients developing diabetes on statin and control therapy in thirteen randomised trials  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N (non-diabetic patients) N on Statin N on control New diabetes cases New diabetes on Statin New diabetes on control 
ASCOT-LLA 7773 3910 3863 288 154 (3.9%) 134 (3.5%) 
HPS  14573 7291 7282 628 335 (4.6%) 293 (4.0%) 
JUPITER 17802 8901 8901 486 270 (3.0%) 216 (2.4%) 
WOSCOPS 5974 2999 2975 168 75 (2.5%) 93 (3.1%) 
LIPID † 6997 3496 3501 264 126 (3.6%) 138 (3.9%) 
CORONA 3534 1771 1763 188 100 (5.6%) 88 (5.0%) 
PROSPER 5023 2510 2513 292 165 (6.6%) 127 (5.1%) 
MEGA 6086 3013 3073 336 172 (5.7%) 164 (5.3%) 
AFCAPS TexCAPS 6211 3094 3117 146 72 (2.3%) 74 (2.4%) 
4S 4242 2116 2127 391 198 (9.4%) 193 (9.1%) 
ALLHAT-LLT 6087 3017 3070 450 238 (7.9%) 212 (6.9%) 
GISSI HF 3378 1660 1718 440 225 (13.6%) 215 (12.5%) 
GISSI PREVENZIONE 3460 1743 1717 201 96 (5.5%) 105 (6.1%) 
TOTAL 91140 45521 45619 4278 2226 (4.89%) 2052 (4.50%) 
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Table 4.5. Sensitivity analyses to further assess the relationship between statin therapy and new-onset diabetes 
 
Specific Analysis 
N 
Odds ratio for 
developing diabetes 
(statin vs. control) 
I2 
(heterogeneity) 
Entire cohort (n=91140) 91140 1.09 (1.02-1.17) 11 
Placebo-controlled trials (MEGA, ALLHAT-LLT, GISSI-
Prevenzione excluded) 
75507 1.10 (1.01-1.20) 21 
Trials which measured FPG post-randomisation (HPS, 
CORONA excluded) 
75033 1.07 (0.97-1.17) 32 
Trials of lipophilic statins (HPS, ASCOT-LLA, 4S, 
AFCAPS TexCAPS) 
32799 1.10 (0.99-1.22) 0 
Trials of hydrophilic statins (WOSCOPS, ALLHAT-LLT, 
CORONA, PROSPER, MEGA, LIPID, JUPITER, GISSI-HF, 
GISSI Prevenzione) 
58341 1.08 (0.98-1.20) 36 
All trials except JUPITER 73338 1.08 (1.01-1.15) 1.5 
All trials except MEGA 85054 1.09 (1.01-1.18) 18 
All trials using 99% CI 91140 1.09 (1.00-1.19)  
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Figure 4.4. Association between statin therapy and incident diabetes in 13 major cardiovascular trials  
NOTE: Weights are from random effects analysis
Overall  (I-squared = 11.2% [95%CI 0.0-50.2%])
LIPID
4S
GISSI HF
MEGA
CORONA
WOSCOPS
PROSPER
HPS
GISSI PREV.
JUPITER
study
ASCOT-LLA
AFCAPS/TEXCAPS
ALLHAT
6997
4242
3378
6086
3534
5974
5023
14573
3460
17802
n
7773
6211
6087
126(6.0)/ 138(6.6)
198(17.3)/ 193(16.8)
225(34.8)/ 215(32.1)
172(10.8)/ 164(10.1)
100(20.9)/ 88(18.5)
75(5.2)/ 93(6.5)
165(20.5)/ 127(15.8)
335(9.2)/ 293(8.0)
96(27.5)/ 105(30.6)
270(16.0)/ 216(12.8)
Events [n (rate [events/1000 pt years])
154(11.9)/ 134(10.5)
72(4.5)/ 74(4.6)
238(16.4)/ 212(14.4)
1.09 (1.02, 1.17)
0.91 (0.71, 1.17)
1.03 (0.84, 1.28)
1.10 (0.89, 1.35)
1.07 (0.86, 1.35)
1.14 (0.84, 1.55)
0.79 (0.58, 1.10)
1.32 (1.03, 1.69)
1.15 (0.98, 1.35)
0.89 (0.67, 1.20)
1.26 (1.04, 1.51)
OR (95% CI)
1.14 (0.89, 1.46)
0.98 (0.70, 1.38)
1.15 (0.95, 1.41)
100.00
6.53
8.88
9.50
8.03
4.65
4.24
6.94
13.91
4.94
11.32
7.07
3.76
10.23
Weight %
1.5 2
 
*Events per 1000 patient years; † Weights are from random-effects analysis; OR: odds ratio; CI: confidence interval 
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Figure 4.5. Associations between different statins and development of diabetes 
.
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.
.
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1.14 (0.89, 1.46)
1.03 (0.90, 1.19)
1.18 (1.04, 1.33)
0.91 (0.71, 1.17)
0.98 (0.70, 1.38)
1.07 (0.86, 1.35)
OR (95% CI)
0.79 (0.58, 1.10)
1.26 (1.04, 1.51)
1.14 (0.84, 1.55)
0.98 (0.70, 1.38)
1.15 (0.95, 1.41)
1.10 (0.89, 1.35)
1.32 (1.03, 1.69)
1.03 (0.84, 1.28)
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0.89 (0.67, 1.20)
1.14 (0.89, 1.46)
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100.00
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4.65
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6.94
8.88
13.91
4.94
7.07
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%
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Figure 4.6. Funnel plot to assess the possibility of publication bias (limited to only those six trials with previously published data) 
Egger’s test p-value = 0.144
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Figure 4.7.1-3. Meta-regression of (4.7.1) baseline age, (4.7.2) baseline BMI, and (4.7.3) on-treatment percentage reduction in LDL-
cholesterol concentration for incident diabetes 
Meta-regression p-value =  0.019
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Meta-regression p-value =  0.177
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Meta-regression p-value =  0.102
WOSCOPS
AFCAPS/TexCAPS
MEGA
GISSI PREVENZIONE
4S
LIPID
ASCOT-LLA
JUPITER
ALLHAT-LLT
GISSI HF
HPS CORONA
PROSPER
.
6
.
8
1
1
.
2
1
.
4
1
.
6
O
d
d
s
 
r
a
t
i
o
s
 
(
9
5
%
 
C
I
s
)
10 20 30 40 50
LDL-cholesterol difference (%) between statin and placebo groups on treatment
 
 
4.7.3. % LDL-  
Cholesterol 
reduction 
 117 
4.4 Discussion 
 
In this meta-analysis of the large statin trials it was possible to demonstrate that 
individuals assigned statin therapy were at slightly increased risk of developing 
diabetes compared with individuals assigned to either placebo or standard care. 
The risk of new-onset diabetes appeared higher in trials with older participants 
in a univariate meta-regression analysis. Results from the trials that included 
FPG measurements and were placebo-controlled were consistent with this novel 
finding. There was also no apparent difference between hydrophilic and 
lipophilic statins which both yielded similar association with diabetes risk.  
 
These results do not definitively prove that statin therapy raises diabetes risk via 
a specific molecular mechanism, but clearly this possibility requires 
consideration. For example, in one study of the effects of various statins on the 
glucose-transporter-4, atorvastatin but not other statins appeared to have a 
detrimental effect on glucose metabolism (114). Conversely, genome-wide scans 
of type 2 diabetes have not identified an association with genes regulating LDL-
cholesterol metabolism or 3-hydroxy-3-methylglutaryl-Co-A reductase, the 
pathway on which statins act to decrease circulating cholesterol (115;116). 
Myalgia and myopathy are relatively common side-effects on statin therapy and 
the possibility that exercise tolerance may be reduced in affected individuals, 
leading to weight gain and higher risk of developing diabetes, requires further 
examination. A modest 0.3kg relative weight gain was noted in rosuvastatin 
recipients compared to placebo recipients in JUPITER (117). While of interest, 
previous studies suggest that this minor difference cannot explain the 25% higher 
diabetes risk observed in JUPITER; for example, in both placebo- and metformin-
treated participants in the Diabetes Prevention Program, risk of new-onset 
diabetes over 3.2 years was 11% higher per 1kg increase in weight (118). Another 
potential explanation for the link between new-onset diabetes and statin 
therapy is that there are residual confounding factors. These may plausibly 
include prolonged survival on statin treatment with increased opportunity to 
develop diabetes, or changing to a healthier lifestyle with resultant weight loss 
and lowered risk for incident diabetes after cardiovascular events, which are 
more likely in placebo than in statin treatment groups. Using ORs has the 
theoretical statistical disadvantage of not factoring in the element of time (i.e. 
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exact follow-up) which is dependent on compliance with medication and 
survival. HRs, which do not have the same weakness, were not available in all 
studies and could not be pooled in this analysis. Nonetheless, extrapolating 
directly from the Cholesterol Treatment Trialists’ (CTT) meta-analysis (20), it 
can be calculated that for every 1000 patients surviving on statin therapy during 
trials completed prior to 2005, 984 patients were alive on control therapy, a 
difference of only 1.6% at the end of the trials. Furthermore, unlike this 
chapter’s meta-analysis, CTT incorporated neither JUPITER (a trial with very few 
deaths) nor the heart failure trials (CORONA and GISSI-HF) in which death rates 
were very similar in both trial arms, as these trials were published subsequently. 
If these were included it would render this difference in survival even smaller. 
Furthermore, given that deaths occur throughout follow-up, it can be reasonably 
argued that the difference in total follow-up between statin and control 
recipients would be half i.e. 0.8%. Consequently, it is highly unlikely that longer 
follow-up or survival on statins can explain the findings of higher diabetes risk. 
This issue is examined further in Chapter 5. 
 
A recent publication has also suggested that statin therapy may lead to a 
deterioration in glycaemia relatively quickly and that higher dose statin therapy 
has more of an effect (119). In this randomised, single-blind, placebo-controlled 
parallel study, 44 patients were allocated to placebo and 42, 44, 43, and 40 
patients were given daily atorvastatin 10mg, 20mg, 40mg, and 80 mg 
respectively. Patients were studied over a period of two months. Treatment with 
atorvastatin 10mg, 20mg, 40mg, and 80mg led to significantly increased fasting 
plasma insulin levels compared to placebo (25%, 42%, 31%, and 45% increases 
respectively). Also, HbA1c levels were increased compared to placebo (2%, 5%, 
5%, and 5% relative increase respectively on the respective increasing doses of 
atorvastatin). Finally, atorvastatin 10mg, 20mg, 40mg, and 80mg decreased 
insulin sensitivity (as estimated by Quantitative Insulin Sensitivity Check Index) 
by 1%, 3%, 3%, and 4% respectively compared to placebo (119). While this study 
found that statin therapy had a potentially detrimental impact on glycaemia in a 
relatively short timeframe, other short-term studies have yielded different 
conclusions. Three studies conducted in animals and humans suggested that 
statin therapy may actually have a beneficial impact on insulin sensitivity (120-
122). Other studies have found no benefit (123-125). The quality of the study by 
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Koh is comparably higher than the other studies however, based on the number 
of participants and study of various statin doses. Nonetheless, this combination 
of findings suggests that the raised risk of incident diabetes with statins could 
represent a chance finding. However, such short-term studies are not necessarily 
informative about long-term risk and it is also important to consider that the 
heterogeneity of diabetes risks in the various randomised statin trials was low (I2 
11%). 
 
To place these findings in a clinical context, it is best to provide results in 
absolute terms also, thereby allowing clinicians and patients to better assess the 
risk: benefit ratio of any new treatment. There were 174 additional cases of 
diabetes in the combined statin groups. However, this equates to only a small 
increase of diabetes in absolute terms. The risk appeared small compared to the 
putative reduction in vascular events. Using data from CTT’s meta-analysis of 
statin trials with 71,370 non-diabetic participants (20), it was calculated that 
statin therapy led to a reduction in major coronary events (coronary heart 
disease death and non-fatal myocardial infarction) of 54 events per 255 patients 
treated for 4 years compared with control therapy for a 1 mmol/L reduction in 
LDL-cholesterol concentration. This composite coronary endpoint also does not 
take into account the likely benefits in terms of reducing strokes and coronary 
intervention and therefore the benefit of statin therapy would be expected to 
be even greater when accounting for these. Importantly, of the 13 trials in CTT 
with non-diabetic individuals, data are provided for incident diabetes in nine 
trials; therefore, the estimate of the risk: benefit described above could be 
slightly inaccurate. Nonetheless the comparison of risk: benefit in this way 
remains informative. Risk benefit considerations may also differ between 
specific groups of patients. For example, statin therapy has not shown 
cardiovascular benefit in two large trials of patients with heart failure (95;102), 
but risk of development of diabetes while on statins was similarly (in terms of 
point estimate), though non-significantly, increased in both trials. Therefore, 
the increase in diabetes may be of more importance in heart failure patients 
where diabetes is known to lead to poor clinical outcomes (126;127). Results 
suggest that clinical decision-making need not be changed for patients in whom 
statin therapy is recommended. It is also relevant to state that ‘statin-induced’ 
diabetes may not necessarily carry equivalent micro- and macrovascular risks 
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compared to the more usual development of diabetes (128). It was not possible 
to address this question with the available data. 
 
 
The finding that statin therapy has an influence on both glycaemia (119) and on 
the development of diabetes (129) is not unusual in the area of cardiovascular 
prevention. It has previously been shown that numerous antihypertensive agents 
have contrasting effects on the development of diabetes. It is well established 
that both thiazides (16) and beta-blockers (17) have detrimental effects on new-
onset diabetes. Nonetheless these agents remain important tools for 
cardiovascular risk reduction. On the other hand, inhibitors of the angiotensin 
system have consistently been shown to reduce the development of diabetes 
(19;130). While these agents are very well established, other lesser known 
medicines also require attention. Nicotinic acid is again being strongly promoted 
as an option for statin-intolerant patients despite knowledge that it also leads to 
higher glucose levels in patients with diabetes (18). It will be important in the 
future to appropriately select and monitor patients for new-onset diabetes 
based not only on known risk factors (family history of diabetes, high BMI) but 
also based on their prescribed medications. 
 
 
Strengths and weaknesses of the analysis require consideration. The meta-
analysis incorporated most of the available large statin trials, thereby providing 
great statistical power. The analysis was only missing data from three other 
trials (with 8985 participants without diabetes at baseline)—CARE, SPARCL, and 
LIPS. The meta-analysis could only be undertaken using summary data, rather 
than individual participant data. Furthermore, ORs were combined in the meta-
analyses rather than HRs which were not available for all trials. However, the 
use of ORs tends to yield very similar results to HRs when event rates are low. 
Inevitably, methods for diagnosis of diabetes varied between the trials. In 
CORONA and HPS, diagnoses were based on physician reporting only, rather than 
on physician reporting and documented biochemical analyses which may be 
considered preferable. Exclusion of these two trials by analysis of the remaining 
eleven trials with biochemical analyses produced a null result (p=010) mainly 
due to the exclusion of the large number of events provided by HPS. Finally, to 
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estimate the total number of person-years of follow-up, it was assumed that the 
median approximated to the arithmetic mean in some cases, and in some trials 
baseline BMI, baseline age, change in LDL-cholesterol concentrations, and 
follow-up were taken from the entire cohort when data specific to non-diabetic 
patients were unavailable. 
 
The variation in diagnostic methods may have contributed to the varying rates of 
developing diabetes between trials. However, the approach taken yielded 
diabetes incidences in keeping with what would be expected in the community, 
with the highest rates being observed in trials with patients known to be at high 
risk of developing diabetes. In particular either one or two glucose 
concentrations of 70 mmol/L were used as a diagnostic criterion, depending on 
the frequency of glucose measurement. Results obtained lend support to this 
pragmatic approach. The two trials with the lowest incidence of diabetes were 
AFCAPS TexCAPS and WOSCOPS, both primary-prevention trials with participants 
clearly at low diabetes risk (low BMIs compared with other primary prevention 
trials like ASCOT-LLA and JUPITER). The four trials with the highest diabetes 
incidence included participants known to be at high risk of developing diabetes. 
PROSPER recruited elderly participants (aged 70–82 years) with or at high risk of 
cardiovascular disease, GISSI Prevenzione recruited patients who had suffered a 
myocardial infarction within the last 6 months, and both GISSI HF and CORONA 
were conducted in patients with heart failure, a condition well-known to lead to 
high risk of developing diabetes. 
 
Following a reanalysis of WOSCOPS data (decided prior to the analyses), this 
trial’s risk of diabetes on pravastatin treatment was reported as non-significant, 
while a significantly reduced risk was reported in Circulation in 2001 (94). 
However, non-standard and unusual criteria were used for diagnosis of diabetes 
in this earlier publication. In particular, the 2001 paper included the 
requirement for a rise in FPG of 2.0 mmol/L or more during the trial from the 
baseline level before diabetes could be diagnosed. Standard criteria for 
diagnosis of diabetes were employed in a reanalysis of WOSCOPS, producing data 
that were easily compared with other trials. This had little impact on the overall 
results as use of 2001 WOSCOPS data would not have changed the overall 
findings. Only results for patients with normal FPG concentrations were 
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previously published for LIPID (40). The risk of developing diabetes on 
pravastatin in LIPID was non-significantly reduced (OR 0.91) but published data 
suggested slightly more cases of diabetes on pravastatin in those with IFG (9.2% 
of survivors on placebo and 9.7% of survivors on pravastatin developed diabetes). 
Data for those with IFG were requested from the LIPID investigators but none 
were available for this analysis. The true OR for diabetes risk in LIPID is thus 
likely to be somewhat closer to a value of 1.0. 
 
The findings suggest that surveillance for dysglycaemia should be considered in 
patients receiving statin therapy. It is now also clear that the development of 
diabetes should be specified as a secondary endpoint in future large endpoint 
statin trials. If possible, reports of long-term follow-up in existing trials should 
also include incident diabetes to further investigate these findings.  
 
This analysis could not conclusively answer the question of whether more 
intensive statin therapy carried a greater risk of developing diabetes than 
moderate dose therapy. To date, only two large statin trials conducted in 
primary or secondary prevention cohorts have compared an intensive statin 
regime with placebo, namely JUPITER (rosuvastatin 20mg vs. placebo) (22) and 
SPARCL (atorvastatin 80mg vs. placebo) (105). JUPITER has already been 
discussed in detail and results showed a 25% increase in new-onset diabetes on 
rosuvastatin; SPARCL was designed to assess the effect of statin therapy in 
patients with a prior stroke or transient ischaemic attack. Recently published 
results showed a 44% increase in new-onset diabetes on atorvastatin in SPARCL 
(131), suggesting that intensive statin regimes may indeed carry greater diabetes 
risk. While no relationship was noted between LDL-cholesterol lowering in the 
meta-analysis (129), it may be important to consider that this was only a 
univariate analysis, that diagnostic criteria for diabetes varied between trials, 
that baseline LDL-cholesterol levels varied between trial populations and that 
timings for cholesterol measurement differed between trials. This may have 
obscured any true relationship between strength of statin (LDL-cholesterol 
lowering) and new-onset diabetes. The LDL-cholesterol meta-regression also 
lacked SPARCL data which may have yielded a more convincing relationship with 
new-onset diabetes. The numbers of additional cases of diabetes in JUPITER and 
SPARCL are not trivial either. In JUPITER it can be estimated that there were 7 
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additional cases of new-onset diabetes for every 10 patients without diabetes at 
baseline protected from suffering a major cardiovascular event (non-fatal 
myocardial infarction, non-fatal stroke, cardiovascular death). Likewise in 
SPARCL, there were approximately 9 additional cases of new-onset diabetes for 
every 10 patients protected from suffering a major cardiovascular event.  
 
The possibility of a dose-dependent relationship between statin use and new-
onset diabetes was examined in a further project and is fully described in 
Chapter 5. 
 
Data described in this chapter were published in the Lancet in 2010 (129). While 
data from SPARCL were not included in the published paper, I have subsequently 
pooled it with data from the other 13 trials. These updated pooled results show 
an increase in OR from 1.09 (13 trials) to 1.11 (14 trials) though there is a 
deterioration in I2 from to 11% to 34% (see Figure 4.8). 
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Figure 4.8. Meta-analysis of new-onset diabetes in 14 large statin trials (including SPARCL) 
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Chapter 5. 
 
Risk of incident diabetes on intensive compared to moderate dose statin 
therapy: a collaborative meta-analysis of randomised trials  
 
5.1 Introduction 
 
Statin therapy significantly reduces cardiovascular events among individuals with 
and without a history of diabetes compared with placebo (132;133). Intensive-
dose statin therapy has also been shown to further reduce cardiovascular events 
compared to moderate-dose statin therapy (132;134;135) – see Figure 5.1. A 
recent meta-analysis of thirteen randomised placebo- and standard care-
controlled trials involving 91,140 individuals, reported that among patients 
treated with statins, the risk of developing diabetes was 9% higher (95% CI 2-
17%) over a 4 year period compared to patients randomised to placebo or 
standard care (129).  
 
Recently, findings of three large endpoint trials comparing intensive to 
moderate-dose statin therapy have suggested an excess risk of incident diabetes 
among those treated with intensive statin regimens (131;136). However, two of 
these trials employed non-standard diagnostic criteria previously used to define 
incident diabetes (94). Additionally, published data from a fourth large clinical 
trial suggested the possibility of a deterioration in glucose control on intensive 
statin therapy (137), and a recent report of 220 hypercholesterolemic patients 
treated with placebo or different doses of atorvastatin and followed for only two 
months found that those on the highest dose developed greater insulin 
resistance, higher insulin levels, and higher HbA1c levels compared to those on 
the lowest dose or placebo (119), suggesting a potential dose effect.  
 
While no significant relationship was observed between the extent of LDL-
cholesterol lowering and new-onset diabetes in the meta-analysis of placebo- 
and standard care-controlled trials (129), most of those trials employed modest 
intensity statins and trial populations also differed greatly which may have 
obscured any meaningful association. 
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Confidence in the observed association between statin therapy and the 
development of diabetes would be enhanced by providing further large scale 
evidence of a dose-dependent association (129). Given the proven cardiovascular 
benefits of statins and the likely increasing use of intensive statin regimens, it is 
important to quantify any potential long-term risks to enable physicians and 
patients to make informed choices. Furthermore, it would be of value to 
investigate whether any specific group of patients is at higher risk of diabetes on 
intensive statin therapy than others. I therefore examined the associations of 
intensive-dose statin therapy compared to moderate-dose therapy with the 
development of diabetes and the occurrence of major cardiovascular events, 
respectively, by conducting a collaborative meta-analysis of published and 
unpublished data from relevant clinical trials. 
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Figure 5.1. The effect of intensive statin therapy compared to moderate dose statin therapy on the risk of myocardial infarction or 
coronary death 
 
 
 
Figure taken from Josan et al (135). Copied under licence from the Canadian Medical Association and © Access Copyright. Further reproduction prohibited 
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5.2 Methods 
 
Search strategy and selection criteria 
 
Data were gathered from large randomised endpoint statin trials primarily 
designed to assess the effect of intensive-dose statin treatment compared to 
moderate-dose therapy on cardiovascular outcomes. Inclusion criteria included 
trials of 1000 or more participants exposed to statin therapy with a minimum 
mean follow-up of one year. The procedure for follow-up visits in both 
treatment arms was required to be identical to avoid bias in ascertainment of 
new-onset diabetes. I searched Medline, Embase and the Cochrane Central 
Register of Controlled Trials with the terms ‘statin’, ‘HMG CoA reductase 
inhibitor’ and names of individual statins as title words and keywords, and 
combined these with a search for the keywords ‘intensive’ or ‘aggressive’ to 
identify trials performed in adult patients (initial search date January 8th 2010, 
updated April 4th 2011; Figure 5.2) and published in English from 1st January 1996 
until 31st March 2011. Abstracts and manuscripts were reviewed and 
discrepancies settled by consensus. Five trials were identified: the Treating to 
New Targets (TNT) trial (138), the Incremental Decrease in End Points Through 
Aggressive Lipid Lowering (IDEAL) trial (139), the Aggrastat to Zocor (A to Z) trial 
(140), the Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis in Myocardial Infarction (PROVE-IT TIMI 22) trial (141) and the 
Study of the Effectiveness of Additional Reductions in Cholesterol and 
Homocysteine (SEARCH) (136). 
 
Data sources 
 
Investigators from all five trials provided data for incident diabetes and major 
cardiovascular events according to a standard data query sheet (Figure 5.3). To 
ascertain whether any specific patient subgroups were at greater risk of 
developing diabetes on intensive statin therapy, data were collected on the key 
endpoints (see below) among those with BMI, HDL-cholesterol, triglycerides, age 
and FPG (where available) above and below the trial medians, as these factors 
are associated with diabetes risk. A PRISMA checklist was also completed (110). 
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Quality assessment 
 
I used an established tool (111) to independently evaluate the quality of each 
trial. Nine characteristics were assessed: randomisation, concealment of 
treatment allocation, similarity of groups at baseline, eligibility criteria, blinding 
of (i) outcome assessors (ii) patient and (iii) care provider to allocated 
treatment, point estimates, and intention-to-treat analysis thereby allowing 
each trial to be awarded a Delphi score of 0 to 9. Disagreement was resolved 
through consensus and discussion. 
 
Endpoints 
 
New-onset diabetes: A patient was considered to have developed diabetes if (i) 
there was an adverse event report of newly diagnosed diabetes during the trial, 
or (ii) he/she commenced glucose lowering medication during the trial, or (iii) 
he/she had two FPG values ≥7.0mmol/L during the trial. For the two trials with 
data published using non-standard diabetes criteria (as in (iii) above but also 
requiring ≥2.0mmol/L increase in FPG from baseline) (131), a reanalysis of the 
data was performed using the standard diagnostic criteria but have also included 
a sensitivity analysis using these non-standard criteria previously employed in 
WOSCOPS (94).  
 
Cardiovascular events: Data were also collected for a composite cardiovascular 
endpoint consisting of cardiovascular death, non-fatal myocardial infarction, 
non-fatal stroke, coronary artery bypass surgery and percutaneous coronary 
intervention as well as data for specific cardiovascular events and all-cause 
mortality. For trials which recruited patients shortly after an acute coronary 
syndrome, the pre-specified trial definitions were used which included only 
those revascularisation procedures not linked to the pre-randomisation index 
event. These consisted of procedures performed >30 days after randomisation in 
PROVE IT-TIMI 22 and only ischaemia-driven procedures in A to Z. 
 
Statistical analysis  
 
To identify potential effects of intensive vs. moderate-dose statin therapy on 
incident diabetes and cardiovascular events, ORs and 95% CIs were calculated 
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from the available data for the number of patients who did not have diabetes at 
baseline and those who developed diabetes and cardiovascular events during 
follow-up. Study-specific ORs were pooled using a random-effects model meta-
analysis to account for between-study heterogeneity which may have been 
introduced by differing methods for diagnosing diabetes available in the trials 
and different trial populations. Statistical heterogeneity across studies was 
quantified using the χ2 (or Cochran’s Q statistic) and I2 statistics, with a p-value 
>0.10 considered statistically non-significant. The I2 statistic is derived from the 
Q statistic [(Q–df/Q)X100], and provides a measure of the proportion of the 
overall variation attributable to between-study heterogeneity (112). Although I 
obtained both published and unpublished information for the meta-analysis, the 
potential for publication bias was still assessed through formal testing namely 
the funnel plot and Egger’s test. To evaluate the effect of statins across 
clinically relevant subgroups (see above), stratum-specific ORs were calculated 
for incident diabetes and major cardiovascular events and combined using 
random-effects meta-analysis. In exploratory analyses we compared results in 
patients with recent acute coronary syndrome to those with stable coronary 
heart disease, and also compared results for trials in which simvastatin 80mg and 
atorvastatin 80mg were the respective intensive regimens. All p-values were 
two-sided and p<0.05 was considered statistically significant. Analyses were 
conducted using Stata version 10.1 (College Station, Texas). 
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Table 5.1. Checklist of PRISMA criteria  
 
Section/Topic Item Checklist item Is this item included in 
the text? 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both Yes 
Abstract 
Structured 
summary 
2 Provide a structured summary including, as applicable, background, objectives, data 
sources, study eligibility criteria, participants, interventions, study appraisal and 
synthesis methods, results, limitations, conclusions and implications of key findings, 
systematic review registration number 
Yes 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Yes 
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design 
Yes 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web 
address), and, if available, provide registration information including registration 
number 
No 
Eligibility 
criteria 
6 Specify study characteristics (such as length of follow-up) and report characteristics 
(such as years considered, language, publication status) used as criteria for eligibility, 
giving rationale 
Yes 
Information 7 Describe all information sources (such as databases with dates of coverage, contact Yes 
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sources with study authors to identify additional studies) in the search and date last searched 
Search 8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated 
Yes 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis) 
Yes 
Data collection 
process 
10 Describe method of data extraction from reports (such as piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data from 
investigators 
Yes 
Data items 11 List and define all variables for which data were sought and any assumptions and 
simplifications made 
Yes 
Risk of bias in 
individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis 
Yes: Delphi score 
Summary 
measures 
13 State the principal summary measures (such as risk ratio, difference in means). Yes 
Synthesis of 
results 
14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (such as I
2 
statistic) for each meta-analysis 
Yes 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such 
as publication bias, selective reporting within studies) 
Yes 
Additional 
analyses 
16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified 
Yes 
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Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally with a flow diagram 
Yes 
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (such as study 
size, PICOS, follow-up period) and provide the citations 
Yes 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, any outcome-level 
assessment (see item 12). 
Yes 
Results of 
individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple 
summary data for each intervention group and (b) effect estimates and confidence 
intervals, ideally with a forest plot 
Yes 
Synthesis of 
results 
21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency 
Yes 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Yes  
Additional 
analyses 
23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, 
meta-regression)  
Yes 
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (such as health care providers, users, 
and policy makers) 
Yes 
Limitations  25 Discuss limitations at study and outcome level (such as risk of bias), and at review 
level (such as incomplete retrieval of identified research, reporting bias) 
Yes 
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Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research 
Yes 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as 
supply of data) and role of funders for the systematic review 
No external funding 
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Figure 5.2. Flow diagram summarising the literature search to identify intensive vs. 
moderate intensity randomised statin trials 
 
5 trials excluded: 
• ALLIANCE: different follow-up in both 
treatment arms 
• SAGE: <1000 participants and surrogate marker 
for primary outcome 
• REVERSAL: <1000 participants and surrogate 
marker for primary outcome 
• POST-CABG: surrogate marker for primary 
outcome 
• METEOR: <1000 participants and surrogate 
marker for primary outcome  
733 papers excluded (most for >1 reason):  
• 211 papers from trial of surrogate CVD markers or 
follow-up <1 year or <1000 patients 
• 71 papers from placebo-controlled trials 
• 115 papers from trials of other agents or other 
treatment modalities 
• 26 papers from trials conducted in patients with 
diabetes 
• 310 papers did not represent randomized 
controlled trials or represent subsequently 
published post-hoc trial analyses 
10 papers from other 
sources 
1218 papers in search of 
Medline, Embase, 
Cochrane Central 
753 papers screened 
after duplicates 
removed 
20 full text articles 
(from 10 trials) 
read 
5 trials included in 
quantitative data synthesis 
 
5 suitable trials identified, data published or in 
press for 3 trials by date of submission; data 
requested from all 5 trials 
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Figure 5.3. Data Collection Sheet used to request data from statin trials with 
unpublished data 
 
Request for data from ________trial: 
Meta-analysis of incident diabetes in intensive vs. standard dose statin trials 
 
7. Total number of non-DM subjects at baseline    ____ 
a. Intensive statin       ____ 
b. Low dose statin       ____ 
 
8. Baseline characteristics of all non-DM participants at baseline, where 
available 
a. Mean age (SD) yrs      ____ (___) 
b. Mean BMI (SD) kg/m2     ____ (___) 
c. Mean fasting glucose (SD) mmol/L    ____ (___) 
d. Mean fasting or random HDL-c (SD) mmol/L  ____ (___) 
e. Mean fasting or random Natural log [trigs] (SD), log mmol/L ____ (___) 
f. Number of male _____ and female _____ non-DM at baseline 
g. Number of current smokers _____ and not current smokers at baseline 
_____ 
 
9. Mean LDL-cholesterol (SD) at: 
a. Baseline: 
i. Intensive statin      ___ (___) 
ii. Low dose statin      ___ (___) 
b. End of study or fixed time during study 
i. Intensive statin      ___ (___) 
ii. Low dose statin      ___ (___) 
 
10. Methods of diagnosis of diabetes – which of the following were used?  
a. Physician reported (i.e. Adverse Event)   YES / NO 
b. Commencement of oral medication or insulin   YES / NO 
c. Biochemistry (2 fasting glucose ≥7.0mmol/L)   YES / NO 
 
11. Number developing diabetes in each group:  
a. Intensive statin       ___  
b. Low dose statin       ___  
c. Hazard ratio for developing diabetes [high vs. low dose] (95%CI) ___ 
(___)                  
 
12. Number developing CVD events in each arm (where CVD events includes the 
following:  
CVD death, non-fatal MI, non-fatal stroke, coronary revascularisation 
[CABG, PCI]) 
a. Intensive statin       ___  
b. Standard/low dose statin     ___  
c. Hazard ratio for CVD endpoints (high vs. low dose) [HR (95%CI)] ___ 
(___) 
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13. Interactions for incident diabetes endpoint: 
a. Dichotomous: Nr developing DM / n 
i. Baseline BMI  
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
ii. baseline fasting glucose (if available) 
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
iii. baseline HDL-c (fasting or random as available) 
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
iv. Baseline TGs 
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
v. baseline age  
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
b. Hazard ratios (95%CI) for developing DM: high vs. low dose 
i. Baseline BMI  
1. > median     ___ (___) 
2. < median     ___ (___) 
ii. baseline fasting glucose (if available) 
1. > median     ___ (___) 
2. < median     ___ (___) 
iii. baseline HDL-c (fasting or random as available) 
1. > median     ___ (___) 
2. < median     ___ (___) 
iv. Baseline TGs 
1. > median     ___ (___) 
2. < median     ___ (___) 
v. baseline age  
1. > median     ___ (___) 
2. < median     ___ (___) 
 
14. Interactions for composite CVD endpoint (see point 6): 
a. Dichotomous: Nr developing composite CVD endpoint / n 
i. Baseline BMI  
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
ii. baseline fasting glucose (if available) 
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
iii. baseline HDL-c (fasting or random as available) 
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
iv. baseline TGs  
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
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v. baseline age  
1. > median high dose ___ / ___ low dose ___ / ___ 
2. < median high dose ___ / ___ low dose ___ / ___ 
b. Hazard ratios (95%CI) for developing CVD endpoint: high vs. low dose 
i. Baseline BMI  
1. > median     ___ (___) 
2. < median     ___ (___) 
ii. baseline fasting glucose (if available) 
1. > median     ___ (___) 
2. < median     ___ (___) 
iii. baseline HDL-c (fasting or random as available) 
1. > median     ___ (___) 
2. < median     ___ (___) 
iv. baseline TGs  
1. > median     ___ (___) 
2. < median     ___ (___) 
v. baseline age  
1. > median     ___ (___) 
2. < median     ___ (___) 
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5.3 Results 
 
The present analysis reports information from five randomised clinical trials 
providing data on 32,752 non-diabetic participants. 
 
The trials 
 
o PROVE-IT TIMI 22: this was a double blinded randomised controlled trial 
comparing the effect of atorvastatin 80mg to pravastatin 40mg in patients 
following an acute coronary syndrome 
 
o A to Z: this was a double blinded randomised controlled trial comparing the 
effect of simvastatin 80mg to simvastatin 20mg in patients following an acute 
coronary syndrome 
 
o TNT: this was a double blinded randomised controlled trial comparing the 
effect of atorvastatin 80mg to atorvastatin 10mg in patients with stable 
coronary heart disease 
 
o IDEAL: this was an open-label blinded endpoint evaluation randomised 
controlled trial comparing atorvastatin 80mg to simvastatin 20mg or 40mg in 
patients who had previously suffered a myocardial infarction 
 
o SEARCH: this was a double blinded randomised controlled trial comparing the 
effect of simvastatin 80mg to simvastatin 20mg in patients who had 
previously suffered a myocardial infarction 
 
Of the 32,752 participants, 2,749 (8.4%) developed diabetes and 6,684 (20.4%) 
experienced a major cardiovascular event over a weighted mean follow-up of 4.9 
years (weighted SD 1.9 years) (Table 5.2, Figure 5.4). Of the 2,749 diagnoses of 
diabetes, 2,059 (75%) were identified by non-biochemical methods (i.e. 
commencement of glucose-lowering medication or adverse event reporting), 219 
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(8%) by elevated FPG values in the trial, and 471 (17%) by more than one method. 
Trials were of high quality with a median Delphi score of 9 (range 6-9) (Table 5.3). 
 
Intensive statin therapy and new-onset diabetes 
 
TNT was the only trial to individually demonstrate a significantly increased risk for 
new-onset diabetes on intensive statin therapy compared to moderate dose 
therapy. All trials gave ORs for new-onset diabetes >1.0. In the combined dataset, 
there were 149 more cases of incident diabetes in participants assigned to intensive 
statin treatment than those receiving moderate therapy, OR 1.12 (95% CI 1.04-1.22) 
(Figure 5.4). In absolute terms there were 2.0 additional cases of diabetes per 1000 
patient years among those receiving intensive statin therapy (18.9 [SD 5.2] cases 
per 1000 patient-years with high-dose statin treatment vs. 16.9 [SD 5.5] cases per 
1000 patient-years with moderate-dose therapy) corresponding to a number needed 
to harm of 498 per year. There was no significant heterogeneity between trials for 
new-onset diabetes (χ2 for heterogeneity = 2.59, p=0.63; I2=0% [95% CI 0-79%]). 
Likewise, there was no evidence of publication bias (p=0.54; Figure 5.5). 
 
Intensive statin therapy and cardiovascular benefit 
 
TNT and IDEAL individually demonstrated significantly reduced risks for 
experiencing cardiovascular events on intensive statin therapy compared to 
moderate dose therapy. In the combined dataset there were 416 fewer patients 
with cardiovascular events on intensive statin therapy, OR 0.84 (95% CI 0.75-0.94) 
(Figure 5.4). In absolute terms there were 6.5 fewer first major cardiovascular 
events per 1000 patient years among those receiving intensive statin therapy (44.5 
[20.4] cases per 1000 patient-years with high-dose statin treatment and 51.0 [23.6] 
cases per 1000 patient-years with moderate-dose therapy) corresponding to a 
number needed to treat (NNT) of 155 to prevent one cardiovascular event per year. 
There was significant heterogeneity between trials for major cardiovascular events 
(χ2 for heterogeneity=15.04, p=0.005; I2=74% [95% CI 36-90%]). However, there was 
no evidence of publication bias (p=0.70; Figure 5.5). ORs for specific components of 
the composite cardiovascular endpoint are provided in Table 5.4, showing similar 
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associations between intensive statin therapy and each cardiovascular endpoint 
component. Intensive-dose statin therapy was not associated with lower all-cause 
mortality compared to moderate-dose statin therapy (OR 0.93, 95% CI 0.81-1.05, 
1318 cases/16408 patients on intensive therapy vs. 1360 cases/16342 patients on 
moderate dose). Intensive statin therapy was also not associated with lower rates 
of non-cardiovascular death as compared to moderate-dose statin therapy (OR 0.98, 
95% CI 0.87-1.10, 559 cases/16408 patients on intensive therapy vs. 571 
cases/16342 patients on moderate-dose). There was no significant heterogeneity 
between trials for all-cause mortality (χ2 for heterogeneity = 7.06, p=0.13; I2=43% 
[95% CI 0-79%]) or for non-cardiovascular death (χ2 for heterogeneity = 3.41, p=0.49; 
I2=0% [95% CI 0-79%]). 
 
Subgroup analyses 
 
Cardiovascular benefit was consistent across all subgroups of participants including 
those defined by age, HDL-cholesterol, triglycerides, BMI (assessed in 4 trials 
(136;138;139;141); n=29,036; 6,192 events) and FPG (assessed in 3 trials 
(138;139;141); n=16,352; 3,436 events) above and below the trial medians at 
baseline (Figure 5.6). The odds of developing diabetes among participants on 
intensive compared to moderate statin therapy was also similar for patients 
differing by age, HDL-cholesterol, BMI (2,626 events) and FPG (1,302 events) levels 
at baseline but was higher in those with triglyceride concentrations below the 
median compared to those with higher triglyceride levels. The trial specific 
medians of these variables are provided in Table 5.5. 
 
Risk: benefit by statin type and trial population 
 
The difference in relative LDL-cholesterol reduction between the more and less 
intensive statin arms was 12-15% in the 2 trials (n=14,301 (136;140)) that studied 
simvastatin 80 mg and 16-22% in the 3 trials (n=18,451 (138;139;141)) that studied 
atorvastatin 80 mg. The odds of developing diabetes was comparable with 
simvastatin 80 mg (OR 1.13, 95% CI 0.93-1.38; I2=0%; 690 cases/7166 patients on 
simvastatin 80mg vs. 634 cases/7135 patients on moderate-dose) and atorvastatin 
 142 
80 mg (OR 1.15, 95% CI 1.03-1.28; I2=0%; 759 cases/9242 patients on atorvastatin 80 
mg vs. 666 cases/9209 patients on moderate-dose) (p=0.56 for interaction) (Figure 
5.7). In contrast, there was no significant cardiovascular benefit over moderate-
dose therapy in the trials of simvastatin 80 mg (OR 0.95, 95% CI 0.88-1.03; I2=0%; 
1396 events/7166 patients on simvastatin 80mg vs. 1448 cases/7135 patients on 
moderate-dose) whereas there was for atorvastatin 80 mg (OR 0.78, 95% CI 0.73-
0.85; I2=14%; 1738 events/9242 patients on atorvastatin 80mg vs. 2102 events/9209 
patients on moderate-dose) (p<0.001 for interaction). Three trials were conducted 
in stable coronary heart disease patients (n=25,853 (136;138;139)) and two in 
patients following a recent acute coronary syndrome (n=6,899 (140;141)). Intensive 
statin therapy was associated with higher odds of incident diabetes following acute 
coronary syndrome (OR 1.15, 95% CI 0.85-1.54; 166 cases/3475 patients on intensive 
therapy vs. 146 cases/3424 patients on moderate-dose) and in stable coronary heart 
disease (OR 1.12, 95% CI 1.03-1.22; 1283 cases/12933 patients on intensive therapy 
vs. 1154 cases/12920 patients on moderate-dose), while cardiovascular events were 
lower in both conditions (OR 0.86 [95% CI 0.76-0.98], 527 events/3475 patients vs. 
589 events/3424 patients; and OR 0.83 [95% CI 0.70-0.98], 2607 events/12933 
patients vs. 2961/12920 patients respectively) (Figure 5.8); there was no significant 
heterogeneity for these outcomes by study cohort.  
 
Sensitivity analyses 
 
In sensitivity analyses, the overall risk of developing diabetes (assessed in three 
trials (136;138;139)) and the reduction in cardiovascular events (assessed in five 
trials), calculated by combining trial-specific HRs, produced similar results to the 
primary analysis (Figure 5.9). Notably, the trial-specific ORs and HRs for new-onset 
diabetes were also very similar (Table 5.6). The risk of developing diabetes on 
intensive statin therapy using non-standard diagnostic criteria in two trials, namely 
TNT and IDEAL, was also qualitatively similar to the primary analysis where 
standard diagnostic criteria were used (OR 1.11, 95% CI 1.03-1.21) (Figure 5.10). 
Fixed-effects model meta-analysis produced similar trial-specific results and 
identical pooled results to random-effects model meta-analysis for new-onset 
diabetes when pooling data from the five trials (OR 1.12 [95% CI 1.04-1.22]. Finally, 
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risk of new-onset diabetes was also analysed using 99% CI as opposed to 95% CI. This 
yielded the following results: OR 1.12 (95% CI 1.01-1.25).
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Table 5.2. Baseline data from five large endpoint trials comparing intensive to moderate dose statin therapy   
 
Patients 
without 
diabetes 
(baseline) 
/ All 
patients 
Trial 
patients 
Intensive / 
moderate 
regimens 
N 
intensiv
e statin/ 
N 
moderat
e dose 
Mean 
follow 
up 
(yr) 
Methods of diagnosing 
diabetes 
BMI 
(kg/m2) 
Age 
(yr) 
HDL-c 
(mmol/L) 
LDL-c 
(mmol/L) 
Relative 
%LDL-c 
reduction
‡ 
Natural 
log (Trig 
mmol/L) 
FPG 
(mmol/L) 
FPG 
taken 
after 
baseline 
PROVE 
IT-TIMI 
22 
(141) 
3395/ 4162 
(82%) 
Recent 
acute 
coronary 
syndrome 
Atorvastatin 
80mg / 
Pravastatin 
40mg 
1707 / 
1688 
2.0 
(0.6) 
(i) Adverse event report 
(ii) DM medication 
(iii) Two FPG ≥7.0mmol/L 
29 (5) 
58 
(11) 
1.0 (0.3) 2.8 (0.8) 22% 
0.57 
(0.44) 
5.8 (0.6) + 
Not 
specified+ 
A to Z 
(140) 
 
3504/ 4497 
(78%) 
Recent 
acute 
coronary 
syndrome 
Simvastatin 
40mg, 
Simvastatin 
80mg / 
Placebo, 
Simvastatin 
20mg 
1768 / 
1736 
2.0 
(1.5-
2.0)* 
(i) Adverse event report 
(ii) DM medication 
- 
60 
(11) 
1.0 (0.3) 2.9 (0.7) 15% 
0.52 
(0.39) 
- - 
TNT 
(138) 
** 
7595/ 
10001 (76%) 
Stable 
coronary 
heart 
disease 
Atorvastatin 
80mg / 
Atorvastatin 
10mg 
3798 / 
3797 
5.0 
(0.5) 
(i) Adverse event report 
(ii) Two FPG ≥7.0mmol/L 
(iii) DM medication 
28 (4) 
61 
(9) 
1.2 (0.3) 2.5 (0.5) 22% 
0.41 
(0.42) 
5.4 (0.6) Annual 
IDEAL 
(139) 
** 
7461/ 8888 
(84%) 
Previous 
myocardial 
infarction 
Atorvastatin 
80mg / 
Simvastatin 
20mg/40mg 
3737 / 
3724 
4.8 
(4.4-
5.0)* 
(i) Adverse event report 
(ii) Two FPG ≥7.0mmol/L 
(iii) DM medication 
27 (4) 
62 
(10) 
1.2 (0.3) 3.2 (0.9) 16% 
0.38 
(0.44) 
5.5 (0.6) Final visit 
SEARC
H (136) 
10797/ 
12064 (89%) 
Previous 
myocardial 
infarction 
Simvastatin 
80mg / 
Simvastatin 
20mg 
5398 / 
5399 
6.7 
(1.4) 
(i) Adverse event report 
 
28 (4) 
64 
(9) 
1.1 (0.4)† 25. (0.6)† 12% 
0.48 
(0.54)† 
- - 
TOTAL 
32752/ 
39612 
(83%) 
- - 
16408 / 
16344 
4.9 
(1.9) * 
- - -   -   - 
 
Continuous variables displayed as mean (SD) or median (IQR) 
* Pooled mean (pooled SD) follow-up; † non-fasting; + 1315 FPG baseline results from the PROVE IT-TIMI 22 participants (equally distributed between treatment 
arms); 
‡ calculated as [LDLc (intensive arm) – LDLc (moderate dose arm)] / LDLc (baseline); ** excludes patients with known diabetes mellitus and/or ≥FPG 7.0mmol/L 
at baseline  
DM diabetes mellitus; FPG fasting plasma glucose; BMI: body mass index 
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Table 5.3. Delphi scores for trials included in meta-analysis 
 
Parameter A B C D E F G H I Total 
           
Trial           
PROVE-IT 
TIMI 22 
1 1 1 1 1 1 1 1 1 9 
A to Z 1 1 1 1 1 1 1 1 1 9 
TNT 1 1 1 1 1 1 1 1 1 9 
IDEAL 1 0 1 1 1 0 0 1 1 6 
SEARCH 1 1 1 1 1 1 1 1 1 9 
 
For definitions of parameters A-I please refer to Table 4.2
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Table 5.4. Pooled event rates and odds ratios for individual components of the composite cardiovascular endpoint 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
includes fatal and non-fatal strokes from IDEAL (139) 
Endpoints Intensive regimen: 
Event rate (SD), 
expressed as events 
per 1000 patient years 
[Events / number of 
patients] 
Moderate-dose: 
Event rate (SD), 
expressed as events 
per 1000 patient 
years [Events / 
number of patients] 
Odds ratio (95%CI) I2 (95% CI) Annual number 
needed to treat 
Cardiovascular 
death 
9.12 (4.78) 
[759 / 16408] 
10.04 (5.85) 
[789 / 16342] 
0.94 (0.83-1.07) 15% (0-82%) 1087 
Non-fatal 
myocardial 
infarction 
13.74 (8.45) 
[912 / 16408] 
15.47 (8.54) 
[1041 / 16342] 
0.87 (0.79-0.95) 0% (0-79%) 578 
Non-fatal stroke * 4.74 (1.43) 
[394 / 16407] 
5.39 (1.36) 
[436 / 16342] 
0.90 (0.78-1.03) 0% (0-79%) 1538 
Coronary 
revascularisation 
27.92 (18.86) 
[1906 / 16407] 
33.78 (21.45) 
[2326 / 16343] 
0.80 (0.71-0.90) 63% (3-86%) 171 
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Table 5.5. Trial-specific medians of five pre-specified predictors of diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* not available  
 
TRIALS Age 
(years) 
Body mass index 
(kg/m2) 
Fasting plasma 
glucose 
(mmol/L) 
HDL-
cholesterol 
(mmol/L) 
Triglycerides 
(mmol/L) 
PROVE-IT TIMI 22 57 28.2 5.4 1.0 1.7 
A to Z 60 * * 1.0 1.6 
TNT 61 27.6 5.4 1.2 1.5 
IDEAL 61 26.6 5.4 1.2 1.5 
SEARCH 65 27.4 * 1.0 1.6 
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Table 5.6. Comparison of hazard ratios and odds ratios for new-onset diabetes in three trials 
 
Trial Hazard ratio (95% CI) Odds ratio (95% CI) 
TNT 1.18 (1.02-1.36) 1.19 (1.02-1.38) 
IDEAL 1.16 (0.96-1.39) 1.15 (0.95-1.40) 
SEARCH 1.07 (0.96-1.20) 1.07 (0.95-1.21) 
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Figure 5.4. Meta-analysis of new-onset diabetes and first major cardiovascular events in five large trials comparing intensive 
statin therapy to moderate dose therapy 
INCIDENT DIABETES
PROVE-IT TIMI 22
A to Z
TNT
IDEAL
SEARCH
Pooled odds ratio
INCIDENT CVD
PROVE-IT TIMI 22
A to Z
TNT
IDEAL
SEARCH
Subtotal  (I-squared = 74.1%, p = 0.004)
101/1707 (5.9%)
65/1768 (3.7%)
418/3798 (11.0%)
240/3737 (6.4%)
625/5398 (11.6%)
315/1707 (18.4%)
212/1768 (12.0%)
647/3798 (17.0%)
776/3737 (20.8%)
1184/5398 (21.9%)
99/1688 (5.9%)
47/1736 (2.7%)
358/3797 (9.4%)
209/3724 (5.6%)
587/5399 (10.9%)
355/1688 (21.0%)
234/1736 (13.5%)
830/3797 (21.9%)
917/3724 (24.6%)
1214/5399 (22.5%)
1.01 (0.76, 1.34)
1.37 (0.94, 2.01)
1.19 (1.02, 1.38)
1.15 (0.95, 1.40)
1.07 (0.95, 1.21)
1.12 (1.04, 1.22)
0.85 (0.72, 1.01)
0.87 (0.72, 1.07)
0.73 (0.65, 0.82)
0.80 (0.72, 0.89)
0.97 (0.88, 1.06)
0.84 (0.75, 0.94)
1.5 2 4
Outcome/Study Intensive
Cases / n (%)
OR (95% CI)Standard
Cases / n (%)
(I2 = 0% (95% CI 0-68%), p = 0.598)
Pooled odds ratio
Odds ratio (more vs. less intensive treatment)
 
OR: odds ratio; CI: confidence interval 
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Figure 5.5. Assessment of publication bias by funnel plot and Egger’s test 
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Figure 5.6. Subgroup analyses for new-onset diabetes and first major cardiovascular events 
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Figure 5.7. A comparison of new-onset diabetes and first major cardiovascular events in trials using atorvastatin 80mg and 
simvastatin 80mg as the respective intensive regimens 
Overall pooled odds ratio
SEARCH
TNT
IDEAL
Simvastatin 80 mg
PROVE IT-TIMI 22
A to Z 
Subtotal pooled odds ratio
Subtotal pooled odds ratio
Atorvastatin 80 mg
625/5398 (11.6%)
418/3798 (11.0%)
240/3737 (6.4%)
101/1707 (5.9%)
65/1768 (3.7%)
587/5399 (10.9%)
358/3797 (9.4%)
209/3724 (5.6%)
99/1688 (5.9%)
47/1736 (2.7%)
1.12 (1.04, 1.22)
1.07 (0.95, 1.21)
1.19 (1.02, 1.38)
1.15 (0.95, 1.40)
1.01 (0.76, 1.34)
1.37 (0.94, 2.01)
1.15 (1.03, 1.28)
1.13 (0.93, 1.38)
1.5 2 4
Statin type Intensive
Cases / n (%)
Standard dose
Cases / n (%)
INCIDENT DIABETES
p-value for heterogeneity = 0.562
Odds ratio (more vs. less intensive treatment)
p-value for heterogeneity < 0.001
Overall pooled odds ratio
Subtotal pooled odds ratio
Subtotal pooled odds ratio
647/3798 (17.0%)
1184/5398 (21.9%)
212/1768 (12.0%)
315/1707 (18.4%)
776/3737 (20.8%)
830/3797 (21.9%)
1214/5399 (22.5%)
234/1736 (13.5%)
355/1688 (21.0%)
917/3724 (24.6%)
0.84 (0.75, 0.94)
0.95 (0.88, 1.03)
0.73 (0.65, 0.82)
0.78 (0.73, 0.85)
OR (95% CI)
0.97 (0.88, 1.06)
0.87 (0.72, 1.07)
0.85 (0.72, 1.01)
0.80 (0.72, 0.89)
1.5 2
Odds ratio (more vs. less intensive treatment)
Intensive
Cases / n (%)
Standard dose
Cases / n (%)
INCIDENT CVD
Simvastatin 80 mg
Atorvastatin 80 mg
 
 153 
Figure 5.8. A comparison of new-onset diabetes and first major cardiovascular events in trials of patients following a recent 
acute coronary syndrome and patients with stable coronary heart disease 
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Figure 5.9. A sensitivity analysis using hazard ratios for new-onset diabetes and first major cardiovascular events 
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Figure 5.10. Meta-analysis of new-onset diabetes using non-standard diagnostic criteria in two trials 
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5.4 Discussion 
 
This study demonstrates that use of intensive statin therapy compared with 
moderate-dose statin therapy was associated with a higher incidence of new-
onset diabetes (OR 1.12). However, intensive statin therapy was associated with 
fewer major cardiovascular events (OR 0.84). In this combined trial population, 
although the risk of new-onset diabetes and the benefit of cardiovascular event 
reduction on intensive therapy were similar in relative terms, when expressed in 
absolute terms there was one additional case of diabetes for every 498 patients 
treated for one year compared to one fewer patient experiencing a 
cardiovascular event for every 155 patients treated for one year. The 
cardiovascular benefit described here may be a conservative estimate as three 
trials have demonstrated that intensive statin therapy also reduces multiple 
cardiovascular events if intensive statin therapy is continued (142-144). These 
findings complement the recent observation of excess risk of developing 
diabetes among statin-treated patients compared to those receiving placebo 
(129).  
 
The benefits of statin therapy were consistent across all subgroups and for each 
component of the primary efficacy endpoint including cardiovascular death. 
Analyses of all-cause mortality were consistent with observations for 
cardiovascular death, although the generalisability of these findings to other 
populations is less clear as these depend upon the relative contributions of 
cardiovascular death (modified by statins) and non-cardiovascular deaths (non 
modifiable by statins) in those populations. For new-onset diabetes, however, 
there was some evidence that the odds of new-onset diabetes was higher among 
individuals with triglyceride concentrations below the median level of 
distribution on intensive statin treatment which, in the absence of a biologically 
plausible mechanism, may be a chance finding given the modest statistical 
significance in the context of multiple statistical tests. The higher incidence of 
new-onset diabetes and lower incidence of cardiovascular events was similar in 
patients following recent acute coronary syndrome and those with stable 
coronary disease. In the trials studied, whose control arms were different but 
comparable, the relative LDL-cholesterol reduction was greater in those that 
used atorvastatin 80 mg than in those that used simvastatin 80 mg (145). 
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Whereas the odds of developing diabetes was similar on both, there was a 
significantly lower odds of cardiovascular events in the trials with high-dose 
atorvastatin but not with high-dose simvastatin (132).  
 
Important questions remain. First, a potential mechanism to explain the findings 
of a higher incidence of diabetes on statin therapy compared to placebo, and 
intensive statin therapy compared to moderate-dose therapy, has not been 
identified. Possibilities include a direct and off-target effect. For example, 
statins may influence muscle or liver insulin action directly, resulting in higher 
diabetes risk. Data from an animal model suggest that statin-induced myopathy 
is associated with the development of muscle insulin resistance, providing a 
potential mechanism (146). Second, it remains unclear whether statin therapy is 
associated with a generalised tendency for an increase in diabetes risk in many 
who take statins or whether there is a specific group of individuals at particular 
risk. Analysis of data from subgroups did not provide conclusive results. Third, 
although statin therapy is associated with a higher incidence of diabetes, to 
what extent this may carry with it the important associated long-term risks of 
developing microvascular disease is unknown. At present there are no large 
clinical studies that have examined the associations of statin therapy with 
microvascular disease. In contrast, fibrate therapy is associated with lower rates 
of microvascular complications (147;148). My colleagues and I hypothesise that 
given that cardiovascular risk from diabetes is modest in the first decade after 
diagnosis (13), and as the benefit of statin therapy increases over time and in 
absolute terms with increasing age (20), net cardiovascular benefit in high-risk 
individuals will still strongly favour statin therapy. Finally, it would be of 
interest to investigate the impact of intensive statin therapy on glycaemic 
control and treatment requirements in patients with established diabetes. One 
consideration to help quantify potential concerns is the establishment of a 
registry to examine these issues of long-term risk. These findings suggest that 
clinicians should be vigilant for the development of diabetes in patients on 
intensive statin therapy.  
 
Strengths of this meta-analysis include the following: first, it was possible to 
include data from all the relevant clinical trials and thereby provide adequate 
power to detect potentially modest effects. Second, access to trial data allowed 
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relevant subgroup analyses. And third, it was possible to provide a direct 
comparison of the potential risk of new-onset diabetes with cardiovascular 
benefit thereby providing clinically useful information. Potential weaknesses 
include the following: first, different methods for diagnosing diabetes were 
available for the five trials and the trials were not designed to assess new-onset 
diabetes. However, the low heterogeneity in new-onset diabetes as well as the 
very similar sensitivity analysis using the non-standard criteria in two trials 
provides confidence in the results obtained. Second, analyses of incident 
diabetes were not pre-specified in the trial designs and only one trial (TNT) 
included regular measurement of FPG as a consequence. Because undiagnosed 
diabetes is relatively common (149), it is possible that the risk of incident 
diabetes in the trial participants may have been somewhat underestimated. 
Third, as all five trials specifically included participants with established 
coronary disease at high risk of future cardiovascular events rather than 
diabetes, these findings may not necessarily be generalisable to populations at 
higher risk of incident diabetes. Fourth, analyses were conducted without access 
to individual participant data.  
 
It is strictly true to say that, by design, the two meta-analyses described in 
Chapters 5 and 6 cannot prove that statin therapy causes new-onset diabetes. 
However, due to the fact that they incorporate data from randomised trials and 
due to the fact that other studies have suggested deteriorations in glycaemia on 
statins, there are no other compelling explanations. The possibility of survival 
bias was already mentioned in Chapter 4. Another powerful argument against 
survival bias is that ORs (which do not factor in survival) and HRs (which do 
factor in survival time) were essentially identical for TNT, IDEAL and SEARCH and 
that pooled HRs for new-onset diabetes produced the same results as pooled ORs 
(1.12). Another suggestion has been that in some statin trials, patients may be 
aware of their treatment allocation despite double-blinding i.e. based on 
knowledge of their lipid results during trials. The argument is that such patients 
may be reassured by their improved lipid results which may lead them to adopt 
poorer lifestyles (less exercise and poor diet with concomitant weight rise) 
which increases risk of diabetes. Again, the small relative rise in weight in 
rosuvastatin recipients in JUPITER compared to placebo (0.3kg) (117) cannot 
explain a 25% increase in diabetes. A final suggestion has been that those 
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allocated to statins in trials may have experienced considerably more side-
effects than those on placebo, leading them to seek medical attention and 
consequently increasing the chance of being screened for diabetes. However, 
side-effect profiles from JUPITER and SPARCL (22;105), trials with 25% and 44% 
increases in new-onset diabetes on statin, were very similar with the results that 
this cannot explain the observed increase in diabetes. 
 
In conclusion, this meta-analysis extends earlier findings of an increased 
incidence of diabetes with statin therapy by providing evidence of a dose-
dependent association.  
 
The results provided in this chapter were published in JAMA in 2011 (150). 
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Chapter 6. 
 
Predictors of development of diabetes in patients with chronic heart failure 
in the Candesartan in Heart Failure Assessment of Reduction in Mortality and 
Morbidity program 
 
6.1 Introduction 
 
Diabetes and chronic heart failure are both common conditions and 
epidemiological studies have demonstrated that they often coexist (24). For 
example, while the prevalence of chronic heart failure in the general population 
is 1-4% (largely dependent on age), this rises to ~12% in patients with diabetes 
(151-153). Similarly, while the prevalence of diabetes is 4-7% in the general 
population, this rises to 6-25% in patients with known left ventricular systolic 
dysfunction and further to 12-30% in those with symptomatic heart failure (24). 
The prevalence of diabetes in clinical trial cohorts with heart failure has 
typically been 20-30% and, though one should be cautious in extrapolating these 
data to the general population, it is clear that diabetes occurs very commonly in 
heart failure. Diabetes is also a risk factor for developing heart failure (24;154).   
 
While diabetes and heart failure commonly coexist as described, there is as yet 
no established explanation for why this occurs. One hypothesis requiring 
consideration is that the reactive hyperadrenergic state found in heart failure 
leads to an increase in the levels of circulating fatty acids which then leads to 
impaired glucose tolerance (IGT) and insulin resistance, possibly via free fatty 
acid-induced mitochondrial uncoupling (Figure 6.1) (155). Further data of 
interest come from a recent observational study in 15 patients with diabetes and 
severe heart failure who were treated with left ventricular assist devices. After 
4 months there were marked reductions in FPG (8.8mmol/L to 5.8mmol/L), 
HbA1c (7.7% to 6.0%) and the need for glucose-lowering medication (six patients 
stopped medication) providing further support for a link between heart failure 
and diabetes (156). 
 
One advantage of recognising this link between diabetes and heart failure is that 
it provides an opportunity to screen for diabetes in a high risk group of patients. 
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There may be additional benefits however. Chronic heart failure patients with 
diabetes are also more likely to be hospitalised (126) and they suffer more 
complications including increased cardiovascular morbidity and mortality than 
patients with chronic heart failure alone (127). Consequently it is possible, 
though as yet unproven, that approaches to reduce progression to diabetes in 
chronic heart failure may benefit patients by allowing targeted preventative 
measures. To achieve this it is necessary to be able to predict new-onset 
diabetes in chronic heart failure but, to date, little work has been done in this 
area. By contrast, diabetes prediction algorithms are available for the general 
population.  
 
Strong predictors of diabetes in the general population are well established. 
They include (i) measures of adiposity such as BMI, waist circumference, waist to 
hip ratio (157) – typically these measurements give univariate AUROC for 
developing diabetes of 0.66-0.73, (ii) dysglycaemia as demonstrated by abnormal 
fasting or post-load glucose levels (158), or elevated HbA1c (159;160) – typically 
these findings give an AUROC of 0.73-0.77, and (iii) combinations of measures of 
adiposity and dysglycaemia (161). These and other weaker predictors have been 
combined in risk algorithms such as the Cambridge Diabetes Risk Score which 
includes age, gender, BMI, family history of diabetes, smoking history and history 
of treatment with antihypertensive or steroid medications (AUROC 0.80) (162). 
Whether these same predictors may be useful in chronic heart failure to predict 
diabetes is unclear given the nature of the disease. For example, patients with 
heart failure are known to develop skeletal muscle atrophy (163) and this 
alteration in the usual balance between body fat and muscle plus potential 
effects on glucose handling by muscle in heart failure may theoretically alter the 
expected relationship between BMI and new-onset diabetes.  
 
In summary, while data on the development of heart failure in patients with 
diabetes are widely available, there have been no data published regarding 
potential predictors of diabetes in patients with chronic heart failure. Using 
retrospective analysis of existing data from a large clinical trial conducted in 
patients with chronic heart failure, I investigated which characteristics were 
associated with development of diabetes.  
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Figure 6.1. In heart failure, increased free fatty acid release from adipose tissue 
inhibits muscular glucose uptake with resultant hyperglycaemia and insulin 
resistance  
 
 
 
 
Adapted from Opie et al (155) and provided with the permission of Elsevier © 
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6.2 Methods 
 
Aims of the analysis 
 
The aim was to identify risk factors for the development of diabetes in chronic 
heart failure and to assess the statistical predictive capabilities of any identified 
risk factors. This was undertaken using data from the previously conducted 
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity 
(CHARM) program. 
 
Agreement for Data sharing with AstraZeneca 
 
In 2008 a data analysis plan was submitted to AstraZeneca with the intention of 
carrying out the analyses described. This was approved by the CHARM steering 
committee and agreed with AstraZeneca (see Figure 6.2). 
 
Background to CHARM 
 
The CHARM program consisted of three parallel trials with complementary 
populations of patients with symptomatic chronic heart failure. The three 
patient groups were (i) patients with chronic heart failure and reduced left 
ventricular ejection fraction (LVEF) (≤0.40) already taking an ACE-inhibitor (the 
CHARM-Added trial) (164), (ii) patients with chronic heart failure and reduced 
LVEF (≤0.40) intolerant to ACE-inhibitor therapy (CHARM-Alternative trial) (165), 
and (iii) patients with chronic heart failure and preserved LVEF (>0.40) (CHARM-
Preserved trial) (166). Results were also published for the combined cohort in 
the CHARM-Overall trial (167). The trial was completed in 2002. The current 
analyses from CHARM were post-hoc and were not prespecified. 
 
CHARM patients: selection 
 
In the combined cohort, 7601 patients, of whom 2163 had diabetes at baseline, 
were randomised to either candesartan or placebo and followed up for a median 
of 38 months. Candesartan therapy was titrated up incrementally to a maximum 
dose of 32mg daily or as much as tolerated. In CHARM, demographic data were 
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available for the majority of the combined cohort but laboratory data were only 
available for 2743 patients, 1021 (37%) with diabetes and 1722 (63%) with no 
history of diabetes, and these patients were recruited in North America. 
Therefore, in the analysis of predictors of the development of diabetes, only 
data from patients with complete datasets (including laboratory data) were 
analysed. Complete datasets (defined as containing all baseline clinical and 
demographic data, medications, blood results and randomisation data) were 
available for 1620 non-diabetic patients out of the 1722. 
 
Diagnosis of diabetes in CHARM 
 
Investigators were asked to report the occurrence of a new diagnosis of diabetes 
for all patients at the end of the CHARM trials. Fasting blood tests were not 
performed as part of the CHARM program, and formal tests for diabetes were not 
done. Details of diagnoses of diabetes (date of diagnosis, details of the criteria 
for diagnosis [whether based on FPG values ≥7.0mmol/L or post challenge 
glucose values of ≥11.1mmol/L or random glucose values ≥11.1mmol/L), any 
hypoglycaemic medication prescribed, and lifestyle modifications prescribed) 
during the study were documented on CHARM case report forms (Figure 6.3) at 
the closing study visit and the physician recording the data was required to make 
the relevant enquiries. Importantly therefore, although CHARM itself did not 
include biochemical methods to diagnose diabetes, it was able to report 
physician diagnosed diabetes rather than self-reported diabetes, and this has 
been shown to be a robust and standard method. 
 
Available data in CHARM 
 
Based on the knowledge that this was the first examination of predictors of 
diabetes in a large heart failure cohort, all available variables were considered 
potential predictors of diabetes and were therefore included in the analyses. 
The following data were available at baseline in CHARM: 
o Demographics and medical history: age, gender, smoking status, medical 
history of myocardial infarction and hypertension, use of medications 
(ACE-inhibitors, B-blockers, diuretic therapy, nitrates, spironolactone, 
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digoxin, calcium channel blockers, lipid-lowering therapy, oral 
anticoagulants) 
o Clinical measurements: BMI, systolic blood pressure, LVEF 
o Symptomatic grading of heart failure: NYHA class II, III and IV (168) 
o Laboratory biochemical analyses: HbA1c, electrolytes, serum creatinine, 
liver enzymes, full blood count and haematological data. All were carried 
out in central core laboratories using standard methods. HbA1c was 
measured on an automated high-performance liquid chromatography 
analyser (Bio-Rad Variant Analyser, GMI, Ramsey, MN) using a Diabetes 
Control and Complications Trial-aligned assay (169). 
o Randomised treatment: placebo or candesartan allocation at baseline 
 
Statistical analysis 
 
With regard to baseline characteristics, continuous and normally distributed data 
are presented as mean (SD), continuous and skewed data as median (25th 
centile, 75th centile) and categorical data as number (percentage).  
 
Univariate and multiple logistic regression analyses were carried out to identify 
those variables associated with the development of diabetes and these are 
expressed as ORs (95% CI). For attempting to identify independent predictors of 
diabetes, two methods of multivariate logistic regression were used: (i) multiple 
logistic regression including only those variables with a significant or borderline 
significant association with incident diabetes on univariate logistic regression 
(variables which demonstrated an association with diabetes and p<0.10 were 
included) and (ii), as an additional check (given the large number of parameters 
identified as potentially relevant), a forward-backward stepwise selection 
process was also performed and results were again expressed as ORs. The 
forward-backward selection procedure starts with estimating an intercept for 
the model, followed by a forward selection step. In this step the score χ2 
statistic for each of the considered factors not yet included in the model is 
computed. If the effect with the largest statistic is significant at a prespecified 
entry significance level, the corresponding factor is added to the model. This is 
followed by a backward selection step. In this step, parameters for the complete 
model, as specified after the previous step, are estimated. The least significant 
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factor that does not meet a prespecified significance level is removed. The 
backward selection step is repeated until no factor is removed. The forward step 
is then repeated and followed by one or more backward elimination steps. The 
selection process terminates if no further factor can be added or if the factor 
just entered is the only factor removed in the subsequent backward elimination.  
 
For the purpose of estimating the ability of variables to predict the development 
of diabetes, AUROC analysis was performed in a stepwise mode whereby AUROC 
was repeatedly estimated as independently predictive variables were added to 
the model. The more recently proposed tools of Net Reclassification 
Improvement and Integrated Discrimination Improvement, which are better 
suited to examining the effect of adding a new variable to an existing risk score, 
were not used. 
 
Note 
 
Given that the CHARM program was an industry funded study, data are held by 
AstraZeneca and not released in raw format.  
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Figure 6.2. Data request sent to and agreed with AstraZeneca 
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Figure 6.3. Section for reporting new-onset diabetes in the CHARM case report 
form  
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6.3 Results 
 
Data for new-onset diabetes in the entire cohort and North American cohort in 
CHARM 
 
In the entire CHARM cohort of 7601 participants randomised to treatment, 2163 
(28.5% prevalence) were known to have diabetes at baseline. Of the 5438 
participants with no known diabetes at baseline, 365 (6.7%) developed diabetes 
during CHARM, an incidence of 21 cases per 1000 patient years. In the North 
American cohort (n=2743) on whom the following results are based, 1021 (37.2% 
prevalence) were known to have diabetes at baseline. Of the remaining 1722 
patients in North America who had blood samples analysed for general 
biochemistry, 1620 had full datasets at baseline including HbA1c results. Over 
the median follow-up period of 2.8 years, 126 (7.8%) of the 1620 initially non-
diabetic North American participants developed diabetes reflecting an incidence 
of 27.8 cases per 1000 patient years.  
 
The new diagnoses of diabetes were made as follows during CHARM: 
o 78 (62%) diagnoses based on elevated FPG 
o 7 diagnoses based on abnormal oral glucose tolerance tests (OGTTs) 
o 5 diagnoses based on a combination of FPG and OGTT 
o 36 cases did not have the method of diagnosis listed on the case report 
forms 
 
Baseline Characteristics of CHARM participants 
 
Baseline characteristics of the 1620 patients whose data are analysed in this 
chapter are provided in Table 6.1. Data are available both for the North 
American cohort combined and also separately for those who did (n=126) and did 
not (n=1494) develop diabetes during CHARM. The mean age of the North 
American cohort was 66.1 years and 67.3% were male. Other characteristics 
include the mean baseline BMI of 28.5kg/m2, a mean LVEF of 0.38 and mean 
HbA1c of 6.3%. A history of hypertension was reported by 62% and 16% were 
current smokers. The majority were on beta-blocker and diuretic therapy and 
most were in NYHA class III. Half the participants were randomised to 
 171 
candesartan and placebo respectively. Differences in the baseline characteristics 
between those who did and did not develop diabetes are dealt with in the 
following section. 
 
Univariate associations of variables with new-onset diabetes in heart failure 
 
Numerous parameters and variables measured at baseline showed significant 
positive associations with new-onset diabetes in univariate analyses (Table 6.2). 
Listed in order of decreasing significance (defined by the Wald Chi squared 
statistic) they are as follows: higher HbA1c (OR 2.30 per 1% increase), higher BMI 
(OR 1.10 per 1kg/m2 increase), lower age (OR 0.97 per 1 year increase), use of 
diuretic therapy at baseline (OR 6.4), use of digoxin therapy at baseline (OR 
1.77), lower serum creatinine concentration (OR 0.99 per 1umol/L increase), 
lower serum potassium concentration (OR 0.53 per 1mmol/L increase), lower red 
cell mean corpuscular volume (OR 0.96 per 1fL increase), higher red cell count 
(OR 1.53 per 1X1012/L increase), use of beta-blocker therapy at baseline (OR 
1.55), higher leukocyte count (OR 1.09 per 1X109/L increase), use of lipid-
lowering therapy at baseline (OR 1.49), use of spironolactone therapy at 
baseline (OR 1.62), lower mean corpuscular haemoglobin (OR 0.92 per 1pg 
increase), higher serum alanine aminotransferase (ALT) concentration (OR 1.01 
per 1U/L increase), and lower serum sodium concentration (OR 0.94 per 
1mmol/L increase). Of these, higher HbA1c and higher BMI were comfortably the 
variables most strongly associated with new-onset diabetes. The data for HbA1c 
and BMI were also examined per SD change. For every one SD higher HbA1c and 
BMI, new-onset diabetes was 79% (OR 1.79 [1.54-2.08]) and 78% (OR 1.78 [1.53-
2.09]) more likely, respectively.   
 
The relationship between BMI and new-onset diabetes was studied after dividing 
participants into BMI quartiles (see Table 6.3) to assess the linearity of the 
relationship. It was clear that a strong linear relationship existed, allowing 
further analyses using BMI as a continuous measure. Those with BMI ≥28.0 kg/m2 
were 4.3 (2.8-6.6) times more likely to develop diabetes than those with lower 
BMI. 
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Independent predictors of new-onset diabetes in heart failure 
 
Two approaches were taken to identify any independent predictors of new-onset 
diabetes in heart failure patients. First, all measures which demonstrated a 
significant or borderline significant relationship with the development of 
diabetes (as defined by p<0.10 in univariate analysis; 17 variables) were included 
in a logistic regression model. In the second approach, a forward-back stepwise 
selection method was employed (see Methods for full explanation). 
 
In the first approach (using p<0.10), the following measures continued to 
demonstrate significant positive associations with new-onset diabetes (in 
decreasing order of significance): higher HbA1c (OR 2.20 per 1% increase), higher 
BMI (OR 1.09 per 1kg/m2 increase), use of lipid-lowering therapy at baseline (OR 
2.12), lower serum creatinine concentration (OR 0.99 per 1umol/L increase), use 
of diuretic therapy at baseline (OR 4.17), higher serum ALT concentration (OR 
1.01 per 1U/L increase) and the use of digoxin at baseline (OR 1.73) (Table 6.2). 
As before, HbA1c and BMI demonstrated highly significant associations with new-
onset diabetes.  
 
In the second approach (stepwise selection), the measures which showed 
significant associations with the development of diabetes were much the same 
as in the above approach (Table 6.4). On this occasion, ORs are provided per SD 
difference in continuous measures. In decreasing order of significance the 
relevant measures were: higher HbA1c (OR 1.78 per 1SD increase), higher BMI 
(OR 1.64 per 1SD increase), use of lipid-lowering therapy at baseline (OR 2.05), 
lower serum creatinine concentration (OR 0.68 per 1SD increase), use of diuretic 
therapy at baseline (OR 4.81), the use of digoxin at baseline (OR 1.65), higher 
serum ALT concentration (OR 1.15 per 1SD increase) and younger age (OR 0.81 
per 1SD increase). Expressed in another way, for every 1% higher HbA1c in this 
second multivariable model, the OR for developing diabetes was 2.28 (1.82-2.85) 
and for every 1kg/m2 higher BMI, the OR for developing diabetes was 1.09 (1.05-
1.12) (data not shown in tables).  
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The predictive capabilities of baseline variables for new-onset diabetes in heart 
failure 
 
To assess the ability of the baseline variables to predict diabetes, factors 
significantly associated with incident diabetes in multivariable analyses were 
analysed by calculating AUROCs. In univariate predictive analysis, AUROC for 
HbA1c alone was 0.72 (Table 6.5). The optimal point for predicting new-onset 
diabetes was at an HbA1c of 6.5% which provided a sensitivity of 0.63 and a 
specificity of 0.70. AUROC for BMI in univariate analysis was 0.71. Using the 
optimal point for diabetes prediction, namely BMI 29.1kg/m2, yielded a 
sensitivity of 0.73 and a specificity of 0.63. For all other factors, AUROCs were 
<0.63 and serum ALT performed the best. 
 
In multivariate analysis, the combination of HbA1c and BMI provided an AUROC 
of 0.79 with a sensitivity of 0.73 and specificity of 0.72 for predicting future 
diabetes (Table 6.6). The addition of other elements, which were significantly 
associated with new-onset diabetes in multivariate logistic regression, improved 
the overall AUROC modestly to a maximum value of 0.82.  
 
 174 
Table 6.1. Baseline characteristics of the 1,620 North American patients with 
full core laboratory datasets in CHARM with no medical history of diabetes at 
baseline, grouped by those who did and did not develop diabetes 
  
All participants No diabetes during 
trials   
Diabetes during 
trials 
All patients  1,620 (100) 1,494 (92.2)  126 (7.8) 
Age (years)  66.1 (12.1) 66.4 ± 12.0  61.5 ± 12.3 
Sex (% male)  1090 (67.3)) 1,008 (67.5)  82 (65.1) 
BMI (kg/m2)  28.5 (6) 28.2 ± 5.9  32.4 ± 6.2 
Smoking habit  
    Non-smoker  489 (30.2) 451 (30.2)  38 (30.2) 
    Previous smoker  877 (54.1) 804 (53.8)  73 (57.9) 
    Current smoker  254 (15.7) 239 (16.0)  15 (11.9) 
Systolic blood pressure (mmHg)  127 ± 19 127 ± 19  130 ± 19 
History of prior myocardial 
infarction  
822 (50.7) 
763 (51.1)  59 (46.8) 
History of hypertension  1000 (61.7) 915 (61.2)  85 (67.5) 
NYHA class  
    II  645 (39.8) 600 (40.2)  45 (35.7) 
    III  938 (57.9) 860 (57.6)  78 (61.9) 
    IV 37 (2.3) 34 (2.3)  3 (2.4) 
Left ventricular ejection fraction 0.38 ± 0.2 0.38 ± 0.2  0.36 ± 0.2 
Drug therapy  
    ACE-inhibitors  698 (43.1) 636 (42.6)  62 (49.2) 
    Beta-Blocker  871 (53.8) 791 (52.9)  80 (63.5) 
    Diuretic therapy  1357 (83.8) 1,235 (82.7)  122 (96.8) 
    Long-acting nitrates  405 (25.0) 380 (25.4)  25 (19.8) 
    Spironolactone  242 (14.9) 215 (14.4)  27 (21.4) 
    Digoxin  848 (52.3) 766 (51.3)  82 (65.1) 
    Calcium channel blocker  383 (23.6) 353 (23.6)  30 (23.8) 
    Lipid-lowering drug  739 (45.6) 670 (44.8)  69 (54.8) 
    Oral anticoagulant  520 (32.1) 484 (32.4)  36 (28.6) 
Laboratory results  
   HbA1C (%)  6.3 (0.7) 6.2 ± 0.7  6.8 ± 0.9 
    Creatinine (umol/L)  99 ± 34 100 ± 35  91 ± 26 
    Potassium (mmol/L)  4.4 ± 0.4 4.4 ± 0.4  4.3 ± 0.4 
    Sodium (mmol/L)  141 ± 3 141 ± 3  140 ± 3 
    ALT (units/L)  18 (13-25) 18 (13–25)  23 (16–33) 
    AST (units/L)  20 (16–25) 20 (16–25)  20 (17–26) 
    Alkaline phosphatase (units/L)  80 (65-97) 79 (65–97)  85.5 (69–106) 
    Bilirubin total (umol/L)  10.0 (6.8-13.7) 10.0 (6.8–13.7)  10.3 (8.0–12.0) 
    Bilirubin direct (umol/L)  2.0 (1.7–4.0) 2.0 (1.7–4.0)  2.0 (1.7–3.4) 
    Haemoglobin (mmol/L)  8.5 ± 1.0 8.5 ± 1.0  8.6 ± 0.8 
    Haematocrit (%)  41.2 ± 4.5 41.2 ± 4.6  41.5 ± 3.7 
    Red cell count (1012/L)  4.5 ± 0.5 4.5 ± 0.5  4.6 ± 0.5 
    MCV (fL)  92.5 ± 5.9 92.6 ± 5.9  91.2 ± 5.3 
    MCH (pg)  30.9 ± 2.4 30.9 ± 2.4  30.5 ± 2.0 
    MCHC (mmol/L)  20.7 ± 0.7 20.7 ± 0.7  20.8 ± 0.7 
    White cell count (109/L)  7.2 ± 2.1 7.1 ± 2.1  7.6 ± 2.1 
    Eosinophils (%)  2.7 (1.7–4.1) 2.7 (1.7–4.1)  2.5 (1.6–3.4) 
    Lymphocytes (%)  25.8 ± 8.6 25.8 ± 8.6  26.8 ± 8.4 
    Basophils (%)  0.3 (0.2–0.5) 0.3 (0.2–0.5)  0.3 (0.2–0.6) 
    Neutrophils (%)  63.9 ± 9.5 63.9 ± 9.5  63.5 ± 9.5 
    Neutrophils band (%)  1 (0–3) 1 (0–3)  0.5 (0–1) 
    Monocytes (%)  6.7 ± 2.7 6.7 ± 2.7  6.6 ± 2.4 
Treatment randomisation  
    Candesartan  805 (49.7) 751 (50.3)  54 (42.9) 
 
BMI: body mass index; NYHA: New York Heart Association; MCV: mean corpuscular volume; MCH: 
mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; ALT: 
alanine-aminotransferase; AST: aspartate aminotransferase; mean (SD), n (%) or median (IQR)
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Table 6.2. Baseline characteristics associated with the development of diabetes in CHARM as analysed by univariate and multiple 
logistic regression analyses 
 
 Univariate logistic regression Multiple logistic regression* 
 
Wald Chi 
Sq P value OR (95%CI) 
Wald 
Chi Sq P value OR (95%CI) 
HbA1C (per %)   58.8 <0.0001   2.30 (1.86–2.84)   43.9 <0.0001   2.20 (1.74–2.78) 
BMI (per kg/m2)  52.7 <0.0001  1.10 (1.07–1.13)  24.7 <0.0001  1.09 (1.05–1.12) 
Age (per year)  19 <0.0001  0.97 (0.96–0.98)  1.3 0.25 0.99 (0.97–1.01) 
Diuretics at baseline (yes vs. no)  13.1 0.0003 6.39 (2.34–17.46)  6.9 0.008 4.17 (1.44–12.05) 
Digoxin (yes vs. no)  8.7 0.003 1.77 (1.21–2.59)  5.9 0.016 1.73 (1.11–2.69) 
Creatinine (per umol/L)  8.5 0.004 0.99 (0.98–1.00)  8.6 0.003 0.99 (0.98–1.00) 
Potassium (per mmol/L)  8.2 0.004 0.53 (0.34–0.82)  3.3 0.07 0.63 (0.39–1.04) 
MCV (per fL)  7.4 0.007 0.96 (0.93–0.99)  0.9 0.34 0.96 (0.89–1.04) 
Red cell count (per 1012/L)  5.7 0.02 1.53 (1.08–2.18)  0 0.97 1.01 (0.65–1.57) 
Beta-Blocker (yes vs. no)  5.1 0.02 1.55 (1.06–2.25)  3.6 0.06 1.50 (0.99–2.27) 
White cell count (per 109/L)  5.1 0.02 1.09 (1.01–1.18)  0.1 0.75 0.99 (0.90–1.08) 
Lipid-lowering therapy (yes vs. no)  4.6 0.03 1.49 (1.03–2.15)  12.8 0.0003 2.12 (1.41–3.20) 
Spironolactone (yes vs. no)  4.5 0.03 1.62 (1.04–2.54)  1.3 0.25 1.35 (0.81–2.23) 
MCH (per pg)  4.4 0.04 0.92 (0.85–1.00)  0.2 0.64 1.04 (0.87–1.25) 
ALT (per units/L)  4.3 0.04 1.01 (1.00–1.02)  6 0.015 1.01 (1.00–1.02) 
Sodium (per mmol/L)  3.9 0.048 0.94 (0.89–1.00)  0.7 0.41 0.97 (0.91–1.04) 
Eosinophils (per %)  3.9 0.049 0.91 (0.83–1.00)  2.5 0.12 0.91 (0.81–1.02) 
Candesartan therapy (placebo vs. 
candesartan)  2.5 0.11 1.35 (0.93–1.95)  
* * * 
ACE-inhibitors (yes vs. no)  2.1 0.15 1.31 (0.91–1.88)  * * * 
Bilirubin direct (per umol/L)  2 0.16 0.94 (0.86–1.03)  * * * 
Long-acting nitrates (yes vs. no)  1.9 0.17 0.73 (0.46–1.14)  * * * 
Systolic blood pressure (per mmHg)  1.9 0.17 1.01 (1.00–1.02)  * * * 
Medical history: hypertension (yes vs. no)  1.9 0.17 1.31 (0.89–1.93)  * * * 
Lymphocytes (per %)  1.6 0.21 1.01 (0.99–1.03)  * * * 
Left ventricular Ejection fraction  1.5 0.22 0.48 (0.15–1.54)  * * * 
MCHC (per mmol/L)  1.3 0.25 1.16 (0.90–1.48)  * * * 
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Basophils (per %)  1.2 0.27 1.32 (0.81–2.15)  * * * 
Haemoglobin (per mmol/L)  1.2 0.28 1.11 (0.92–1.35)  * * * 
NYHA (III or IV vs. I or II)  1 0.33 1.21 (0.83–1.76)  * * * 
Medical history: prior myocardial 
infarction (yes vs. no)  0.8 0.36 0.84 (0.59–1.21)  
* * * 
Alkaline phosphatase (per units/L)  0.8 0.38 1.00 (1.00–1.01)  * * * 
Oral anticoagulant therapy (yes vs. no)  0.8 0.38 0.84 (0.56–1.25)  * * * 
Haematocrit (%)  0.7 0.41 1.02 (0.98–1.06)  * * * 
AST (per units/L)  0.6 0.44 1.00 (1.00–1.01)  * * * 
Bilirubin total (per umol/L)  0.6 0.44 0.99 (0.96–1.02)  * * * 
Sex (female vs. male)  0.3 0.58 1.11 (0.76–1.63)  * * * 
Neutrophils (per %)  0.3 0.6 1.00 (0.98–1.01)  * * * 
Monocytes (per %)  0.1 0.73 0.99 (0.92–1.06)  * * * 
Calcium channel blocker (yes vs. no)  0.002 0.96 1.01 (0.66–1.55)  * * * 
Smoking habit (current or past vs. none)  0 0.99 1.00 (0.67–1.49)  * * * 
 
*Only factors with P < 0.10 on univariate logistic regression were included in this multiple factor logistic regression.  
For abbreviations see Table 6.1 
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Table 6.3. Diagnosis of new-onset diabetes according to BMI quartiles 
 
 Developed diabetes during study 
BMI group No Yes 
≤ 24.25 kg/m2 400 (98.0%) 8 (2.0%) 
24.25-27.70 kg/m2 383 (95.3%) 19 (4.7%) 
27.71-31.65 kg/m2 368 (90.9%) 37 (9.1%) 
>31.65 kg/m2 343 (84.7%) 62 (15.3%) 
 
BMI: body mass index
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Table 6.4. Multiple logistic regression of baseline characteristics with stepwise 
selection of all effects predicting the development of diabetes in chronic heart 
failure 
 
 Wald Chi sq P OR (95% CIs) 
HbA1C 51.6 <0.0001 1.78 (1.52–2.08) 
BMI 26.6 <0.0001 1.64 (1.36–1.98) 
Lipid-lowering 
therapy 
12.1 0.0005 2.05 (1.37–3.07) 
Serum creatinine 9.7 0.0018 0.68 (0.54–0.87) 
Diuretic therapy 8.6 0.0033 4.81 (1.69–13.69) 
Digoxin therapy 5.2 0.0221 1.65 (1.08–2.54) 
ALT (U/L) 4.9 0.0269 1.15 (1.02–1.31) 
Age 3.9 0.0476 0.81 (0.65–1.00) 
 
ORs are expressed per 1 SD change in age, BMI, ALT, HbA1C, and creatinine
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Table 6.5. Receiver operating characteristic curve analysis for single factor 
logistic regression models predicting development of diabetes mellitus 
 
Effect AUROC 
HbA1c 0.723 
BMI 0.712 
Digoxin (yes vs. no) 0.569 
Lipid-lowering therapy (yes vs. no) 0.550 
Creatinine (umol/L) 0.580 
Diuretic therapy 0.571 
ALT (U/L) 0.626 
Age (years) 0.619 
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Table 6.6. Receiver operating characteristic curve analysis for the multiple 
logistic regression, with stepwise selection and addition of effects, predicting 
development of diabetes mellitus 
 
Step Effect entered Effect removed AUROC 
1 HbA1c - 0.723 
2 + BMI - 0.788 
3 + Digoxin (yes vs. no) - 0.800 
4 + Lipid-lowering therapy (yes vs. 
no) 
- 
0.802 
5 + Creatinine (umol/L) - 0.809 
6 + Diuretic therapy - 0.813 
7 + ALT (U/L) - 0.816 
8 + Age (years) - 0.816 
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6.4 Discussion 
 
Analysis of data from the CHARM program confirmed the high prevalence and 
incidence of diabetes in patients with chronic heart failure. An estimated 
incidence of 21–28 cases per 1,000 patients per year (mean age 66 years) 
contrasts with the incidence of diabetes of 16.8 cases per 1,000 population per 
year (age 65–79 years) and 11.2 cases per 1,000 population per year (age 45–64 
years) from the National Health and Nutrition Examination Survey in 2003 in 
which self-reporting of diabetes was used (170). Data available from 1,620 of 
these patients in CHARM, of who 126 developed diabetes, showed that the two 
most powerful independent predictors of diabetes in the program were HbA1C, a 
measure of dysglycaemia, and BMI. Both gave AUROCs very similar to those 
expected in the general population. Given the worse outcomes of chronic heart 
failure described in patients with diabetes (24), the ability to better identify 
individuals at risk of diabetes may allow the clinician to take steps (e.g. lifestyle 
improvement) to reduce this risk with resultant better clinical outcomes. In view 
of evidence that HbA1C is a predictor of cardiovascular death, hospitalisation, 
and total mortality in not only diabetic but also non-diabetic patients with 
chronic heart failure, its measurement in patients with chronic heart failure may 
have clinical potential, and future studies that include FPG will allow further 
assessment of this. This is on the background of emerging support for the use of 
HbA1C as part of a screening strategy for diabetes (171).  
 
The independent associations of certain characteristics with the development of 
diabetes, namely use of lipid-lowering therapy, use of digoxin, and lower serum 
creatinine concentration, plus the strong association of diuretic use at baseline 
require further examination and explanation. With regard to baseline therapies, 
I have already confirmed the association between statin therapy and risk for 
incident diabetes in previous chapters (129;150), but these associations may also 
reflect confounding factors rather than any statin treatment effect. I am not 
aware of any data suggesting that digoxin therapy influences the development of 
diabetes. One possibility is that patients receiving both digoxin and diuretic 
therapies have more severe chronic heart failure requiring more intensive 
therapy, and, therefore, these are serving as proxies of heart failure severity. 
There is evidence that worse chronic heart failure predicts diabetes (172;173), 
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although, interestingly, neither NYHA status nor LVEF predicted new-onset 
diabetes in the present analysis. Further studies are needed to examine these 
issues. Furthermore, there are powerful data from the field of hypertension 
showing an increased incidence of diabetes on thiazide diuretic therapy relative 
to both placebo and other antihypertensive agents (174). The proportions of 
patients taking loop and thiazide diuretics in CHARM were not available. Those 
receiving multiple medications may have had blood samples for biochemical 
analyses taken more often outside the trial, thereby increasing the chance of 
detecting diabetes if FPG analyses were also performed. As shown in CHARM 
(167) and elsewhere, the use of ACE-inhibitors and ARBs leads to a rise in serum 
creatinine concentration, and so this finding may reflect confounding effects of 
treatments on diabetes risk rather than any direct association between renal 
function and diabetes risk. In addition, lower creatinine concentrations could 
partially reflect reduced muscle mass and thus a biologically plausible 
mechanism linking lower creatinine levels to elevated higher diabetes risk.  
  
The increase in risk of diabetes per unit increase in serum ALT was admittedly 
modest and of uncertain clinical significance in this analysis; furthermore, 
elevation in serum ALT may occur as a result of hepatic congestion in heart 
failure. However, it should be recognised that the association between serum 
ALT and risk of diabetes concurs with findings in the general population. Serum 
ALT, a hepatocellular enzyme, is a reasonable marker of fat accumulation in the 
liver in non-alcoholic fatty liver disease (175). Non-alcoholic fatty liver disease is 
itself a condition strongly linked to insulin resistance, type 2 diabetes, and 
obesity. Serum ALT has previously been shown to predict diabetes in different 
populations, including hypercholesterolaemic men in Scotland (176) and a 
general population cohort in Japan (177), but to my knowledge this is the first 
evidence of any association in patients with chronic heart failure. This finding 
implies that liver fat is relevant to the pathogenesis of diabetes in patients with 
chronic heart failure, as it is in individuals without this condition.  
 
The finding that younger age was an independent predictor of diabetes was 
unexpected. It may simply be that younger patients with heart failure have a 
longer survival time and consequently a greater chance to develop diabetes. An 
alternative explanation is that younger patients with chronic heart failure may 
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represent a slightly different phenotype with higher BMI and higher risk of 
diabetes compared with that of older patients. There are data to support this 
suggestion; in a substudy of 2,107 patients in CHARM, the prevalence of obesity 
(BMI ≥30 kg/m2) was four times higher in patients with chronic heart failure aged 
<50 years than in patients aged ≥80 years (data not shown). Irrespective of the 
above findings, it should be noted that age did not significantly improve AUROC 
for prediction beyond other measures.  
 
The strengths of the present analysis are the number of incident cases of 
diabetes and number of patients included in the program, together with 
excellent baseline phenotyping. There are also potential weaknesses that must 
be highlighted. Given that identifying predictors of diabetes was not a 
predetermined outcome of the CHARM program, these findings must be treated 
as post hoc. In addition, all data are limited to North American patients. Ideally, 
the diagnoses of diabetes would have been carried out uniformly under 
controlled circumstances in all patients, although pragmatic factors, as occurs in 
clinical practice, dictated otherwise. I cannot, therefore, exclude the possibility 
that patients with undiagnosed diabetes at baseline were included in the 
analysis. It would also have been preferable to measure and include FPG results 
and serum lipids, particularly serum triglycerides, but the patients were non-
fasting and so these parameters were not available. Finally, potentially useful 
data such as family history of diabetes were not available. Nevertheless, the 
results provide the first comprehensive examination of predictors of diabetes in 
patients with chronic heart failure and provide a useful framework for further 
study. 
 
In summary, the strongest predictors of development of diabetes in patients 
with chronic heart failure in the CHARM program were HbA1C and BMI, in line 
with prior observations in the general population. Other minor independent 
predictors of diabetes in part reflected disease severity or drug-associated 
diabetes risk, but their addition did not substantially improve prediction of 
diabetes. These findings suggest that simple predictors would serve well to 
identify those patients with chronic heart failure at elevated risk for developing 
type 2 diabetes. Identification of high-risk individuals may allow application of 
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approaches that reduce progression to diabetes in patients with heart failure 
and potentially result in better clinical outcomes.  
 
Data included in this chapter were published in Diabetes Care in 2009 (178). 
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Appendix.  
 
Effect of intensive control of glucose on cardiovascular outcomes and death 
in patients with diabetes mellitus: a meta-analysis of randomised controlled 
trials  
 
Please see the Acknowledgements and Declaration. This section is included as I 
made a significant contribution to the conduct of the project and because it 
provides an important back-drop to my theme of the interplay between 
glycaemia and cardiovascular disease. In particular, it should be noted that this 
work was led by Professor Kausik Ray and Dr Rao Seshasai, that Professor Ray 
wrote the first draft of the published paper and that Dr Seshasai was chiefly 
responsible for the statistical analyses. 
 
A1. Introduction 
 
Type 2 diabetes mellitus is a well established risk factor for cardiovascular 
disease. To date several observational studies have shown a positive correlation 
between measures of glycaemic control and both cardiovascular outcomes and 
microvascular disease independent of risk factors known to cluster with diabetes 
(179-181). As a result of such observations, randomised controlled trials have 
been conducted to assess whether more intensive control of glucose results in a 
reduction in long term clinical events and prolongs life compared to standard 
(less intensive) therapy. In contrast to the significant benefits demonstrated on 
microvascular outcomes (46;63), individually these trials have failed to show 
consistent beneficial effects on cardiovascular events (45;46;64;182). 
 
Such inconsistent evidence has resulted in the American Heart Association, the 
American College of Cardiology and the ADA providing a conservative class IIb 
recommendation with level of evidence A (183) for the benefit of glycaemic 
control on cardiovascular disease. It is possible, however, that the relevant 
trials were individually underpowered to demonstrate clinical benefit 
particularly if event rates were lower than expected due to better control of 
risk factors, if duration of therapy was shorter than might be needed to observe 
a clinical benefit (184) or possibly if the differences in glycaemic control were 
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less than might be needed to show a significant benefit. To address such 
uncertainties we quantitatively assessed whether more intensive control of 
glucose among individuals with type 2 diabetes mellitus results in a reduction in 
cardiovascular events and is safe compared to less intensive therapy. This report 
presents data from a literature-based meta-analysis of published randomised 
controlled clinical trials whose goal was to assess the impact of differential 
glycaemic control on cardiovascular outcomes.  
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A2. Methods   
 
Data sources 
 
We searched MEDLINE, Cochrane Central and EMBASE databases for articles 
published in English from January 1970 to January 2009 using criteria [“glucose 
OR HbA1c”] AND [“Cardiovascular disease”] AND [“diabetes mellitus”] limited to 
randomised controlled trials. This initial search provided 2439 articles which 
were further screened for inclusion using titles, abstracts and/or full texts. We 
supplemented the electronic search by a hand search of reference lists of 
relevant publications including meta-analyses and reviews (Figure 7.1).  
 
Study selection   
 
Our predefined inclusion criteria for clinical trials were carefully considered and 
included all of the following: 1) randomisation of individuals with type 2 
diabetes mellitus to a glucose lowering regimen vs. a control regimen (including 
placebo, usual care or less intensive glycaemic control) and which demonstrated 
a clinically significant difference in glycaemic control between treatment groups 
during follow up; 2) outcome trials which included cardiovascular events in the 
primary endpoint and which reported complete information on effect estimates 
or provided information in publications which would allow for effect estimates 
to be calculated for all of the following endpoints: non-fatal myocardial 
infarction, coronary heart disease events defined as fatal or non-fatal 
myocardial infarction, stroke and all-cause mortality; 3) trials conducted on 
stable individuals i.e. excluding studies of intensive glycaemic control in an 
acute hospital setting. Trials which met the above inclusion criteria were 
identified, with available information on cardiovascular outcomes and glycaemic 
control in principal publications, secondary publications and study web-sites. 
 
Six trials initially screened were eventually excluded. One trial, A Diabetes 
Outcome Progression Trial (ADOPT), did not aim to assess cardiovascular 
outcomes in the primary endpoint (61), and another trial, Rosiglitazone 
Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes 
(RECORD), was not designed to compare intensive to moderate glucose-lowering 
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(185); also, only interim RECORD data on some of the outcomes of interest were 
available without information on HbA1c during follow up at the time of 
conducting this analysis. The Diabetes REduction Assessment with ramipril and 
rosiglitazone Medication (DREAM) trial was excluded as this was conducted 
among individuals with IGT (186) and the University Group Diabetes Program  
(UGDP) trial was excluded as it had a mixture of subjects with both diabetes and 
IGT and did not provide information separately on those with diabetes or effect 
estimates for each outcome of interest in each treatment arm (187;188). Two 
further trials, STENO 2 and Kumamato, were excluded as the former tested 
multiple interventions and therefore did not purely assess intensive glucose 
control (189) and the latter did not report on the individual endpoints of interest 
but a composite endpoint of cardiovascular events which included peripheral 
vascular disease and angina (190). The search yielded five randomised controlled 
trials which fulfilled our important a priori study selection criteria. The five 
trials involving a total of 33,040 participants were: the United Kingdom 
Prospective Diabetes Study (UKPDS) which combines stratified data on the 
intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment (UKPDS 33) (63) and the effect of intensive blood-
glucose control with metformin vs. placebo in overweight patients (UKPDS 34) 
(64), the PROspective pioglitAzone Clinical Trial In macroVascular Events 
(PROactive) (42;191;192), the Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Evaluation (ADVANCE) (46), the 
Veterans Affairs Diabetes Trial (VADT) (48;193) and Action to Control 
Cardiovascular Risk in Diabetes trial (ACCORD) (45). 
 
Data extraction 
 
Together with three colleagues I abstracted information in duplicate using a 
standardised format from all relevant studies and where necessary, a fifth 
investigator, Professor Kausik Ray, adjudicated any discrepancies. Information 
was obtained on several baseline characteristics of the participants, on the 
absolute number of events (non-fatal myocardial infarction, coronary heart 
disease, stroke and all-cause mortality), and the event rates in each arm of 
randomisation. Where event rates could not be directly abstracted, they were 
calculated using published information on average follow-up duration and the 
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number of participants in each randomisation group. Information regarding 
HbA1c at baseline and during follow up was abstracted from the published 
reports. Follow-up duration was reported as a mean in PROactive and ACCORD 
and as a median in UKPDS, ADVANCE and VADT. For the purposes of 
approximation of the number of person years of follow up, the median in the 
latter 3 studies was assumed to approximate to the arithmetic mean. 
 
Statistical analysis 
 
While three out of five studies included in this meta-analysis provided 
information on HRs and CIs for each of the four main outcomes of interest, two 
of the studies did not but instead provided information on absolute numbers of 
events. Therefore, to standardise the reporting of our results, OR and 95% CIs 
were calculated from raw data from each trial. To assess the effect of more 
intensive vs. less intensive control of glucose on different outcomes, we 
conducted a random effects model meta-analysis which assumes that the true 
underlying effect varies between studies. Statistical heterogeneity across trials 
was assessed using the χ2 (p value) and I2 statistics, with a p>0.1 considered 
statistically non-significant. The I2 statistic is derived from Cochran’s Q i.e. χ2 
statistic [(Q – df/Q)*100] and provides a measure of the proportion of the overall 
variation that is attributable to between-study heterogeneity. In addition we 
assessed the likelihood of presence of publication bias using funnel plots and 
Egger test. To calculate the absolute rates of each endpoint of interest we 
divided the absolute number of events reported by the number of person years 
of follow up in the more vs. less intensive glucose control arms. Summary data 
for each endpoint were obtained by combining rates across studies using a 
random-effects model meta-analysis, as rates varied considerably between the 
studies. Other summary characteristics are presented as weighted means. For 
each analysis UKPDS 33 and 34 are combined using random effects or weighted 
means as appropriate and reported as UKPDS. As a sensitivity analysis, the main 
results (ORs) were compared with corresponding rate ratios in a random effects 
meta-analysis. All p values reported were two-sided and a p-value less than 0.05 
was considered to be statistically significant. Analyses were performed using 
Stata version 10.1 (Stata Corp, College Station, Texas). 
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Figure A.1. Flow diagram of selection of studies for inclusion in present meta-
analysis 
2439 citations identified in Medline, 
Embase, Cochrane Central and 
through search of reference lists of 
relevant articles and discussion with 
experts in the field
16 full text articles from 11 trials were 
assessed for inclusion
2423 excluded based on titles and/or abstracts due to not 
fulfilling the inclusion criteria (subjects were Type 1 
Diabetics, intervention not targeted to glucose control, 
acutely ill populations, assessed intermediate endpoints 
only, not randomized controlled trials, reviews, studies of 
mechanisms, comparison of hypoglycaemic agents but not 
intensive v.s. standard therapy) 
6 publications covering 5 trials fulfilled 
criteria (UKPDS 33 and 34 counted as 
separate publications but as one trial)
6 trials excluded: 1 trial did not pre-specify cardiovascular events as 
primary or secondary outcome (ADOPT), 1 trial excluded as it included 
individuals with impaired glucose tolerance as well as diabetes and 
provided incomplete information on all arms for each endpoint of
interest (UGDP), 1 trial excluded as change in HbA1c in treatment 
groups not available and interim analysis (RECORD), 1 trial excluded 
as only subjects with impaired glucose tolerance included (DREAM), 1 
trial excluded as cardiovascular events not included in primary 
endpoint, cardiovascular endpoints included were not definitive (e.g. 
claudication and angina) and endpoints were not clearly adjudicated 
(Kumamoto). 1 trial excluded as it tested multiple interventions and not 
purely intensive vs standard glucose lowering, and reported on a 
composite CV endpoint instead of individual end-points (STENO 2).
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A3. Results 
 
Study population 
 
Table A.1 reports the study design, baseline demographic characteristics, the 
duration of follow-up and the average HbA1c in the 5 studies included in this 
meta-analysis. The definitions of diabetes and eligibility criteria for each study 
are shown in Table A.2. Overall, there were 33,040 subjects in predominantly 
western populations who had diabetes on average for 8 years prior to enrolment. 
One study (UKPDS) enrolled subjects within the first year following diagnosis 
whereas the remaining 4 studies enrolled subjects with long-standing diabetes. 
Information on a prior history of macrovascular disease was available in 4 studies 
and ranged from 32% to 100% with one study (PROactive) mandating 
macrovascular disease in the eligibility criteria. The mean age of subjects in 
these five trials ranged from 53 to 66 years (weighted mean 62 years), with the 
proportion of women ranging from 3 to 42% (weighted mean 38 %). The average 
baseline LDL-cholesterol across studies was 3 mmol/L, the systolic blood 
pressure was 140 mmHg, and the baseline HbA1c was 7.8%. During an average 
follow-up of 4.95 years HbA1c was 0.9% lower in the more intensive treatment 
group compared to the less intensive group. 
 
Event rates by differential glycaemic control    
 
Table A.1 reports the definitions of the vascular endpoints used in the five 
trials. During approximately 163,000 person years of follow up, 1497 non-fatal 
myocardial infarctions, 2318 coronary events, 1127 fatal and non-fatal strokes 
and 2892 deaths from any cause were recorded. Table A.3 reports the event 
rates per 1000 person years of follow up in the more vs. less intensively treated 
populations in each trial. According to this combined data set there were 2.3 
fewer myocardial infarctions or 2.9 fewer coronary events for every 200 more 
intensively treated patients for 5 years (1000 person years of follow up). The 
event rates for strokes and all-cause mortality were not statistically different 
between the two arms. 
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Effect of more intensive glucose control on risk reduction 
 
Figures A.2 to A.5 show the effects of more vs. less intensive control of glucose 
on non-fatal myocardial infarctions, coronary events, stroke and death from any 
cause respectively. More intensive control of glucose significantly reduced non-
fatal myocardial infarctions by 17% (OR 0.83, 95% CI 0.75-0.93) and coronary 
heart disease events by 15% (OR 0.85, 95% CI 0.77-0.93). There was no strong 
statistical evidence of heterogeneity in the effect estimate between studies for 
either non-fatal myocardial infarctions (I2 = 0.0%, 95% CI 0.0 – 69.3%, p=0.61) or 
for coronary events (I2 = 0.0%, 95% CI 0.0 – 52.7%, p=0.78). There was no 
significant effect of more intensive control of glucose on stroke OR 0.93, 95% CI 
0.81-1.06) or on death from any cause (OR 1.02, 95% CI 0.87-1.19). While there 
was no significant heterogeneity observed for strokes (I2 = 0.0%, 95% CI 0.0 – 
62.0%, p=0.70) there was considerable heterogeneity across studies for the 
outcome of all-cause mortality (I2 = 58.0%, 95% CI 0.0 – 84.4%, p=0.049). Rate 
ratios for more intensive vs. less intensive glycaemic control provided 
comparable results (Figure A.6). There was no strong evidence of publication 
bias from examination of funnel plots (Figure A.7). Overall there was no 
significant effect of intensive glucose lowering on heart failure (OR 1.08, 95% CI 
0.90-1.31, I2 = 62.9%), but considerable heterogeneity was observed across 
studies when separated by differential glitazones use, with the combination of 
the PROactive (100% glitazone use in the active arm) and ACCORD (92% glitazone 
use in the intensive treatment arm and 58% in the standard treatment arm) 
trials being associated with a significant excess risk of heart failure, but with no 
evidence of excess risk in the other three trials. (Figure A.8). Data on 
cardiovascular death and thus non-cardiovascular death were limited to 4 
studies as the UKPDS study did not have data on this endpoint. In the 4 studies 
which allowed for comparison between the types of death reported, there were 
no significant differences between the intensity of glucose reduction and type of 
death (Figure A.9). The effect of intensive glucose reduction on myocardial 
infarctions, coronary heart disease events, stroke and heart failure in this 
restricted cohort were consistent with the main results (Figure A.9).  
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Effect of more intensive glucose control on hypoglycaemia and weight gain 
 
Table A.4 reports the effects of more intensive glucose control on 
hypoglycaemia and weight gain. As expected the proportion of subjects who 
experienced any hypoglycaemic episode was greater in the more intensive 
treatment group compared with the less intensive group (weighted averages 
38.1% vs. 28.6% more vs. less intensive groups respectively). Overall, severe 
hypoglycaemia was much less common and the proportion of subjects ranged 
from 0.7% to 8.5%. However, severe hypoglycaemia was almost twice as common 
in the more intensively treated group (weighted averages 2.3% vs. 1.2% of 
subjects, more vs. less intensive groups respectively). On average subjects 
receiving more intensive glycaemic control were 2.5 kg heavier at the end of 
study.  
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Table A.1. Baseline characteristics and treatment protocols of five clinical trials comparing different glucose lowering regimens among 
individuals with diabetes mellitus 
 
Study Location Year N 
Mean 
age 
(yrs) 
Duration 
since DM 
diagnosis 
(yrs) 
% 
Males 
% 
Smokers 
% with 
CVD† 
Mean 
SBP 
(mmHg) 
Mean LDL 
(mmol / L) 
Mean 
BMI 
(kg/m2) 
Mean 
baseline 
HbA1c 
(%) 
Treatment given 
Average 
follow-
up (yrs) 
Total 
Person 
years of 
follow-up 
Mean 
HbA1c 
over 
 follow-
up 
(Control)  
Mean 
HbA1c 
over 
 follow-up 
(Intensive) 
UKPDS 
(63;64) 
England 
23 centres 
1998 4620 53 < 1 59 30 NS* 136 3.53 28 7.1 
Treatment with Sulfonylurea 
or insulin or metformin, target 
FPG <6mmol/l vs. control with 
standard diet, target 
FPG<15mmol/l 
10.1 46,237 7.9 7.0 
PROactive 
(42) 
321 
centres in 
19 
countries‡ 
2005 5238 62 8 66 14 100 143 2.90 31 7.9 
Treatment with Pioglitazone 
PO 15-45mg (plus current 
medication) vs. control with 
current medication 
2.9 15,059 7.6§ 7.0§ 
ADVANCE 
(46) 
215 
centres in 
20 
countries± 
2008 11,140 66 8 58 14 32 145 3.12 28 7.5 
Treatment with gliclazide 
modified release PO 30-120mg 
+/- metformin, 
thiazolidinedione, glinide, 
acarbose or insulin, target 
HbA1c ≤ 6.5% vs. control with 
standard therapy per local 
guideline 
5.0 55,700 7.3 6.8 
VADT (48) USA 2008 1791 60 12 97 17 40 132 2.78 31 9.4 
Treatment with maximal dose 
metformin plus rosiglitazone 
(BMI>27) or glimepiride plus 
rosiglitazone (BMI<27) vs. 
control with half-dose of same 
5.6 10,030 8.4 6.9 
ACCORD 
(45) 
USA & 
Canada 
2008 10,251 62 10 61 14 35 136 2.71 32 8.3 
Treatment with metformin, 
sulfonylurea, glinide, 
thiazolidinedione, acarbose, 
insulin or combination, target 
HbA1c <6% vs. control with 
standard therapy, target 
HbA1c 7-7.9% 
3.5 35,879 
 
7.5 
6.4 
Total / 
Average** 
- - 33,040 62 8 62 16 - 140 3.00 30 7.8 - 4.95 162,905 7.5 6.6 
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Table A.1 footnote 
 
† CVD: Cardiovascular disease, includes MI, revascularisation procedure, stroke, peripheral arterial disease, etc. (defined differently across studies) 
‡ Austria, Belgium, Denmark, Estonia, Finland, Czech Republic, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, , Norway, Poland, Slovakia, 
Sweden, Switzerland, UK 
± Australia, Canada, China, Czech Republic, Estonia, France, Germany, Hungary, India, Ireland, Italy, Lithuania, Malaysia, Netherlands, New Zealand, Philippines, 
Poland, Russia, Slovakia, UK 
§ For PROactive mean HbA1c level at end of follow-up was taken 
* Excluded individual with current angina or heart failure, and those with more than major vascular event in the past or myocardial infarction in the previous year 
** Pooled across studies weighting by study size.  
FPG: Fasting plasma glucose; SBP: systolic blood pressure; CVD: cardiovascular disease; BMI: body mass index 
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Table A.2. Definitions of diabetes and clinical end-points used in clinical trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* UKPDS 33 and 34 used the same criteria for defining endpoints  
 ACCORD ADVANCE PROactive UKPDS* VADT 
Diabetes Diagnosis of Type 2 DM defined according to the 1997 
ADA criteria for 3 months or longer AND an HbA1c level 
≥7.5%. 
Eligibility relied on a diagnosis of 
Type 2 DM at age 30 years or older & 
pt is 55 years or older at entry, with 
the diagnosis made 10 or more years 
before entry. Specifically there were 
no entry criteria for HbA1c 
concentration or fasting blood 
glucose. 
All pts diagnosed with type 2 DM. 
HbA1c above upper limit of normal 
i.e. local equivalent of 6.5% for a 
DCCT (Diabetes control & 
complications trial) traceable assay, 
despite existing treatments with diet 
alone or oral glucose lowering 
agents, with or without insulin. 
Pts with new diagnosis referred within 2 
weeks of first diagnosis of type 2 DM. Eligible 
pts had a fasting plasma glucose of 
<6.00mmol/L on two mornings 1-3 weeks 
apart. 
All pts diagnosed with type 2 
DM. Centrally measured HbA1c 
level >4sd above normal mean 
i.e. ≥7.5%. Or local HbA1c 
≥8.3%. 
Non-fatal MI Prolonged ischaemic symptoms lasting >20 minutes and 
raised cardiac enzymes and/or serum CK-MB. Included 
Q-wave MIs, non Q-wave MIs, silent MIs, probable non Q-
wave MIs, MI after cardiovascular invasive interventions, 
MI after coronary bypass graft surgery and MI after non-
cardiovascular surgery. 
ICD 9 code 410 Survived more than 24h after onset 
of symptoms, and in absence of PCI 
or CABG, had at least two of: 
symptoms suggestive of MI, ECG 
evidence of MI, raised serum cardiac 
markers; or after PCI or CABG 
patient had ECG evidence of MI. 
Included Silent MI (defined as new Q-
waves on 2 contiguous leads or R-
wave reduction in praecordial leads 
without a change in access 
deviation). Data refers to first event 
of that type.  
 
WHO clinical criteria with ECG/enzyme 
changes or a new pathological Q-wave. ICD9 
code 410. 
 
First events of non-fatal MIs. 
Not further specified. 
Stroke Definite ischaemic stroke: CT or MRI within 14 days of 
onset of focal neurological deficit lasting more than 2 
hours with evidence of brain infarction; no 
intraparenchymal haemorrhage, no significant blood in 
the subarachnoid space. Also included definite primary 
intracerebral haemorrhage, subarachnoid haemorrhage, 
stroke of unknown aetiology, non-fatal stroke after 
cardiovascular invasive interventions and non-fatal 
stroke post non-cardiovascular surgery. 
Death due to cerebrovascular events 
and non-fatal stroke. 
 
Acute focal neurological deficit 
lasting for longer than 24 hours or 
resulting in death within first 24 
hours of symptoms. Data refers to a 
first event of that type. 
Major strokes defined as signs or symptoms 
for 1 month or longer. Non-fatal strokes - 
ICD9 codes 430-434.9 and 436 and fatal 
strokes ICD9 codes 430-438.9 
 
 
First events of strokes. 
Total Coronary 
Heart Disease 
Non-fatal MI and fatal MI. Death due to coronary heart disease 
(incl. Sudden death) and non-fatal 
MI. 
Non-fatal MI excluding silent MI plus 
cardiac mortality (fatal MIs plus 
death from other cardiac disease) 
Data refers to first event of that 
type. 
Nonfatal MI (ICD9 code 10) + Fatal MI (ICD9 
codes 410-414.9, 428-428.9) 
 
First non-fatal MIs and fatal 
MIs. 
Heart Failure 
 
Congestive Heart Failure Death or hospitalisaion for 
Congestive Heart Failure (with documented clinical and 
radiological evidence) 
Death due to heart failure, 
hospitalisation for heart failure, or 
worsening New York Heart 
Association class 
Those requiring hospital admissions Not associated by MI, with clinical symptoms 
confirmed by Kerley B lines, rales, raised 
JVP or 3rd heart sound ICD9 codes 411-428.1 
New or worsening heart failure 
Cardiovascular 
Mortality 
Death from MI, heart failure, arrhythmia, invasive CV 
interventions, CV causes after non-CV surgery, stroke, 
unexpected death presumed to be from ischaemilc CV 
disease occurring within 24 hours after the onset of 
symptoms and death from other vascular diseases 
 Includes all cardiovascular deaths 
that occurred as a first event 
ICD codes 430-438.9 Includes first events of Deaths 
from MI, Congestive heart 
failure, Coronary 
Revascularisation, Stroke, 
Cerebrorevascularisation, 
Complications of occlusions, 
peripheral revascularisation, 
sudden death and pulmonary 
embolus 
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Table A.3. Event rates for various outcomes in five clinical trials included in a meta-analysis of more vs. less intensive glucose control † 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Rates are given per 1000-person years 
 
** Non-fatal strokes only  
 
Ω CHD includes cardiac mortality 
 
Ψ Combined rates were calculated by pooling study specific rates using random-effects model meta-analysis 
 
NB. Where rates were not available for a specific endpoint in a given study the total person years in each study arm (which was used to calculate the event rates) 
was estimated using the average follow-up in each study 
Non-fatal myocardial 
infarction 
Coronary heart disease Stroke All-cause mortality 
Study 
More 
Intensive 
Less  
Intensive 
More 
Intensive 
Less  
Intensive 
More 
Intensive 
Less  
Intensive 
More 
Intensive 
Less  
Intensive 
 
UKPDS (63;64) 
7.2 9.1 12.8 16.7 4.5 5.0 16.2 19.5 
 
PROactive (42) ** Ω 
15.9 19.0 21.9 26.7 11.5 14.1 23.6 24.6 
 
ADVANCE (46) 
5.5 5.6 11.1 12.1 8.5 8.8 17.9 19.1 
 
VADT (48) 
12.8 15.5 15.4 17.9 5.6 7.2 20.4 18.9 
 
ACCORD (45) 
10.4 13.1 11.4 13.8 4.2 4.0 14.3 11.3 
 
Combined Ψ 
10.0 12.3 14.3 17.2 6.8 7.7 18.3 18.6 
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Table A.4. Numbers of adverse events in five clinical trials included in a meta-analysis of more vs. less intensive glucose control 
 
Any hypoglycaemic event  
[N patients (%)] 
Serious hypoglycaemic event 
[N patients (%)] 
Mean Weight gain (kg) 
Study 
More Intensive 
Less  
Intensive More Intensive 
Less  
Intensive 
More 
intensive 
Less 
Intensive Difference 
 
UKPDS 606 (19.8) 146 (9.4) 39 (1.3) 11 (0.7) - - 2.4 
 
PROactive ∆ 726 (27.9) 528 (20.1) 19 (0.7) 11 (0.4) 3.6 -0.4 4 
 
ADVANCE  Ω 2952 (53.0) 2116 (38.0) 150 (2.7) 81 (1.5) -0.1 -1 0.9 
 
VADT  δ 1333 events (26.7)* 383 events (7.6)* 76 (8.5) 28 (3.1) 8.2 4.1 4.1 
 
ACCORD^  830 events (4.6)* 261 events (1.5)* 538 events (3.0)* 179 events (1.0)* 3.5 0.4 3.1 
 
Combined Ψ 38.1 28.6 2.3 1.2 2.4 -0.1 2.5 
 
 
*these values indicate number of events (instead of number of individuals) and values given in parentheses are event rates per 100 person-years; these values were 
not included in the calculation of the combined proportion 
∆ Any hypoglycaemic episodes refer to those with symptoms compatible with hypoglycaemia. Serious episodes are those that required hospital admission 
Ω Hypoglycaemia defined as blood glucose<2.8 mmol/l or the presence of typical signs and symptoms of hypoglycaemia without another apparent cause. Patients 
with transient dysfunction of the central nervous system, who were unable to treat themselves, requiring help from another person, were said to have serious 
hypoglycaemia. Also note that both treatment groups lost weight, expressed as negative weight gain 
δ Any episodes are those hypoglycaemic episodes with symptoms, and serious episodes are life threatening, or those that cause hospitalisation, disability, death or 
incapacity 
^ Any hypoglycaemic event refers to events requiring any form of assistance. Serious events are those that required medical assistance. For weight gain, numbers 
are mean weight gain for each group at 3 yrs of follow up  
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Figure A.2 Odds ratios showing effect of differential blood glucose control on non-fatal myocardial infarction 
 
I-squared = 0% (95% CI 0% to 69.3%), p = 0.61
Random effects model
Overall
ADVANCE
Study
ACCORD
PROactive
VADT
UKPDS
0.83 (0.75, 0.93)
0.98 (0.78, 1.23)
Odds Ratio (95% CI)
0.78 (0.64, 0.95)
0.83 (0.64, 1.06)
0.81 (0.58, 1.15)
0.78 (0.62, 0.98)
100.00
21.86
Weight (%)
28.86
18.03
9.44
21.81
1.4 .6 .8 1.2 1.4 1.6 1.8 2
Intensive therapy better Standard therapy better
3071/1549 221/141
2605/2633 119/144
5571/5569 153/156
892/899 64/78
5128/5123 186/235
743/75417267/15773
N participants
Intensive/
Standard
therapy
N events
Intensive/
Standard
therapy
Odds Ratio
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Figure A.3. Odds ratios showing effect of differential blood glucose control on coronary heart disease events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Coronary heart disease events in PROactive included non-fatal myocardial infarction and death from all cardiac mortality 
I-squared = 0% (95% CI 0% to 53%), p = 0.78
Random effects model
Overall
UKPDS
PROactive*
Study
ACCORD
ADVANCE
VADT
0.85 (0.77, 0.93)
0.75 (0.54, 1.04)
0.81 (0.65, 1.00)
Odds Ratio (95% CI)
0.82 (0.68, 0.99)
0.92 (0.78, 1.07)
0.85 (0.62, 1.17)
100.00
8.59
20.22
W
25.68
36.48
9.03
eight 
(%)
1.4 .6 .8 1.2 1.4 1.6 1.8 2
Intensive therapy better Standard therapy better
Odds Ratio
N participants
Intensive/
Standard
therapy
N events
Intensive/
Standard
therapy
3071/1549 426/259
2605/2633 164/202
5571/5569 310/337
892/899 77/90
5128/5123 205/248
17267/15773 1182/1136
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Figure A.4. Odds ratios showing effect of differential blood glucose control on stroke 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* includes only non-fatal strokes
I-squared = 0% (95% CI 0% to 62%), p = 0.70
Random effects model
Overall
ACCORD
ADVANCE
PROactive*
UKPDS
VADT*
0.93 (0.81, 1.06)
1.05 (0.76, 1.46)
0.97 (0.81, 1.16)
0.81 (0.60, 1.08)
Odds Ratio (95% CI)
0.91 (0.51, 1.61)
0.78 (0.47, 1.28)
100.00
16.21
51.38
20.47
Weight (%)
5.18
6.76
1.4 .6 .8 1.2 1.4 1.6 1.8 2
Intensive therapy better Standard therapy better
N participants
Intensive/
Standard
therapy
N events
Intensive/
Standard
therapy
Odds Ratio
Study
3071/1549 160/78
2605/2633 86/107
5571/5569 238/246
892/899 28/36
5128/5123 76/72
17267/15773 588/539
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Figure A.5. Odds ratios showing effect of differential blood glucose control on all-cause mortality 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
I-squared = 58% (95% CI 0% to 84%), p = 0.049
Random effects model
Overall
ADVANCE
ACCORD
UKPDS
VADT
PROactive
Study
1.02 (0.87, 1.19)
0.93 (0.82, 1.05)
1.28 (1.06, 1.54)
0.79 (0.53, 1.20)
1.09 (0.81, 1.47)
0.96 (0.77, 1.19)
Odds ratio (95% CI)
100.00
29.38
23.64
10.05
15.46
21.47
Weight (%)
1.4 .6 .8 1.2 1.4 1.6 1.8 2
Intensive therapy better Standard therapy better
Odds Ratio
N participants
Intensive/
Standard
therapy
N events
Intensive/
Standard
therapy
3071/1549 539/302
2605/2633 177/186
5571/5569 498/533
892/899 102/95
5128/5123 257/203
17267/15773 1573/1319
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Figure A.6. Rate ratios showing effect of differential blood glucose control on various clinical outcomes 
 
 
* Rates given per 1000 patient years 
† Combined rates were calculated by pooling study specific rates using random-effects model meta-analysis 
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Figure A.7. Funnel plots of effect estimates for various clinical outcomes 
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Figure A.8. Odds ratios showing effect of differential blood glucose control on heart failure 
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Figure A.9. Composite forest plot of clinical outcomes in studies with available information on these outcomes* 
 
 
* List of contributing studies include: PROactive, ADVANCE, VADT & ACCORD
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A4. Discussion 
 
This literature-based meta-analysis, with carefully considered a priori inclusion 
criteria, identified five relevant clinical trials involving 33,040 participants with 
approximately 163,000 person-years of follow-up and reports information on 
1497 non-fatal myocardial infarctions, 2318 coronary heart disease events, 1127 
fatal and non-fatal strokes, and 2892 deaths from any cause. The summation of 
evidence from these trials demonstrated consistently that more intensive 
glycaemic control has cardiovascular benefit compared to less intensive therapy 
in type 2 diabetes. These data have demonstrated that over an average 
treatment period of approximately 5 years, a lowering in HbA1c of 0.9% resulted 
in a significant 17% reduction in the risk of non-fatal myocardial infarctions, a 
significant 15% reduction in coronary events, and a non-significant 7% trend 
towards a reduction in stroke, with no significant statistical heterogeneity 
observed across studies that varied considerably with respect to participant 
characteristics, baseline HbA1c levels and, more importantly, the hypoglycaemic 
regimens used. There was however no significant impact of more intensive 
glycaemic control on all-cause mortality with evidence of considerable 
heterogeneity across studies.  
 
The UGDP study (194) in the early seventies of more intensive glycaemic control 
vs. usual care suggested an excess mortality with sulphonylureas compared with 
standard care but with potential benefits of insulin based regimens. This study 
was small and compared about 200 patients in each of the more intensively 
treated groups to a common control group. In contrast, the much larger UKPDS 
study, which compared more intensive to standard glycaemic control, failed to 
demonstrate cardiovascular benefit (63) although among a small subgroup of 753 
overweight individuals randomised to metformin vs. usual care there was 
evidence of a clinical benefit favouring more intensive glucose control (64). Post 
hoc observational data from UKPDS suggested that for every 1% reduction in 
HbA1c there was a 14% reduction in risk of myocardial infarction (181) and more 
recently an extension of the initial randomised groups in the UKPDS study has 
demonstrated a reduction in myocardial infarction and death from any cause 
with both metformin and sulphonylurea-insulin regimens despite the fact that 
HbA1c levels were similar during the extension phase (184), suggesting that 
 208 
these initial studies were underpowered to assess the impact of intensive 
therapy on cardiovascular outcomes.   
 
Recently, two large studies have been conducted which despite significant 
differences in HbA1c have suggested that there may not be significant short-
term benefits on macrovascular events (45;46). Furthermore the ACCORD trial 
(45) suggested that there may be an excess risk of death from any cause. An 
earlier meta-analysis (195) comprising data from UKPDS and two additional small 
studies (which recorded in total 60 additional cardiovascular events) (190;196) 
suggested that there was a 19% reduction in the combined endpoint of acute and 
non-acute cardiovascular events which included revascularisation. The absence 
of prior convincing data and possible harm has led consensus groups to provide a 
conservative level of endorsement (class IIb recommendation) for the 
cardiovascular benefits of more intensive glycaemic control (i.e. “usefulness and 
efficacy are less well established by evidence or opinion, with data derived from 
multiple randomised clinical trials or meta-analyses”) (183). The present 
quantitative analysis of randomised controlled trials is the largest to date in 
terms of event numbers, and the combined data refute such assertions and 
provide reliable large-scale evidence of a consistent beneficial effect of more 
intensive control of glucose on non-fatal myocardial infarction and coronary 
events. Furthermore, overall there appears to be no increment in risk of all-
cause mortality. Of note the risk reduction of 17% in myocardial infarction for a 
0.9% difference in HbA1c is broadly consistent with observational data from the 
UKPDS study. Although there was a trend towards benefit for stroke, there were 
372 fewer events compared to myocardial infarctions and thus less power to 
ascertain whether a significant benefit exists.  
 
The implications and the context of these findings with regard to public health 
policy merit careful consideration in the context of the established benefits of 
intensive glucose control on microvascular disease. There is now well 
established evidence that among individuals with diabetes, statin therapy and 
more intensive blood pressure control reduce macrovascular events and, in 
contrast to the present findings, also reduce all-cause mortality by 9% and 27%, 
respectively (133;197-199). Despite the benefits of statin therapy and blood 
pressure control individuals with diabetes remain at elevated risk of vascular 
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events with even higher absolute rates observed among those with diabetes and 
existing cardiovascular disease. This suggests that further interventions to safely 
reduce vascular risk are needed. The present analysis demonstrates that within 
this combined dataset with an average mortality rate of 18.6 per 1000 person 
years of follow up (control group weighted mean), approximately 2 myocardial 
infarctions or 3 coronary events are prevented for about every 200 individuals 
who achieve a further 0.9% reduction in HbA1c over 5 years (from a baseline 
HbA1c of 7.84%). These correspond to NNT over 5 years of 87 and 69 
respectively. These figures are considerably more modest than comparable 
figures per mmol/L LDL-cholesterol reduction or for a 4 mmHg lower BP (8.2 and 
12.5 cardiovascular events prevented) (133;199). Given the burden of vascular 
risk among individuals with diabetes, a global approach to vascular risk involving 
multiple interventions including stricter glycaemic control appears to be 
warranted.  
 
As always, for any given therapy there is also the potential for harm. As 
expected, more intensive glucose control was associated with a relative 2.5 kg 
increase in weight and nearly a doubling in severe hypoglycaemic episodes. 
General inspection of the published data would indicate that the two studies 
(ACCORD and VADT) with increased mortalities had i) the longest diabetes 
durations at baseline of 10 and 11.5 years, ii) highest HbA1c at baseline, iii) 
greater weight gains in the intensive groups (other than PROactive), and iv) 
incurred more than a doubling in the measured rates of serious hypoglycaemic 
events, whereas other trials had less than a doubling of such events. These data 
potentially indicate that the higher mortality risk in ACCORD and VADT could be 
potentially linked to both hypoglycaemia and greater weight gain. In addition, 
the ACCORD study had a significantly higher risk of cardiovascular death and 
non-coronary cardiovascular deaths. Several interesting features of the 
treatment strategies used in ACCORD also merit careful consideration in light of 
the proposed adverse side effects of hypoglycaemia on vascular deaths. In 
ACCORD, a target HbA1c below 6% was achieved rapidly among the intensively-
treated individuals through early and aggressive use of insulin including, where 
necessary, the use of bolus doses. Additionally, a greater proportion of subjects 
within the intensively-treated group received rosiglitazone at the end of follow-
up (91%) compared with those receiving standard treatment (58%) (25). In 
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contrast, in ADVANCE, an HbA1c target of ≤6.5% was achieved much more 
slowly, with much less use of insulin and often with longer acting preparations. 
In addition to pharmacological interventions, participants were encouraged to 
adopt a favourable lifestyle and were closely monitored for outcomes and 
adverse events. While the data presented in our meta-analysis cannot 
substantiate or refute such mechanistic associations, a practical clinical 
approach may be to lower HbA1c steadily with care taken to avoid severe 
hypoglycaemia. Furthermore, it may be appropriate to aim for less stringent 
glycaemia targets in patients with more advanced disease (longer duration and 
higher baseline HBA1c) (200).   
 
Limitations 
 
The present study has some potential limitations which should be considered. 
First, meta-analysis remains retrospective research that is influenced by the 
methodological rigour of the included studies, the degree of comprehensiveness 
of search strategies and the possibility of publication bias. We tried to minimise 
the likelihood of bias by developing a detailed protocol a priori, by performing a 
meticulous search of published and unpublished studies, and by using explicit 
criteria for study selection, data extraction and analysis. Therefore some 
notable studies were not eligible for our meta-analysis for legitimate reasons. 
We believe we have been robust in our approach and that the resultant evidence 
is more applicable as a result. Second, as in other meta-analyses, these results 
should be interpreted with caution as individual studies varied considerably with 
respect to the demographic characteristics of the participants, the duration of 
follow-up and the pharmacological interventions used to control glucose in the 
intensively treated groups. Therefore this study can only provide information on 
whether more intensive control of glucose is safe and effective at reducing 
macrovascular events compared to less intensive therapy, rather than providing 
evidence of superiority or harm of any particular glucose lowering regimen. This 
being said, we did not observe any statistically significant heterogeneity across 
studies with respect to effects of glucose reduction on non-fatal myocardial 
infarctions, coronary events or strokes. Such data together with the vastly 
differing ancillary metabolic effects of differing glucose regimens (metformin, 
sulphonylureas, insulin, glitazones etc) included in the five trials, suggests their 
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common action to lower glucose must be at least partially responsible for the 
observed vascular risk benefits. Although there was no effect on all-cause 
mortality, significant heterogeneity was observed across studies which could not 
be further clarified without access to individual participant data. Third, there 
were not sufficient data to analyse the effects of intensive glycaemic control 
within various subgroups. Such analyses are more informative when done using 
individual participant data and similar approaches are also needed to determine 
whether there is a significant correlation between the magnitude of HbA1c 
lowering and cardiovascular events and all-cause mortality. Therefore, the 
present findings will help encourage the establishment of the collective pooling 
and harmonising of individual participant data analogous to that of blood 
pressure and cholesterol which have proved highly informative. Fourth, we used 
ORs rather than HRs (which were only available in a proportion of studies) to 
maximise the published information that was available. In sensitivity analyses 
we conducted random effects meta-analyses using rate ratios which provided 
effect estimates of similar magnitude to the ORs presented. With respect to the 
calculation of rates, the median number of person years of follow up in 3 studies 
was assumed to approximate the arithmetic mean in the 2 other studies. In 
variables with a skewed distribution such as follow-up time, the median is 
usually not a good approximation of the mean. 
 
Conclusion 
 
In this meta-analysis, based on aggregate data on 33,040 men and women from 
five clinical trials yielding approximately 163,000 person-years of follow-up, we 
observed that a 0.9% further reduction in HbA1c reduced non-fatal myocardial 
infarctions by 17% and coronary events by 15% with no excess risk of death 
among individuals with type 2 diabetes mellitus. Our findings provide 
reassurance about the efficacy of glycaemic control for vascular risk reduction. 
However, the lack of clear benefit on all-cause mortality with glycaemia 
reduction, compared to strong evidence for such a benefit with lipid-lowering 
and blood pressure reduction, reinforces the critical importance of the latter 
modalities to reduce cardiovascular disease and all-cause death in individuals 
with diabetes. Future studies are required to assess the optimum methods for 
achieving better control of glycaemia and to assess whether guidelines should 
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recommend a specific reduction in HbA1c or a specific reduction in HbA1c or 
different target levels of control in different populations. 
 
This manuscript was published in the Lancet in 2009 (88). 
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Conclusions and future work 
 
In my thesis I have explored various aspects of the complex relationship between 
glycaemia and cardiovascular disease. Below I have listed the main conclusions 
from each chapter together with areas where future work should be directed: 
 
Chapter 2: A systematic review of event rates in clinical trials in diabetes 
mellitus: the importance of quantifying baseline cardiovascular disease history 
and proteinuria and implications for clinical trial design 
Cardiovascular endpoint event rates in trials of patients with diabetes are often 
much lower than anticipated in pre-trial power calculations and it is clear that 
basing pre-trial power calculations on population data is problematic. 
Consequently, there is a need in trials to have simple and robust inclusion 
criteria which identify patients with diabetes who are at particularly high risk of 
cardiovascular events. Data from large trials convincingly demonstrate that 
patients with known cardiovascular disease and/or proteinuria are at 
substantially higher risk than those without these features; while this is to be 
expected, the magnitude of the difference in risk is surprising and it is apparent 
that those with uncomplicated diabetes actually have a low absolute 
cardiovascular event rate. These points are highly relevant as indicated by 
recent guidance regarding glucose-lowering therapies released by the FDA (29). 
Following release of meta-analysis results suggesting that rosiglitazone may 
actually increase the risk of cardiovascular events (25), the FDA recognised the 
fact that demonstrating improvement in a surrogate marker (i.e. HbA1c) on a 
medication does not guarantee patient safety and that large randomised clinical 
trials are required to establish safety. Numerous glucose-lowering agents have 
recently been released or are under development. Each will be required to 
demonstrate cardiovascular safety in a large trial. It is therefore hoped that the 
data provided from this analysis may assist those designing such trials. As I did 
not have access to individual participant data in my analysis, it was not possible 
to analyse the impact of various risk factors in a multivariable fashion or in 
subgroups. This would require agreement from trialists to contribute trial data 
and analysis would require highly specialised statisticians, along the lines of the 
ERFC based at the University of Cambridge. Nevertheless, such a project could 
be of even greater benefit to those planning trials of not only glucose-lowering 
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agents but all cardiovascular agents in those with diabetes. Newer biomarkers 
such as NTproBNP and troponin may also provide incremental information, 
facilitating identification of patients with diabetes at high risk of events. 
 
Chapter 3: Fasting plasma glucose in non-diabetic participants and the risk for 
incident cardiovascular events, diabetes, and mortality: results from the West 
of Scotland Coronary Prevention Study 
FPG in the non-diabetic range has little, if any, association with the risk of 
cardiovascular events. Certainly it appears that adding FPG results to existing 
risk prediction equations would be highly unlikely to yield any substantial 
improvement. By contrast, higher FPG levels in the non-diabetic range carry 
markedly elevated risks for developing diabetes. These contrasting risks for 
cardiovascular events and new-onset diabetes have been demonstrated in 
previous large clinical trials of glucose-lowering strategies. For example, in the 
Diabetes Prevention Program (201), both lifestyle modification therapy and 
metformin therapy were able to greatly reduce the risk of developing diabetes. 
Fewer trials have been conducted to assess the effect of glucose-lowering in 
patients with IGT and IFG. In the largest clinical trial to date (n=9,306 patients 
with IGT), nateglinide therapy did not reduce cardiovascular events compared to 
placebo (HR 0.94 95%CI 0.82-1.09) (202) though post-challenge glucose 
concentrations were actually higher in the nateglinide recipients. This does not 
necessarily mean that no glucose-lowering agents will be valuable in non-
diabetic patients. I am currently involved in a meta-analysis where we are 
collecting published and unpublished data for trials of glucose-lowering 
therapies in individuals with IFG and IGT which will be pooled to assess any 
cardiovascular benefits. One possibility is that beneficial effects may take 
substantial amounts of time to develop. Also, some agents are known to have 
pleiotropic effects. For example, metformin therapy leads to weight loss and 
moderate reductions in serum cholesterol even in statin users (203). I am also 
currently investigating the effect of metformin on change in carotid intima 
media thickness (a surrogate marker of cardiovascular disease) in patients with 
existing coronary heart disease but not diabetes in a placebo-controlled 
randomised clinical trial, the Carotid Atherosclerosis:MEtformin for insulin 
ResistAnce (CAMERA) study (204). In addition, UK researchers have proposed a 
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large clinical endpoint trial of metformin in patients without diabetes, the 
Glucose Lowering In Non-diabeTic hyperglycaemia (GLINT) study. 
 
Chapters 4 and 5: Statins and risk of incident diabetes: a collaborative meta-
analysis of randomised placebo- and standard care-controlled statin trials; Risk 
of incident diabetes on intensive compared to moderate dose statin therapy: a 
collaborative meta-analysis of randomised trials 
The use of statin therapy is associated with an increased risk of developing 
diabetes compared to placebo, and intensive statin therapy is associated with a 
further risk of new-onset diabetes compared to moderate dose therapy. While 
the benefits of cardiovascular risk reduction certainly outweigh this newly 
identified risk when treating patients according to established guidelines, the 
risk is not trivial as demonstrated by the finding that intensive statin therapy 
leads to one additional case of new-onset diabetes for every three patients 
protected from a cardiovascular event (cardiovascular death, non-fatal 
myocardial infarction, non-fatal stroke, coronary revascularisation). The key 
question is now to identify the explanation for this increase in diabetes. As 
discussed in chapters 4 and 5, there are data from animal models to support the 
hypothesis that statin therapy leads to peripheral (skeletal muscle, adipose 
tissue) insulin resistance. Further studies on animal models are required 
together with suitably powered and designed insulin clamp studies in humans to 
establish the culprit organ / organs and molecular pathways. Second, it would 
be of value to determine whether this increase in new-onset diabetes actually 
leads to the increased risk of microvascular and macrovascular disease 
associated with diabetes. Given the apparent modest effect of statins on new-
onset diabetes plus the time taken for such complications to occur, this matter 
may be impossible to address. Third, it would be of interest to study whether 
the use of statins leads to a long term increase in diabetes risk, and what the 
influence of statin withdrawal is. Fourth, further studies of existing data should 
examine whether statin therapy has any detrimental effect on glucose control or 
the need for glucose-lowering therapy in those with known diabetes. And fifth, 
further study should be directed towards identifying any subgroup of statin 
recipients at particular risk. I am in the process of applying for Fellowship 
funding to investigate these areas. Of interest, the ongoing placebo-controlled 
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J-PREDICT study is specifically designed to evaluate the impact of pitavastatin 
therapy on the development of diabetes in 1,240 participants with IGT. 
 
Chapter 6: Predictors of development of diabetes in patients with chronic heart 
failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality 
and Morbidity program 
The prevalence of diabetes in patients with chronic heart failure is high and the 
strongest statistical predictors of diabetes are BMI and HbA1c, similar to the 
general population. Since publication of the data in this chapter, other studies 
of observational data have been published. Given the apparent link between 
heart failure morbidity and diabetes (24), one area of particular interest is the 
use of glucose-lowering agents in those with heart failure. Use of metformin in 
patients with chronic heart failure has long been contra-indicated. However, 
observational data reveal that metformin is actually used quite frequently in 
heart failure patients and that this may even be beneficial (205;206). Various 
trials should be considered. One is the use of metformin in patients with existing 
diabetes and heart failure to assess its impact on cardiovascular events and all-
cause death. Another option is the use of metformin in patients with heart 
failure alone to assess not only cardiovascular benefit but also any effect on 
new-onset diabetes. To date researchers at the University of Dundee have led 
the way in this area and they are currently conducting the TAYSIDE trial (207) 
which, it is hoped, will lead to the conduct of a large clinical trial of metformin 
in heart failure. I am also currently involved in an analysis of the EMPHASIS-HF 
database, in which patients with chronic heart failure were recruited, to assess 
the effect of the mineralocorticoid antagonist, eplerenone, on new-onset 
diabetes.  
 
Appendix: Effect of intensive control of glucose on cardiovascular outcomes and 
death in patients with diabetes mellitus: a meta-analysis of randomised 
controlled trials 
Intensive glucose-therapy reduces the risk of non-fatal myocardial infarction but 
not other cardiovascular events in patients with type 2 diabetes. The clinical 
application of glucose-lowering remains highly controversial following 
publication of the relevant trials and subsequent analyses. The key issues are 
the effects of intensive glucose-lowering on all-cause mortality and 
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cardiovascular mortality and these remain unresolved. Crucially, we do not yet 
understand the reasons for increased mortality on intensive-glucose lowering 
noted in two trials, nor do we know with confidence in which, if any, subgroups 
of patients clinicians should target or avoid intensive glucose-lowering though 
more recent data do suggest that those with no existing cardiovascular disease 
are most likely to derive cardiovascular benefit (208). Further clinical trials are 
required to address these uncertainties. Numerous large clinical trials are 
already underway to assess the cardiovascular safety of glucose-lowering agents 
in patients with diabetes and IGT. These include trials of gliptin therapy (TECOS 
[sitagliptin], SAVOR-TIMI 53 [saxagliptin], EXAMINE [alogliptin]), glucagon-like 
peptide-1 analogues (EXSCEL [exenatide], LEADER [liraglutide], ELIXA 
[lixisenatide], T-emerge 8 [taspoglutide]), and other agents (ORIGIN [insulin 
glargine], ACE [acarbose], ALECARDIO [aleglitazar]). Given the close relationship 
between diabetes and chronic heart failure, a sensible addition to the usual 
cardiovascular endpoints of these trials such as cardiovascular death, myocardial 
infarction and stroke, would be the development of heart failure. One important 
consideration to keep in mind, according to some experts in this area, is to avoid 
a ‘glucocentric’ approach to cardiovascular risk reduction in patients with 
diabetes (209). This is supported by the clinical evidence where intensive-
glucose lowering, which is challenging for clinician and patient, has produced 
only modest benefit on non-fatal myocardial infarction unlike cholesterol- and 
blood pressure-lowering strategies which have demonstrated far greater clinical 
benefits (133;199). 
 
In summary, it is clear that the relationship between cardiovascular disease, 
glycaemia and diabetes is complex. While cardiovascular disease and diabetes 
often coexist in patients and while patients without either condition may often 
be at elevated risk of developing both, risk factors for these differ substantially. 
Indeed, risk factors common to both cardiovascular disease and diabetes vary 
substantially in their contributions to risk of developing each. Consequently, 
treatments that target any particular risk factor may have the expected effect 
on one condition but little, or even an unexpected, effect on the other.
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